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Summary 	
Substantial evidence has been generated demonstrating that the immune 
system is important for controlling tumour development. This includes colorectal 
cancer (CRC).  
 
Current dogma states that patients capable of mounting anti-tumour immune 
responses have increased survival. As a result, therapies to enhance anti-
tumour immune responses are an attractive treatment strategy for cancer 
patients. However, the long-term effect of generating such responses is not fully 
understood. Our laboratory has previously shown that an IFN-γ response 
towards the tumour antigen Carcinoembryonic antigen (CEA) is associated with 
tumour recurrence in CRC patients. In contrast, a 5T4 IFN-γ response provided 
a protective advantage. In this thesis, reasons to explain this observation were 
explored.  
 
Firstly, anti-CEA IL-17A and dual IFN-γ/IL-17A responses were investigated to 
determine if high frequencies of IL-17A could potentially outweigh a beneficial 
IFN-γ response. Infiltration of CD4+ T cell subsets into tumours from CEA 
responding and non-responding patients was also examined. Results revealed 
that CEA specific IL-17A responses were not up-regulated in CRC patients 
compared to healthy donors, nor were they increased compared to IL-17A 5T4 
specific responses. IL-17A+ CD4+ T cell infiltration was also not increased within 
patients harbouring a CEA T cell response. However, infiltration of other T 
helper subsets was reduced. These data imply that IL-17A release is not 
responsible for early tumour recurrence. Results also suggest that tumours 
developing within CEA responding patients may be less immunogenic and 
hence more aggressive. 
 
Investigations were also made to assess if a blood CEA T cell response was 
associated with increased intestinal permeability. Data obtained via Ussing 
chamber experiments suggests that a high magnitude CEA response is 
associated with reduced gut integrity in the right side of the colon. Further 
experiments are required, but it is possible that increased permeability could 
allow translocation of microbial products, leading to an inflammatory 
environment that could aid tumour development.  
 
It’s hoped that such findings will help to explain the potential long-term effects of 
generating anti-tumour immune responses. This knowledge would be beneficial 
when selecting targets for immunotherapy. 
 
 
 
 
	 IX	
List of Abbreviations 
Ag/AgCl Silver/silver chloride 
ALDH Aldehyde dehydrogenase 
AOM Azoxymethane 
AP Adenoma patient 
APC Antigen presenting cell 
APC gene Adenomatous polyposis coli  
CAC Cancer associated cachexia 
CD Cluster of differentiation 
CEA Carcinoembryonic antigen 
CFTR Cystic fibrosis transmembrane conductance regulator 
CRC Colorectal cancer 
CTLA-4 Cytotoxic T-lymphocyte antigen 4 
DAMP Danger associated molecular patterns 
DC Dendritic cell 
DSS Dextran sodium sulphate 
EGFR epithelial growth factor receptor 
ELISpot Enzyme linked immunosorbent spot assay 
EMT Epithelial-mesenchymal transition 
ENaC Epithelial soidum channel  
FACS Fluorescence activated cell sorting  
FAP Familial adenomatous polyposis  
FITC Fluorescein isothiocyanate  
fMLP N-formyl-L-methionyl-L-leucyl-L-phenylalanine  
FMO Fluorescence minus one 
FoxP3 Forkhead box P3 
FSC Forward scatter 
GI Gastrointestinal  
HA Haemagglutinin  
HLA Human leukocyte antigen 
HSC Hematopoietic stem cell 
IBD Inflammatory bowel disease 
IDO Indoleamine 2,3-dioxygenase  
IFN-γ Interferon-gamma 
IL Interleukin 
IPEX Immunodysregulation polyendocrinopathy enteropathy X-linked 
Isc Short circuit current 
JAM-A Junction adhesion molecule A 
LAG-3 Lymphocyte activation gene 
LN Lymph node 
LPS Lipopolysaccharide 
mAB Monoclonal antibody 
MAGE Melanoma-associated antigen  
MCA Methylcholanthrene 
MHC Major histocompatibility complex  
MMR Miss match repair 
MSI Microsatellite instability 
mTEC Medullary thymic epithelial cells 
MVA Modified Vaccinia Virus Ankara 
NBFS Neutral buffer formalin solution 
NSAID Non-steroidal anti-inflammatory drugs 
OS Overall survival 
PBMC Peripheral blood mononuclear cell 
	 X	
PD Potential difference 
PFS Progression free survival 
PGE2 Prostaglandin E2 
PHA Phytohaemagglutinin  
PMA Phorbol Myristate Acetate  
PP Peptide pool 
PPD Purified protein derivative 
PRR Pattern recognition receptor 
pTreg Peripheral Treg 
R Resistance 
RAG Recombinant activating gene 
SAA-1 Serum Amyloid A1 
SFB Segmented filamentous bacteria  
SFC Spot forming cell 
SSC Side scatter 
STAT Signal transducer and activator of transcription 
TAA Tumour associated antigen 
TaCTiCC Trovax and cyclophopsphamide treatment in colorectal cancer 
TAM Tumour associated macrophage 
TAP-1 Transporter associated with Antigen Processing 1  
Tg Transgenic 
TGF-β Transforming growth factor beta  
Th T helper 
TIL Tumour infiltrating lymphocyte 
TNF-α Tumour necrosis factor-alpha 
TRA Tissue restricted antigen 
Treg T regulatory cell 
TSA Tumour specific antigen 
TSLP Thymic stromal lymphopoietin  
tTreg Thymic Treg 
VEGF Vascular endothelial growth factor 
VELIPI Vascular emboli, lymphatic invasion, and perineural invasion 
WT Wild type 
ZO Zonula occludens 
 
 
 
 
 
 
 
 
 								
 	
	 XI	
List of Figures 
Figure 1.1 Structure of the TJ found between epithelial cells. ............................. 3	
Figure 1.2. Routes of passage across the epithelial barrier ................................. 5	
Figure 1.3 Representative diagram of the epithelial layer of the small and large 
intestine. ..................................................................................................... 11	
Figure 1.4. Colonisation with SFB induces Th17 cells. ...................................... 22	
Figure 1.5. Canonical Wnt Signalling. ................................................................ 42	
Figure 1.6. Dukes’ staging of CRC. ................................................................... 45	
Figure 2 1. Isolation of PBMC from whole blood. ............................................... 80	
Figure 2.2. PBMC plate layout. .......................................................................... 80	
Figure 2.3. FluoroSpot assay principle. ............................................................. 82	
Figure 2.4. Ussing Chamber Electrodes and Chambers. .................................. 87	
Figure 2.5. The principle of Ohm’s law. ............................................................. 90	
Figure 2.6. Electrical current and paracellular probe passage involved in Ussing 
experiments. ............................................................................................... 91	
Figure 3.1. CRC cancer patients secreting IFN-γ in response to CEA are at a 
greater risk of tumour recurrence. .............................................................. 95	
Figure 3.2. Examples of IFN-γ, IL-17A and IFN-γ/IL-17A dual secretion after 
stimulation with CEA peptide pools. ........................................................... 99	
Figure 3.3. Examples of IFN-γ, IL-17A and dual IFN-γ/IL-17A secretion after 
stimulation with 5T4 peptide pools. .......................................................... 100	
Figure 3.4. Examples of IFN-γ, IL-17A and dual IFN-γ/IL-17A secretion after 
stimulation with control antigens HA, PPD and PHA. .............................. 101	
Figure 3.5. Percentage of CRC patients with a CEA and 5T4 response is similar 
to that seen within our previous study (Scurr et al 2015). ........................ 104	
Figure 3.6. CEA responses are present within healthy donors and CRC patients.
 ................................................................................................................. 105	
Figure 3.7 The percentage of IFN-γ secreting 5T4 responding patients declines 
with advanced disease. ............................................................................ 106	
Figure 3.8. Magnitude of IFN-γ but not IL-17A CEA and 5T4 responses decline 
in CRC patients. ....................................................................................... 107	
Figure 3.9. An IL-17A CEA or 5T4 specific response occurs alongside an IFN-γ 
response. ................................................................................................. 110	
Figure 3.10. CEA specific and 5T4 specific IFN-γ responses are higher in 
magnitude than IL-17A in CRC patients. .................................................. 111	
Figure 3.11. CEA specific and 5T4 specific IFN-γ responses are higher in 
magnitude than IL-17A in HD. .................................................................. 112	
Figure 3.12. There is no difference in magnitude of response towards CEA and 
5T4. .......................................................................................................... 113	
Figure 3.13. Serum CEA levels do not correlate with a CEA specific PBMC 
response. ................................................................................................. 114	
Figure 3.14. CEA expression can be detected on tumours but does not correlate 
with the presence of a PBMC response. .................................................. 115	
Figure 3.15. Representative gating strategy used to analyse CD3+ CD4+ 
PBMCs. .................................................................................................... 119	
Figure 3.16. Representative gating strategy used to analyse CD3+ CD4+ colon 
cells and TILs. .......................................................................................... 121	
Figure 3.17. CEA responding patients have lower percentages of CCR6+, 
FoxP3+ and IFN-γ+ T lymphocytes. .......................................................... 122	
Figure 3.19. No difference was found between CD3+CD4+ cells from 5T4 
responders and non-responders. ............................................................. 124	
Figure 3.20. IL-17A and IL-10 secretion showed no difference between CEA or 
5T4 responders or non-responders. ......................................................... 126	
	 XII	
Figure 4.1. The Ussing chamber system. ........................................................ 136	
Figure 4.2. Design of the Ussing chamber system. ......................................... 137	
Figure 4.3. Schematic of the electrical circuit used in the Ussing chamber 
system. ..................................................................................................... 141	
Figure 4.4 A stimulation protocol of four pulses was adequate to determine 
tissue resistance. ..................................................................................... 143	
Figure 4.5. Calculation of electrical resistance. ............................................... 145	
Figure 4.6. Optimised dissection and mounting technique gives rise to negative 
PD values, indicative of healthy tissue. .................................................... 146	
Figure 4.7 Baseline electrical resistance identifies regions permeability ......... 150	
differences. ...................................................................................................... 150	
Figure 4.8. Lucifer yellow passage across colonic epithelium is higher than 4kDa 
FITC-dextran passage. ............................................................................ 151	
Figure 4.9. Loss of oxygen reduces electrical resistance and increases 
paracellular permeability. ......................................................................... 152	
Figure 4.10. 3% Dextran Sodium Sulphate causes intestinal inflammation and 
increase intestinal permeability. ............................................................... 154	
Figure 4.11. Depletion of T-regulatory cells causes autoimmunity. ................. 157	
Figure 4.12. T-regulatory cell depleted mice show increased intestinal 
permeability. ............................................................................................. 158	
Figure 5.1. Human biopsy samples remained viable within Ussing chambers for 
up to 90 minutes. ...................................................................................... 167	
Figure 5.2. Baseline Ussing measurements show regional variation in healthy 
colonic biopsies. ....................................................................................... 168	
Figure 5.3. Lesion biopsies show increased permeability but tissue obtained 
>5cm from the adenoma site does not. .................................................... 172	
Figure 5.4. Higher magnitude CEA-specific IFN-γ T cell responses correlate with 
increased intestinal permeability in the right side of the colon but not the 
left. ........................................................................................................... 175	
Figure 5.5 CEA-specific IL-17A T cell responses do not correlate with intestinal 
permeability. ............................................................................................. 176	
Figure 5.6. CEA-specific IFN-γ/IL-17A dual T cell responses do not correlate 
with intestinal permeability. ...................................................................... 177	
Figure 5.7 5T4-specific IFN-γ T cell responses do not correlate with intestinal 
permeability. ............................................................................................. 178	
Figure 5.8. 5T4-specific IL-17A T cell responses do not correlate with intestinal 
permeability. ............................................................................................. 179	
Figure 5.9. 5T4-specific IFN-γ/IL-17A dual T cell responses do not correlate with 
intestinal permeability. .............................................................................. 180	
Figure 5.10. Schematic showing the hypothesis that increased intestinal 
permeability helps drive bacterial induced inflammation, aiding tumour 
progression in CEA responding patients. ................................................. 184	
	 XIII	
List of Tables 
Table 1. Claudin expression in mammalian intestine ........................................... 5	
Table 2.1. Surgical CRC patient characteristics where cultured CEA and 5T4 
responses have been analysed (note that 1 patient had two tumours). ..... 64	
Table 2.2. Endoscopy patient characteristics where cultured CEA and 5T4 
responses or intestinal permeability was analysed. ................................... 65	
Table 2.3. Dukes’ staging parameters ............................................................... 65	
Table 2.4. TNM staging parameters .................................................................. 65	
Table 2.5. CEA 20mer peptide sequences ........................................................ 69	
Table 2.6. 5T4 20mer peptide sequences ......................................................... 70	
Table 2.7. Details of flow cytometry human antibodies. ..................................... 72	
Table 2.8. Details of flow cytometry mouse antibodies ...................................... 72	
Table 2.9. Details of Krebs buffers and concentrations. .................................... 76	
Table 2.10. Shandon tissue processor cycles for colonic tissue samples ......... 78	
Table 2.11. Haematoxylin and eosin staining protocol ...................................... 93	
Table 4.1. Alterations to Ussing experiments investigated to obtain reliable 
electrical readings. ................................................................................... 147	
	 1	
Chapter 1. General Introduction  
1.1 The gastrointestinal tract 
The gastrointestinal (GI) tract is a hollow muscular tube. It starts at the oral 
cavity, continuing through the oesophagus, stomach, intestines and rectum to 
the anus, where waste is then expelled.  The function of the GI tract is to absorb 
nutrients from the breakdown of food, with many organs including salivary 
glands, the pancreas and liver providing enzymes to aid digestion. Intake of food 
however makes it possible for exogenous organisms such as bacteria, fungi and 
viruses to also enter. In particular, microorganisms that symbiotically inhabit the 
intestine are termed the microbiota. They do not simply reside within the gut but 
rather can be beneficial to the host. Microbiota are capable of digesting fibre to 
generate short chain fatty acids (SCFA), which the host can use as an energy 
source (1). Moreover, they can synthesise vitamin B and K as well as 
metabolise bile acids derived from the liver (2-4). The microbiota can also 
influence host immunity through interactions with immune cells or by producing 
various metabolites. This host–microbiota relationship within the intestine is 
highly regulated by various mechanisms to maintain a healthy gut. Accordingly, 
examining dysregulation of this system and its impact on intestinal disease is a 
rapidly expanding field. 
 
1.1.1 Intestinal Epithelial cells 
Intestinal epithelial cells lie between the microbiota and the host, creating an 
important physical barrier. As well as being necessary to provide water and 
nutrient absorption, epithelial cells have two major roles to maintain gut health in 
relation to the microbiota: “segregation” and “mediation”. Segregation is defined 
as the separation of host cells in the lamina propria from the microbiota, while 
mediation describes the transmission of signals from the gut microbiota to 
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immune cells (5). Cytokine or chemokine signalling can induce immune 
responses or deliver antigens to antigen presenting cells (APCs) to promote 
tolerance (discussed later within this Chapter). However, the structure of 
epithelial cells themselves is critical for creating a barrier to maintain healthy 
intestinal function. 
 
1.1.1.1 Tight Junctions 
Tight junction (TJ) protein complexes link intestinal epithelial cells, sealing the 
paracellular space to regulate the permeability of ions, solutes and separate the 
microbiota from the host (Figure 1.1). Structurally, the TJ is composed of 
proteinaceous filaments termed “strands”, spanning the extracellular space to 
interact with adjacent cells. Crucially, the “tightness” of the TJ is determined by 
the protein composition within the strands themselves and not only by strand 
number. Farquhar and Palade first encapsulated the ultrastructure of the TJ in a 
seminal paper in 1963 (6). However, it was not until 1986 that the first TJ protein 
zonula occludens-1 (ZO-1) was identified by immune-electron microscopy (7). 
This was followed by the discovery of other peripheral “scaffolding” membrane 
proteins ZO-2 and ZO-3 that engage with actin filaments of the cell cytoskeleton 
(8). Interacting with ZO-1, the first transmembrane protein to be discovered was 
occludin, a member of the Tight Junction-Associated Marvel domain-containing 
protein (TAMP) family (9). In vitro work revealed that overexpression of occludin 
reduced paracellular permeability in Madin-Darby canine kidney cell lines. 
Meanwhile transfer of a terminally truncated occludin resulted in increased 
paracellular leakage of small molecule tracers (10).  However, occludin deficient 
mice had normal levels of intestinal paracellular permeability compared to 
experimental controls. This indicated that other TJ proteins are present to 
maintain TJ structure and function. 
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Figure 1.1 Structure of the TJ found between epithelial cells.  
TJ strands are composed of various claudins, occludin and JAM proteins. This seals the 
paracellular space by associating with scaffolding proteins ZO-1/2/3 which are 
connected to the cell cytoskeleton. 		
1.1.1.2 Claudin molecules 
Many studies have emphasised the importance of the large claudin family of TJ 
transmembrane proteins, which share no sequence homology with the TAMP 
family. There are twenty-seven known members of the claudin family (11), with 
morphological and functional studies proving that they are critical for effective 
barrier formation (12). Claudins are capable of forming pores within the TJ 
strand structure but also regulate strand number and complexity (13, 14). 
Moreover they are important for transmitting actomyosin tension across the TJ 
(15). In cells that naturally lack TJs, such as fibroblasts, Furuse and colleagues 
demonstrated that claudins are sufficient to reconstitute strand-like networks 
between cells. (13). In context with this, it is now thought that TJ structures 
undergo continuous remodelling in response to extracellular signals and stimuli, 
with claudin switching playing a key role (16).  
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Paracellular passage, between epithelial cells, can be classified by two 
mechanisms termed the “pore” and “leak” pathways (Figure 1.2). The leak 
pathway allows flux of large molecules in a non-selective manner. In contrast, 
the pore pathway is charge and size selective, allowing passage of small ions 
and uncharged molecules across the TJ. Studies show that claudins can 
function as paracellular pores and generally can be classified into two 
categories: “Tight” sealing claudins or “leaky” pore forming claudins. For 
example, claudin-2 was the first claudin found to increase permeability, by 
mediating selective passage of the cations Na+ and K+ as well as water (12). 
After stimulation of epithelial cells with inflammatory cytokines such as TNF-α 
and within inflammatory bowel disease (IBD) patients, claudin-2 is highly 
upregulated within the intestine (17). As a result, permeability to cations is 
increased, causing diarrhoea in patients. In contrast, claudin-1, which is widely 
expressed in the intestine, is known for its barrier‐forming ability, reducing ionic 
passage along with claudin-3 and 4 (14). Expression of claudin-3 is higher within 
colonic epithelium compared the rest of the intestine (18). This is a common 
feature of claudin molecules, with distinct areas of the intestinal tract expressing 
various claudin proteins at different levels (Table 1) (19). Further to this, a crypt-
lumen distribution of claudins has been identified. Claudins 2, 10 and 15 localise 
to the crypt base while claudins 3, 4, 7 and 8 are expressed on luminal epithelial 
cells (19). An alteration to claudin composition not only allows passage of ions 
but can also permit the translocation of bacterial products. Tsukita and 
colleagues investigated the role of claudin-7 in a conditional knockout mouse 
model. Results showed that claudin-7 deficiency allows for enhanced 
paracellular flux of the bacterial product N-formyl-L-methionyl-L-leucyl-L-
phenylalanine (fMLP) (20). fMLP is released by intestinal bacteria and is a major 
chemotactic product known to drive intestinal inflammation. Transportation of 
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fMLP usually occurs transcellularly via the PepT1 receptor on colonic epithelial 
cells, a receptor that is abnormally over-expressed in IBD patients (21, 22). 
However, claudin-7 deficient mice have revealed it is possible for fMLP to 
translocate via the paracellular route, even when all other TJ proteins are 
present (20). This demonstrates a key function of claudin molecules within the 
TJ.  	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Routes of passage across the epithelial barrier 
Paracellular passage describes the movement of substances between epithelial cells 
and is composed of pore and leak pathways. Transcellular passage describes the 
movement of molecules through the cell itself. 
 	
Table 1. Claudin expression in mammalian intestine 
	
Adapted from Lu et al. (2013) and Garcia-Hernandez et al. (2017) (19, 23) 
Intestinal Segment Claudin expression 
Duodenum 1, 2, 3, 4, 5, 7, 12, 15 
Jejunum 1, 2, 7, 2, 15 
Ileum 2, 7, 8, 12, 15 
Large intestine 1, 3, 4, 7, 8, 12, 15 
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1.1.1.3 Junction Adhesion Molecules 
Junction Adhesion Molecules (JAM) are another component of the TJ structure, 
belonging to the Ig superfamily. The JAM family consists mainly of three closely 
related proteins: JAM-A, B and C, which are widely expressed in many cell 
types. This includes neutrophils and monocytes as well as endothelial and 
epithelial cells (24). Current evidence indicates that mucosal epithelial cells of 
the intestine mostly express JAM-A, which is directly involved in TJ formation 
and maintenance (25). JAM-A has a key role in facilitating the recruitment of 
scaffolding proteins ZO-1, 2 and 3 and aids in the assembly of the TJ structure 
(26). Even though not directly involved in TJ strand formation, JAM-A depletion  
still results in increased permeability within human epithelial cell monolayers 
(25). This finding has been validated in JAM-A deficient mice, showing  
increased in paracellular flux of the 4 kD FITC dextran probe compared to wild 
type animals (27). In addition, JAM-A deficient mice are more susceptible to 
Dextran Sodium Sulfate (DSS)-induced colitis compared to controls. This 
indicates that JAM-A depletion facilitates at least in part the development of 
inflammatory conditions through the induction of a “leaky” mucosal barrier. Loss 
of JAM-A has also been implicated in the up-regulation of specific claudin 
molecules such as claudin-5 and claudin-10, suggesting that JAM-A can further 
regulate the molecular composition of the TJ and hence impact the permeability 
of small molecules (27, 28).  
The proteins mentioned, as well as others, play key roles in the formation of the 
TJ structure to maintain close contact between individual epithelial cells. 
Therefore, it is easy to see that loss or change in function of such molecules can 
have detrimental effects on the integrity of the intestinal barrier.  	
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1.1.1.4 Electrolyte transport  
Intestinal epithelial cells have the major role of absorbing nutrients, including 
sugars, salt (NaCl) and water. This is achieved as epithelial cells are polarised 
structures, having a sophisticated system of ion pumps, channels and 
transporters at apical and basolateral epithelial membranes. Na+ absorption is in 
fact the driving force for all other ionic movements across the cell. Na+ 
absorption occurs by electroneutral transport via Na+/H+ exchangers (NHE) on 
the apical membrane (29). However, electrogenic Na+ absorption via specific 
channels, such as ENaC channels, at the apical surface also takes place. Such 
channels allow Na+ to diffuse down a concentration gradient into epithelial cells. 
At the baslolateral membrane active transport of Na+ ions out of the cell is 
mediated by the electrogenic Na+, K+-ATPase pump. Each pump cycle results in 
the extrusion of three Na+ ions in exchange for the basolateral uptake of two 
K+ ions. This results in the net transfer of one positively charged Na+ ion across 
the basolateral membrane (30). The movement of Na+ alters the osmolarity of 
the extra cellular fluid, resulting in water accompanying the flow of Na+ across 
the epithelial barrier into the body. Also present are channels to dissipate the K+ 
uptake by the ATPase pump to maintain the membrane potential.  
Cl- movement across epithelial cells occurs in a passive manner. However, it 
can also occur by electroneutral pathways involving Na+/H+ and 
Cl−/HCO3− exchange at the apical surface. A key Cl- channel is the CFTR 
receptor, which is responsible for secreting Cl- across the apical membrane (29). 
The CFTR is mutated within cystic fibrosis patients. This leads to insufficient Cl- 
secretion, the development of thick intestinal mucus and an inability to properly 
absorb nutrients across the gut (31). Alterations in Cl- secretion are also 
associated with excessive diarrhoea, such as that seen during cholera infection 
(32).  
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Transporters to absorb nutrients have also been identified and can utilise the 
mechanisms of Na+ absorption. In particular SGLT1 located on the apical 
membrane is responsible for glucose and galactose uptake from the lumen. 
SGLT1 is electrogenic and uses the Na+ gradient to transport Na+ and sugar in a 
2:1 ratio against a sugar gradient into the cell. Studies show that GLUT2, 
present on the basolateral membrane then facilitates movement of the sugars 
into the interstitium (33). Another key transporter identified is the 
monocarboxylate transporter 1 (MCT1). It functions as an H+-coupled electro-
neutral transporter and aids in the absorption of SCFAs. This includes butyrate 
and propionate, the products of bacterial fermentation, which the host can use 
as an energy source (29).  
Studies investigating ionic movements have clearly demonstrated that efficient 
and continuous ionic transportation across epithelial cells is key to maintaining a 
healthy intestinal environment.  
 
1.1.2 Mucus layer 
Aside from TJs other physical barriers exist within the intestine to segregate the 
microbiota. The mucus layer and the glycocalyx, a meshwork of carbohydrate 
glycolipids able to trap organisms, form on top of intestinal epithelial cells 
(Figure 1.1). A study by Johansson and colleagues shows that the mucus layer 
in the large intestine, produced by goblet cells, is extremely thick compared to 
the small intestine. Most likely this is in defence of the vast quantity of intestinal 
bacteria (~1013) that reside within the colon (34). The mucus layer extends 
approximately 150µm above intestinal epithelial cells and is composed of an 
innermost firm layer and a looser outer layer. Identified by composite agarose-
PAGE (AgPAGE) the major component of both layers was found to be the highly 
O-glycosylated mucin protein MUC-2, which forms gel-like structures (34). The 
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inner mucus layer is a stratified layer containing polymerised MUC-2 and is 
anchored to epithelial cells, efficiently excluding bacteria. Accordingly, it was 
found that MUC-2 deficient mice have bacteria in direct contact with epithelial 
cells (34). Proteolytic cleavage of MUC-2 results in a less condensed outer 
mucus layer, which is inhabited by intestinal microbes. It has been shown that 
the microbiota can use MUC-2 as an energy source. However, in the absence of 
dietary fibre numbers of mucin-degrading bacterial species increase, resulting in 
inner mucus layer degradation and risk of mucosal invasion (35).  
 
1.1.3 Chemical barriers 
 Epithelial cells also provide a chemical barrier against microbial invasion 
(Figure 1.3). In the small intestine, paneth cells are able to secrete anti-microbial 
peptides such as defensins and cathelicidins (36). Both are capable of 
interacting with the negatively charged microbial cell membrane and cause 
damage by creating pore-like holes (37). In conjunction with this, epithelial cells 
secrete immunoglobulin A (IgA). IgA is the most abundant antibody within 
mucosal secretions and is released in a dimeric form (dIgA). dIgA is produced 
by plasma cells within lymphoid tissue and then trancytosed across epithelial 
cells, mediated by the polymeric immunoglobulin receptor (pIgR) (38). pIgR 
binds dIgA at the basolateral membrane of the epithelial cell and the complex is 
then displayed at the apical surface. Subsequently the complex undergoes 
proteolytic cleavage, resulting in secretion of dIgA at the mucosal surface. 
Secretory IgA (sIgA) is able to bind bacterial epitopes, preventing commensal 
bacteria from adhering to the mucosal surface. A small pIgR derived polypeptide 
remains within the sIgA structure after cleavage. Termed the secretory 
component it maintains stability of the antibody and helps anchor sIgA to the 
mucus layer. Furthermore, sIgA can inhibit microbial motility via unspecific 
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binding of bacteria through the presence of sticky glycan molecules. sIgA is able 
to neutralise pathogens not only within the lumen but also within intestinal 
epithelial cells themselves. Moreover, it can carry out its functions without 
activating complement, thus preventing any untoward inflammation within the 
gut (39). Antimicrobial peptides and IgA are thought to be extremely important in 
preventing invasion at the mucosal surface. However, within the large intestine 
there are no paneth cells present, therefore no anti-microbial peptides are 
produced. Recently, a study by Okumura et al. identified the molecule Lypd8 in 
the mouse colon (40). It was shown that this highly glycosylated protein is 
expressed in epithelial cells at the uppermost layer of the large intestinal gland 
and is secreted into the intestinal lumen. Lypd8 preferentially bound to 
flagellated bacteria, including those from the Proteus, Helicobacter and 
Escherichia genera. This binding inhibited bacterial motility and prevented 
invasion of the inner mucus layer (40).  In the human colon Lypd8 was also 
present, however expression was reduced within samples obtained from IBD 
patients (40). Proteus and Helicobacter have both been associated with IBD 
pathogenesis (41-43). In relation to this, it was found that Lypd8 -/- mice had 
increased numbers of these bacteria invading the inner mucus layer and 
intestinal crypts of the large intestine. Furthermore Lypd8 -/- mice also had an 
amplified susceptibility to dextran sodium sulphate (DSS) induced inflammation 
(40). This data indicates that Lypd8 is important for segregation of intestinal 
bacteria within the colon to preserve gut homeostasis. Furthermore, loss of 
Lypd8 may be important within intestinal disease. 
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Figure 1.3 Representative diagram of the epithelial layer of the small and large 
intestine. 
Epithelial cells form a barrier between the microbiota within the lumen and the lamina 
propria, joined together by tight junctions (TJs). Mucus layers are present to prevent 
bacterial invasion alongside the secretion of anti-microbial peptides and IgA. IgA is 
released from plasma cells that differentiate in gut associated lymphoid tissue (GALT) 
before travelling to the lamina propria. Lypd8 secretion occurs in the large intestine. 
Small intestine 
Large intestine 
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1.2 Immune responses 
All leukocytes arise from hematopoietic stem cells (HSCs) residing within the 
bone marrow. Various growth factors such as IL-2, IL-4, GM-CSF and flt3 ligand 
are produced to support HSC differentiation into downstream lineages by bone 
marrow stromal cells. This includes cells of the innate arm of the immune 
system such as macrophages, neutrophils, eosinophils, basophils and dendritic 
cells. During pathogen invasion innate cells respond first, recognising foreign 
antigens in a non-specific manner via pattern recognition receptors (PRRs). 
Receptors such as TLRs or C-type lectins can recognise conserved features of 
foreign pathogens such as lipoteichoic acid on the cell wall of Gram-positive 
bacteria, LPS on the membrane of Gram-negative bacteria, flagellin, double 
stranded RNA or b-glucans found within fungal cell walls. Furthermore, 
molecules released by stressed or necrotic cells such as HMGB1 and IL-33 can 
trigger activation of innate cells via danger associated molecular pattern 
receptors (DAMPs).  Activation of innate cells results in pathogens being 
engulfed and destroyed by the release of toxic chemicals (superoxide) and 
degradative enzymes (lysozyme). 
Following initiation of the innate response an adaptive immune response is 
generated. This is a delayed but specific response, produced by T and B 
lymphocytes. Like innate cells, B cells develop within the bone marrow. 
However, T cell pre-cursors migrate from the bone marrow to mature within the 
thymus before being released into the circulation. 
 
1.2.1 T cell development in thymus 
It was work carried out by Miller and colleagues in the 1960s that first suggested 
that the thymus supported T cell development. Early studies showed that mice 
without a thymus from the time of birth were susceptible to infection, had 
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atrophic lymphoid structures and had low levels of circulating lymphocytes (44). 
Furthermore, Miller demonstrated that foreign skin grafts from rats were able to 
survive within athymic mice, while wild type mice showed rejection (44). Also 
observed was that removal of the thymus was associated with a marked 
reduction in the number of lymphocytes in lymphoid tissues. However, numbers 
were not as reduced in areas where antibody formation usually occurred. This 
led to investigations demonstrating that two distinct and separate lymphocyte 
lineages existed, one derived from the thymus: the T cell, and one responsible 
for antibody production: the B cell. 
 
Mechanisms behind thymic T cell development are now better understood and 
have shown that education of T cells within the thymus is critical for the 
development of central tolerance. Reported by Owen et al., lymphoid progenitor 
cells seed the thymus as early as embryonic day (ED) 11.5 in mice (45) and by 
the eighth week of gestation within humans (46). T cell precursor entry to the 
thymus initially occurs in a vasculature independent manner during 
embryogenesis, with CCL21 and CCL25 having a role. In plt/plt mice that 
naturally lack CCL21 and within CCR7 (the receptor for CCL21) deficient mice, 
numbers of thymocytes were lower compared to normal mice until ED 14.5 (47).  
Furthermore, mice deficient in CCR9, the receptor for CCL25 had a 3-fold 
decrease in the number of thymocytes until ED 17.5 (48). In the postnatal 
thymus progenitor cells are located in an area harbouring a well-developed 
blood supply, close to the medullary junction. This indicates that cells can 
transmigrate from the vasculature system into the thymus. Studies report this 
migration is regulated by the adhesive interaction of PSGL1 expressed on 
progenitor cells and P-selectin expressed by thymic endothelium (49).  
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Once in the thymus progenitor cells undergo development into T cells, however 
approximately only 1-3% of all thymocytes succeed survival and export into the 
circulation (50, 51).  Upon entry thymocytes migrate to the outer subscapsular 
zone of the thymic cortex and generate a random TCR via VDJ recombination. It 
is thought that at this stage T cells commit to being an αβ or γδ T cell (52). Both 
T cell types are present within vertebrates but have key differences. γδ cells, 
unlike αβ T cells are located primarily at epithelial surfaces and are able to 
recognize and respond to a broad range of antigens. This includes non-classical 
MHC molecules, heat shock proteins, and lipids (52). In contrast, αβ T cells 
recognise antigens via classical MHC/peptide complexes and are found 
primarily within lymphoid tissue. Within the subcapsular zone of the thymus αβ T 
cells will also up-regulate the co-stimulatory molecules CD4 and CD8, to 
become double positive (DP) cells. DP cells will undergo a process of positive 
selection with cortical thymic epithelial cells expressing MHC/peptide 
complexes. Thymocytes able to recognise the MHC/peptide complex are 
provided with survival signals such Psmb11 and cathepsin, for the selection of 
CD8+ and CD4+ cells respectively (53, 54). The now single positive (SP) 
thymocytes undergo a process of negative selection within the thymic medulla, 
migrating there via CCR7 and CCL21/CCL19 chemokine interactions. Here 
CD4+ and CD8+ T cells interact with APCs such as medullary thymic epithelial 
cells (mTECs) and dendritic cells, leading to the deletion of auto-reactive T cells. 
mTECs are able to express many tissue restricted antigens (TRA), allowing for 
the deletion of T cells that are specific for antigens found within the periphery. 
Anderson and colleagues showed that expression of TRAs is regulated by the 
transcription factor Aire within mTECs. Insulin and casein are prime TRA 
examples (55). Aire deficient mice have an autoimmune phenotype with 
autoantibody production and inflammatory cell infiltration into multiple tissues 
(55). This is also seen within human Aire deficiency, which results in 
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autoimmune polyendocrinopathy syndrome type 1 (APS-1) (56). Another 
transcription factor, Fezf2, has been identified as a regulator of TRA expression 
(57). mTECs can be classified into mTEChi and mTEClo based on expression of 
MHC class II and CD80. It was found that approximately 30-40% of mTECs are 
mTEChi and express Aire. Meanwhile 40-50% of mTECs are mTEClo, 
expressing Fezf2 and are Aire negative (58). A Fezf2 conditional knockout 
model showed upregulation of CCL2, secretion of autoantibodies and an 
increased number of activated T cells in secondary lymphoid organs. In addition, 
as with Aire deficiency, cellular infiltration into tissues was increased. However, 
the spectrum of autoimmunity did vary from Aire deficient mice, indicating that 
Fezf2 and Aire regulate different TRAs (58). This leads to deletion of different 
auto-reactive T cells and an altered autoimmune phenotype.  
 
Once educated, mature thymocytes must leave the medulla and enter the 
circulation. Egress from the adult thymus requires the sphingosine-1-phosphate 
receptor 1 (SIP1). This receptor is expressed by mature thymocytes and binds to 
the high concentration of circulating S1P in serum (59). Due to thymic education 
T cells now in circulation are governed by central tolerance to prevent auto-
reactivity and autoimmunity.  
 
The co-receptors CD4 and CD8 distinguish T helper and cytotoxic T cells, 
respectively. Cytotoxic T cells can kill their target in a cell-to-cell contact manner 
through the release of enzymes such as granzyme B and perforin. They are 
activated through the recognition of peptide/MHC class I on APCs. Helper CD4+ 
T cells recognise peptide/MHC class II complexes. They coordinate the immune 
response through supporting cytotoxic T cell responses, macrophage activation, 
and aiding B cells to produce antibody. There are many different subtypes of 
CD4+ T cells with Th1 and Th2 being the first identified. However, regulatory T 
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cells (Tregs), Th22, Th9, T follicular helper and Th17 cells have subsequently 
been discovered; all of which have various functions in order to maintain a broad 
response to infection and disease. Th1, Th17 and Treg cells are thought to be 
relevant to colorectal cancer, the disease focused on within this thesis.  
 
1.3 T helper cell subsets 
1.3.1 Th1 cells 
	
It was formally shown in 1986 that mouse CD4+ cells could be subdivided into 
two subsets, designated Th1 and Th2 on the basis of their pattern of cytokine 
production (60). This was made possible due to technical advances within the 
field; the ability to clone T cells and the development of cytokine assays. 
Mossman and Coffman were able to investigate the cytokine production of a 
stable panel of T cell clones, observing that cells stimulated with antigen could 
produce IL-2, IFN-γ, GM-CSF and IL-3. These cells are now known as Th1 cells 
which can also produce TNF-α and lymphotoxin-α (LT-α) to potentiate their 
effector functions (61). In contrast Th2 cells produce IL-4 and IL-5 (60). It was 
also noticed that Th1 and Th2 cells were associated with different classes of 
antibody production. Th2 cells enhance IgE synthesis while Th1 cells promote 
IgG2a release. This was in keeping with the finding that IL-4 controls class 
switching to IgE, and IFN-γ controls switching to IgG2a (62). 
 
In the early 1990s the group of Romagnani identified Th1 and Th2 cells within 
human peripheral blood (63). This was achieved using large panels of CD4+ T 
cell clones, specific for the intracellular bacterium Mycobacterium tuberculosis 
and for the extracellular helminth Toxacara canis. It was observed that 
M.tuberculosis mostly stimulated IFN-γ production while Toxocara clones were 
mainly IL-4/IL-5 producers (63).  
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1.3.1.2 Th1 cell development  
Bacterial antigens drive dendritic cells and macrophages to produce IL-12, 
which is the key cytokine required to drive Th1 cell development. IL-12 
stimulation promotes Th1 cell activation and expansion through transcription 
factors STAT-1 and STAT-4, required to induce the transcription factor T-bet 
(TBX21 in humans). T-bet is essential as it binds to the IFN-γ promoter to 
induce its secretion. On the other hand IL-4 is required to promote Th2 
expansion through activation of the transcription factors STAT-6 and GATA-3.  
 
1.3.1.3 Th1 cells in disease 
Uncontrolled Th1 responses have been associated with many inflammatory 
diseases such as rheumatoid arthritis, multiple sclerosis and IBD. The hallmark 
of Th1 cell infiltration is increased levels of IFN-γ, as well as TNF-α, seen within 
all the aforementioned conditions. Treatments to reduce Th1 associated 
immunity have proved beneficial in some cases, such as anti-TNF-α, which can 
reduce inflammation in IBD. However, recent studies have revealed that the 
Th17 subtype of CD4+ T cells also contribute to the pathogenesis of such 
diseases, inducing inflammation and autoimmunity alongside Th1 cells.  
 
1.3.2 Th17 cells 
Prior to the discovery of Th17 cells, studies had already suggested a role for the 
Th17 associated cytokine IL-17A, first described by Rouvier et al. (64), within 
inflammatory conditions. In vitro work demonstrated that IL-17A was associated 
with IL-8 secretion to recruit neutrophils to sites of inflammation. IL-17A deficient 
mice also showed resistance to the development of inflammatory arthritis (65). 
In 2005 Park and colleagues first described CD4+ Th17 cells within mice, 
observing that they are capable of producing IL-17A (66). Further studies have 
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shown Th17 cells can also secrete IL-17F, IL-21 and IL-22. However, IL-17A is 
the most well studied Th17 associated cytokine. IL-17A is mainly produced by 
activated Th17 cells but can also be produced by gd, NK T cells and ILC3s. 
Binding of IL-17A to its receptor, which is found on many cell types including 
neutrophils, macrophages and non-haematopoietic cells such 
as fibroblasts and epithelial cells, stimulates the transcription factor TRAF6 via 
the adapter protein ACT-1. This leads to the activation of NFkB and MAPK 
pathways. This results in increased activation of macrophages and endothelial 
cells to produce mediators such as IL-6, IL-8, TNF-a, IL-1b, GM-CSF, PGE2, 
nitric oxide and matrix metalloproteinases. Other important roles of IL-17A 
include the recruitment of granulocytes, upregulation of chemokine receptors 
and aiding in T cell proliferation (67) (68). 
 
IL-17A secretion by Th17 cells is strongly induced by IL-23, which is released by 
macrophages and dendritic cells. IL-23 shares a subunit, called p40, with the 
Th1 promoting cytokine IL-12. In vivo studies demonstrated that IL-23 was 
important for the development of autoimmune brain inflammation within 
experimental autoimmune encephalomyelitis (EAE), the mouse model of 
multiple sclerosis (69). Until this discovery in 2003 it had been assumed that IL-
12 and Th1 development was the main driver of this disease. To determine the 
involvement of IL-23, Cau and colleagues used a series of genetically modified 
mice: p19-/- mice that lack IL-23, p35-/- mice that lack IL-12 and p40-/- mice that 
lack both cytokines. It was found that only mice lacking both IL-23 and IL-12 
were resistant to EAE development (69). Control animals showed that p19+/- 
mice and p35-/- mice had concentrated cellular infiltration of the spinal cord but 
this was not detected when IL-23 was absent, shown in p19-/- and p40-/- animals. 
The group also demonstrated that gene transfer of IL-23 into the CNS of p19-/- 
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and p40-/- mice reconstituted EAE. Furthermore, by administering IL-12 and IL-
23 to p40-/- mice it was observed that IL-12 alone was not sufficient to stimulate 
disease. However, IL-12 followed by IL-23 gave intense EAE comparable to that 
seen within WT control mice (69). This data provided evidence to show that IL-
23 and not IL-12 signalling was key to EAE development. As IL-23 was 
associated with IL-17A producing cells such findings at the time supported the 
idea that a subset of T cells existed with particular IL-17A secreting functions. 
 
1.3.2.1 Th17 cell maintenance 
Reports show that IL-6, IL-21 and low doses of transforming growth factor-β 
(TGF-β) are required for the differentiation of naive T cells into Th17 cells 
(70). Up-regulation of the transcription factors STAT-3 and RORγt are also 
essential. RORC is the homologue for RORγt in humans. Yang and 
colleagues demonstrated the importance of STAT-3 using a cre-recombinase 
STAT-3 KO mouse, developed as STAT-3 knockdown is embryonically lethal 
(71). Investigations demonstrated that upon stimulation of STAT-3 deficient 
CD4+ cells, surrounded by a cocktail of Th17 promoting cytokines, RORγt 
expression and IL-17A secretion were reduced. Furthermore STAT-3 was 
required for up-regulation of the IL-23 receptor on Th17 cells, important for 
stabilisation of Th17 cells (71). In another study, Ivanov et al. showed that 
RORγt drives cytokine release from Th17 cells. Using RORγt deficient mice it 
was observed that IL-17A production from CD4+ T cells was drastically 
reduced compared to WT animals (72).  
 
Th17 cells and Th1 cells express different chemokine receptors. Th1 cells 
circulate lymphoid tissues and gain entry into sites of inflammation, with 
CXCR3 and CCR5 being the main chemokine receptors expressed. CXCR3 
and CCR5 bind a variety of chemokines such as CXCL9, CXCL10, CXCL11 
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and CCL3, CCL4 and CCL5, respectively. However, Th17 cells primarily 
home to mucosal sites such as the gut and skin, through expression of the 
chemokine receptor CCR6 that binds to CCL20 (73). One function of IL-17A is 
to promote chemokine expression, guiding Th17 cells to the intestine where 
there is a multitude of pathogens. This associates with findings showing the 
importance of Th17 cells in the defence against extracellular bacteria and 
fungi, where Th1 and Th2 cells are less effective. In particular Th17 cells are 
important for responses against the fungal pathogen Candida albicans. 
Patients failing to clear Candida infections suffer from chronic mucocutaneous 
candidiasis and have extremely low levels of IL-17A production (74). 
Mutations within the transcription factor STAT-3 are associated with 
autosomal dominant Hyper IgE syndrome, characterized by elevated IgE 
levels as well as recurrent skin and pulmonary infections (75). As STAT-3 
induces Th17 cell differentiation and IL-17A signalling, which leads to 
neutrophil recruitment and enhanced survival of macrophages, patients 
present with impaired innate responses. Consequently, patients often suffer 
with recurrent infections. 
 
Importantly IL-17 and IL-22 play a role in the expression of antimicrobial 
peptides such as defensins at mucosal sites. IL-22 is thought to defend 
against pathogens including bacteria within the intestine as its receptor is 
expressed on intestinal epithelial cells. In support of this, IL-22 deficient mice 
show increased susceptibility to infection with Clostridium rodentium, an 
enteric mouse pathogen compared to WT control mice (76).  
 
1.3.2.2 Development of Th17 cells by the microbiota  
As mentioned previously intestinal epithelial cells, as well as segregating 
bacteria, have the role of mediating the crosstalk between the microbiota and 
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host immune cells. A prime example comes from the development of Th17 cells 
in the intestine. Germ-free mice lack Th17 cells but they develop upon 
microbiota colonisation. In particular Ivanov and colleagues observed that 
experimental mice obtained from different vendors displayed marked differences 
in Th17 cell proportions within the gut (77). Furthermore, transfer of microbiota 
from one vendor but not the other into germ free mice resulted in Th17 cell 
development. The group were able to demonstrate that signals from a specific 
commensal microbe called segmented filamentous bacteria (SFB) transferred 
into germ free Swiss Webster mice resulted in robust accumulation of Th17 cells 
in the lamina propria of the small and large intestine. SFB, which are gram-
positive, anaerobic, spore-forming bacteria, were sufficient to induce strong IL-
17 and IL-22 production from CD4+ T cells (77). Moreover, SFB did not affect 
IFN-γ secretion or alter other IL-17A secreting cells (NK or γδ T cells) indicating 
specificity for Th17 cell induction. A member of the acute phase response 
proteins called serum amyloid A (SAA-1), which is induced during infection and 
inflammation is also generated in response to SFB colonisation. SAA-1 can act 
as a cytokine, inducing IL-8 and TNF-α within neutrophils as well as IL-23 in 
monocytes and intestinal epithelial cells. Co-cultures of naïve CD4+ T cells with 
intestinal lamina propria derived DCs demonstrated that through SAA-1 
induction of IL-23, DCs stimulate a Th17 differentiation program with 
upregulation of effector cytokines and RORγt (77). In a follow up study in 2014 
the group provided in vivo evidence that CD11c+ DCs and macrophages can 
promote Th17 differentiation through MHC class II presentation of SFB antigens 
(78, 79) (Figure 1.4). 
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Figure 1.4. Colonisation with SFB induces Th17 cells.  
SFB adhere to intestinal epithelial cells stimulating the release of SAA. SAA acts upon 
neutrophils and DC to express cytokines including IL-8, IL-1β, TNF-α and IL-23, 
respectively. IL-23 promotes Th17 cell development. SFB antigens are also presented 
by intestinal macrophages and DCs to induce Th17 cells. This leads to IL-17 and IL-22 
production, stimulating antimicrobial peptide release by epithelial cells. 
 
1.3.2.3 Th17 cells in inflammatory bowel Disease (IBD) 
Th17 cells are protective at mucosal sites but their involvement in intestinal 
disease has been recognised by many groups. IBD describes mainly two 
conditions: Ulcerative colitis (UC) and Crohn’s disease (CD). The pathologies 
are characterised by ulceration of the mucosal lining of the intestine, resulting in 
symptoms such as abdominal pain, chronic diarrhoea, fever and rectal bleeding. 
As well as Th1 cells, the inflamed gastrointestinal mucosa harbours a large 
infiltration of Th17 and IL-23 producing cells, accompanied by inflammatory 
cytokines (80). Moreover, increased expression of IL-17A mRNA can be 
detected in faecal content during active CD as well as within gut tissue (80). 
Genome wide association studies (GWAS) have reported that several 
polymorphisms in Th17 related genes, such as STAT-3 and the IL-23 receptor 
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associate with IBD susceptibility, supporting a role for Th17 cells in disease 
pathogenesis (81, 82). Shown by CD4+ T cell transfer models, Th1 cells and 
their associated cytokine IL-12 promote IBD inflammation. This can be 
abrogated with an anti-IL-12 monoclonal antibody, a treatment shown to have 
some effectiveness in human CD trials (83). However, as within EAE studies, it 
was proven that anti-IL-12 was also blocking IL-23 function. A study by Hue et 
al. demonstrated using two complementary models of intestinal inflammation (H. 
hepaticus triggered innate immune model and adoptive transfer of naive CD4+ T 
cells into C57BL/6 p35-/-, p19-/- and p40-/- RAG-/- recipients) that IL-23 was key to 
the promotion of gut inflammation (84). However, a new member of the IL-12 
family called IL-35 was identified relatively recently. IL-35 is comprised of the IL-
12 associated alpha subunit IL-12p35 as well as an EbI3 subunit. Therefore, 
mice deficient in p35 lack the IL-35 cytokine as well as IL-12. In light of this, it 
was suggested that IL-35 depletion might be masking the role of IL-12 in T cell 
mediated colitis. To clarify the contribution of IL-12 and IL-23 signalling Imamura 
and colleagues compared the efficacy of a monoclonal antibody against IL-
12/IL-23p40 with that of an anti-IL-23 specific subunit antibody, within CD4+ T 
cell transfer models in SCID mice. Results confirmed that IL-23 signalling is 
indeed essential for the development of intestinal inflammation with both IL-23R 
and IL-12/IL23p40 antibodies completely inhibiting the development of colitis 
(85). Furthermore, a study by Tang and colleagues has demonstrated that 
expression of SAA-1, the acute phase protein shown to drive Th17 responses, is 
associated with intestinal inflammation in IBD (86). Together this data suggests 
a link between Th17 cells, the microbial community and IBD pathogenesis. 
 
On the other hand, some studies in experimental models of colitis have reported 
a tissue protective role for Th17 cells. For example, neutralisation of IL-17A 
within mice was found to aggravate dextran sodium sulphate (DSS) driven 
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intestinal inflammation (87). Furthermore, compared to WT mice, IL-22 deficient 
mice show increased inflammatory processes during DSS treatment also (88). It 
has been suggested that a reduction in Th17 cells actually reduces tissue 
protective responses, such as the release of anti-microbial peptides, efficient 
epithelial cell proliferation, goblet cell mucus production and claudin regulation 
within TJs (89). In agreement with this there has been little success in human 
trials aiming to target IL-17A. For example, even though the drug secukinumab 
demonstrated beneficial effects of IL-17A blockage in psoriasis and rheumatoid 
arthritis studies, there was no therapeutic effect of neutralising IL-17A in a study 
enrolling 59 CD patients (90). Secukinumab actually had higher rates of adverse 
events (fungal infections) than the placebo arm of the trial (90). In contrast 
promising data has emerged from a biological therapy called Ustekinumab. It 
targets both IL-12 and IL-23 cytokines, via blocking the shared p40 subunit (91). 
Data from phase 2 and 3 trials showed good induction and maintenance of 
clinical responses in CD patients. There were significant reductions in disease 
associated C-reactive protein and fecal calprotectin levels. Ustekinumab was 
recently been approved for used by the FDA in 2016 (91). Other IL-23 blocking 
antibodies are under investigation with the hope of inhibiting in part the 
development of pathogenic Th17 cells. 
 
1.3.2.4 Th17 cell plasticity 
It has been established that once a CD4+ T cell commits to a Th1 or a Th2 
lineage, conversion to any other lineage is not possible, thus resulting in stable 
phenotypes. However, Annunziato and colleagues reported that within the 
intestine of CD patients Th17 cells could secrete both IFN-g and IL-17A (92). In 
vitro experiments using PMA/ionomycin demonstrated that incubation of Th17 
cells with the Th1 promoting cytokine IL-12 led to the production of IFN-g and IL-
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17A (Th1/Th17 cells) or IFN-g instead of IL-17A (non-classical Th17 cells). 
Furthermore, IL-12 stimulation upregulated the Th1 associated transcription 
factor T-bet and down regulated RORγt expression, indicating that Th17 cells 
can convert to a Th1 phenotype. Analysis of Th17 cell clones expanded in vitro 
showed selective expression of IL-23R, CCR6 and RORγt. Both Th17 and 
Th17/Th1 cells were able to aid in B cell antibody production and had low 
cytotoxic potential (92). Continuing with this work, Cosmi et al. observed that 
Th1 cells derived from Th17 cells express CD161, a Th17 cell progenitor 
marker, unlike conventional Th1 cells (93). This could make it possible to 
identify IFN-g secreting cells that were originally Th17s. 
The role of Th17/Th1 IFN-g/IL-17A producing cells in disease is not understood. 
However it has been shown that IBD patients have increased numbers of these 
dual producing cells within peripheral blood and gut tissue compared to healthy 
controls (92).  In a study by Harbour et al., a Th17 transfer model was used to 
evaluate Th1/Th17 cells within colitis (94). Th17 polarized cells were generated 
from IL-17FThy1.1 mice, utilised as IL-17F is a dominant cytokine expressed early 
on during Th17 cell commitment. Transfer of IL-17FThy1.1 Th17 cells into Rag 
deficient recipients resulted in a faster onset of colitis but with a severity 
comparable with that seen by transfer of CD45RBhi CD4+ naïve T cells. It was 
observed that three distinct subsets arose from the transferred cells: IL-17A only 
expressing, IL-17A/IFN-g expressing and IFN-g only expressing Th17 cells. 
Interestingly transfer of Th17 cells polarized from IFN-g-/- mice into rag deficient 
recipients failed to induce intestinal inflammation, indicating that IFN-g 
expression from Th17 cells is required for colitis development (94). It has been 
highlighted that pathogens can also influence cytokine production from Th17 
cells. In vitro and in vivo evidence shows that naïve CD4+ T cell stimulation with 
C.albicans mostly resulted in Th17/Th1 cells, secreting both IFN-γ and IL-17A, 
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with upregulation of both T-bet and RORγt expression (95). In contrast 
stimulation with S.aureus resulted in IL-17A secretion from Th17 cells with no 
IFN-γ production and no T-bet expression. However, after re-stimulation with 
antigen pulsed APC or CD3/CD28 stimulation C.albicans and S.aureus-specific 
cells transiently downregulated IL-17A expression, regaining the original 
cytokine profile as cells reverted to the resting state. S.aureus-specific but not 
C.albicans-specific cells also were able to secrete IL-10, demonstrating 
regulated expression of IL-17A by certain microorganisms (95).  
 
1.3.3 T regulatory cells (Tregs) 
Tregs are a CD4+ T helper subset capable of regulating the activity of other 
immune cells. T cell mediated immunosuppression was identified not long after 
it was discovered that the thymus was a key component of the immune system. 
Original studies by Nishizuka and Sakakura showed that thymectomy of day 3 
neonatal mice resulted in autoimmunity, while thymectomy at 7 days did not. 
This indicated that suppressive cells are released from the thymus after 
conventional T cells (96, 97). In 1995, Sakaguchi and colleagues convincingly 
showed that CD4+ suppressive cells migrating from the thymus after day 3 could 
be identified by expression of the IL-2 receptor, CD25 (98). Elimination of CD4+ 
CD25+ cells from BALB/c mice triggered the production of circulating 
autoantibodies and the generation of inflammatory lesions within a wide range of 
organs. The resulting histopathology was similar to that seen within human 
autoimmune diseases such as autoimmune-gastritis, systemic lupus 
erythematosus and rheumatoid arthritis (98). Restoring the CD4+ CD25+ cell 
population prevented autoimmune disease. Furthermore, CD4+ CD25+ cells 
could transfer tolerance to lymphopenic and thymectomy mice, indicating that 
CD25 expressing CD4+ cells were important for maintaining peripheral tolerance 
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by T-cell mediated control of self-reactive T cells (98, 99). The discovery of the 
CD25 marker converged with a population of Tregs identified as CD45RBlo, 
shown to prevent the generation of colitis upon transfer. However, subsequent 
studies showed that the majority of regulatory activity within the CD45RBlo group 
was restricted to CD25+ cells, validating CD25 as a good marker for suppressive 
T cells (100). Due to their ability to suppress immune responses to both self and 
foreign antigen, now known as Tregs, these CD4+ CD25+ suppressive cells have 
not only been implicated in autoimmune disease but also in tolerance, allergy 
and anti-tumour immunity (discussed later).  
 
Although initially CD25 was beneficial for identifying Tregs, the downside was 
that activated conventional T cells also transiently express CD25. Many 
investigations led to a number of markers being associated with Tregs, including 
expression of GITR, CTLA-4, LAG-3 and CD127 (101). Nonetheless, transient 
expression on other T cell subsets during activation was again an issue.  
However, discovery that the transcription factor Forkhead box 3 (FoxP3) is 
highly expressed in CD4+ CD25+ but not in CD4+ CD25- cells fundamentally 
altered Treg characterisation (102) . Today, Tregs are typically identified using a 
combination of markers and are characterised as being CD3+, CD4+, CD25+ 
FoxP3+ and CD127lo/- (103). For experimental procedures surface markers 
remain crucial for Treg isolation. As Foxp3 is found intracellular, requiring 
permeabilisation of cells for staining, most often CD4+ T cells are sorted based 
on high CD25 expression and low CD127 expression, a marker found to be 
down regulated on suppressive T cells in peripheral blood (104). Of note, 
Foxp3+ CD25- cells do also exist (3-5% of PBMC) and in vitro studies have 
shown they can have suppressive abilities (104).  
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1.3.3.1 Identification of Foxp3 
Observations of patients with the severe autoimmune condition immune 
dysregulation polyendocrinopathy X-linked syndrome (IPEX) led to the 
identification of FoxP3 as a marker for Tregs (105). Alongside this, the Brunkow 
group investigated the scurfy mouse, which was originally described by Godfrey 
et al. as having a general autoimmune phenotype, similar to that seen in IPEX 
patients (106). Brunkow and colleagues identified that the FoxP3 gene, part of 
the forkhead/winged-helix protein family of transcriptional regulators was 
defective due to a frame shift mutation within scurfy mice. This results in hyper-
responsiveness of CD4+ T cells and the onset of autoimmune disease, 
characterised by wasting and multi-organ-lymphocytic infiltrates (107). A study 
by Fontenot et al. then reported that FoxP3 is highly expressed in CD4+ CD25+ 
Tregs and that it is required for Treg cell development, with FoxP3 deficient 
mice lacking a Treg population (102). Furthermore, the authors showed that 
expression of FoxP3 is required to promote the suppressor functions of Tregs. 
CD4+ CD25- T cells transduced with a retrovirus expressing FoxP3/GFP or GFP 
alone were injected into RAG deficient mice. Mice given the GFP-CD4+ CD25- 
cells developed autoimmune wasting disease but animals receiving the 
FoxP3+/GFP-CD4+ CD25 cells displayed no signs of disease for the entire 
experimental period (102). The data highlighted that the lethal autoimmune 
syndromes seen in scurfy mice and IPEX result from Treg deficiency rather than 
a cell intrinsic defect of Tregs (102). In a follow-up study Fontenot and 
colleagues developed a Foxp3GFP reporter mouse to investigate FoxP3+ Tregs 
during ontogeny. The group were able to demonstrate as originally suggested 
by Nishizuka and Sakakura and then by Asano et al., that FoxP3 expressing 
Treg development is substantially delayed in the thymus relative to conventional 
thymocytes (96, 99, 108). In 2007 the same group developed a new mouse 
strain, engineered to express the diphtheria toxin receptor under the FoxP3 
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gene promoter. Therefore in this system selective depletion of FoxP3+ cells 
could be achieved upon injection with diphtheria toxin, resulting in an 
autoimmune phenotype similar to that seen in FoxP3 deficient mice (109). 
 
1.3.3.2 Survival and maintenance of Tregs 
Unlike conventional T cells, Treg survival and proliferation is strictly dependent 
on IL-2. IL-2 deficient mice are deficient in Tregs (110). Also shown to be 
necessary for Treg survival is TGF-b. TGF-b knockout mice are also deficient in 
Tregs. Marie and colleagues demonstrated that this is due to down regulation of 
FoxP3 within the periphery as thymic output of Tregs was normal (111). Also 
important are co-stimulatory molecules such as CD28 and ICOS, both of which 
provide survival and proliferation signals to Tregs. 
 
1.3.3.3 Treg subsets 
Several lines of evidence suggest that FoxP3+ Tregs consist of two 
developmentally different subsets: thymus-derived Tregs (tTreg) and peripheral-
derived Tregs (pTreg). tTregs develop from the thymus while pTregs arise from 
the thymus as conventional T cells but can convert to FoxP3 expressing Tregs 
in peripheral tissues.  
1.3.3.3.1 tTregs 
tTregs develop independently of environmental stimulation, subjected to positive 
and negative selection processes like conventional thymocytes in the thymus. It 
is thought that tTregs are generated as a result of thymocytes recognising self-
MHC/peptide complexes with avidity higher than that of conventional T cells but 
not too high to avoid negative selection. A study by Jordan et al. took advantage 
of transgenic mice that have T cells bearing a high avidity TCR specific for the 
common influenza protein haemagglutinin (HA) (112). The mice were crossed 
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with transgenic animals expressing the HA protein. It was found that in double 
transgenic mice (expressing both TCR and antigen) the CD4+ cells specific for 
HA were not clonally deleted but in fact a large proportion (30%) of the 
population were CD25+ cells. In contrast only 13% of peripheral T cells were 
CD25+ within HA transgenic animals. This indicates that specificity for self-
peptide is important for directing the selection of tTregs (112). After leaving the 
thymus tTregs can be found in circulation but mostly reside within the gut and 
peripheral lymph nodes in a quiescent state until activation (113).  
 
FoxP3 is not sufficient to distinguish tTregs from pTregs therefore a specific 
tTreg marker would be useful. In 2010 Shevach’s group published that Helios, a 
member of the Ikaros transcription factor family, could be detected in all 
thymocytes but only within a proportion of CD4+ FoxP3+ cells in peripheral 
tissues (114). The group showed that neither mouse nor human naive T cells 
induced to express Foxp3 in vitro by TCR stimulation or antigen specific FoxP3+ 
T cells induced in vivo expressed Helios. This suggested that Helios could be a 
specific marker for tTregs. However, further studies have disputed this, 
providing evidence that Helios expression can be induced in pTregs both in vitro 
and in vivo, possibly depending on APC derived influences (115). A second 
marker, neuropillin-1 has also been suggested as a tTreg marker(116), however 
again this has been disputed within the field (117).  
1.3.3.3.2 pTregs 
It is established that conventional CD4+ T cells can be converted into Tregs 
within the periphery. pTregs are generated upon TCR stimulation with cognate 
antigen in the presence of TGF-b. The intestinal lamina propria is the best 
example of an environment where pTregs thrive. Accordingly, upon adoptive 
transfer of TCR transgenic naïve FoxP3- CD4+ T cells, followed by oral exposure 
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to the cognate antigen an increased number of donor derived FoxP3+ pTregs 
can be detected within the gut (118). Interestingly it has been demonstrated that 
the autoimmune pathology associated with FoxP3 deficiency cannot be 
completely rescued by transfer of FoxP3+ tTregs alone. Co-transfer with FoxP3- 
CD4+ cells was required, indicating an essential non-redundant role for pTregs 
(119). The intestinal microbiota can also affect the generation of Tregs in the 
colon. Both germ free and antibiotic-treated animals have reduced Treg 
numbers and decreased expression of activation markers such as CTLA-4 and 
ICOS compared to wild type controls (120). However, in the small intestine the 
microbiota does not affect Treg numbers to the same extent. Instead reports 
indicate that Tregs within the small intestine accumulate in response to dietary 
antigens (121). pTregs generation is also dependant on interactions and signals 
from intestinal epithelial cells, macrophages, innate lymphoid cells and 
importantly dendritic cells (DC). There are various subsets of intestinal DCs but 
CD103+ DCs show the greatest ability to induce pTregs (122). In contrast 
CD103- DCs are not as effective. CD103+ DCs are migratory, potent antigen-
presenting cells that are able to sample luminal contents by extending dendrites 
across the intestinal epithelial barrier (123). pTreg generation by DCs relies on 
many factors. In particular the microbiota are capable of stimulating IECs to 
release of indoleamine 2,3-dioxygenase (IDO), thymic stromal lymphopoietin 
(TSLP) and WNT ligands. These condition DCs to express the receptor 
aldehyde dehydrogenase (ALDH) (124). ALDH is capable of metabolizing 
vitamin A from the gut into retinoic acid, which in combination with TGF-β 
promotes pTregs to differentiate (124). The gut homing markers CCR9 and 
a4b7 are also upregulated by retinoic acid (125). The ability of intestinal DCs to 
induce pTregs makes them a key driver of oral tolerance within the gut.  
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1.3.3.4 Mechanisms of Treg suppression 
Tregs have a multitude of mechanisms to suppress immune responses. This 
can be either direct by targeting effector T cells or indirect by targeting DCs to 
prevent immune activation of effector cells.  
1.2.2.4.1 Metabolic disruption 
Competition for IL-2 has been documented as a method of Treg suppression in 
many studies. Tregs express all components of the CD25 receptor, providing 
them with high affinity for IL-2 over conventional T cells that only express CD25 
after TCR activation (126). This leads to local cytokine deprivation and inability 
of conventional cells to proliferate and survive. Borsellina and colleagues have 
also demonstrated that CD39 expressed on both CD25+ and CD25- Tregs can 
disrupt effector cell function. Exogenous ATP is hydrolysed by CD39 into ADP 
and 5’AMP, which can be converted further by the ectonucleotidase CD73 
(127). Treatment with adenosine inhibitors has been shown to reverse this 
suppression (127).   
1.2.2.4.2 Suppressive cytokines 
Tregs can exert their suppressive effects through the release of soluble factors 
such as TGF-b, IL-10 and IL-35 (128). Li et al. have shown that TGF-b deficient 
animals develop T cell mediated autoimmunity a few weeks after birth and mice 
that lack TGF-b responsiveness show a similar phenotype (129, 130). It has 
been repeatedly observed that TGF-β is required for Treg survival but there has 
been some controversy over whether membrane bound TGF-β can suppress 
target cells in a cell-to-cell contact manner. A study by Nakamura et al. 
suggested that membrane bound TGF-β on Tregs could be delivered to CD25- T 
cells where it can be converted into an active form (131). Further analyses 
indicated that no active or latent TGF-β could be detected on the cell surface of 
resting FoxP3+ Tregs. However, after TCR activation a high number of Tregs did 
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show positive staining for LAP, presumably having expressed latent TGF-β. It is 
thought that release of TGF-β causes “infectious tolerance”, promoting further 
conversion of FoxP3- cells into FoxP3+ cells (132). 
Tregs also secrete the inhibitory cytokines IL-10 and IL-35. The use of IL-10 
blocking antibodies or IL-10 deficient Tregs diminishes the protective effect 
Tregs normally have in transfer models of colitis (133). Furthermore the IL-10 
locus was identified as a susceptibility region for the development of UC, 
highlighting an important role for IL-10 in abrogating intestinal inflammation 
(134). Collinson et al. have shown that IL-35 secretion by Tregs can directly 
inhibit the proliferation of conventional T cells (135). Further to this Wei et al. 
observed that IL-35 and IL-10 expressing Tregs have a distinct activation status, 
suggesting that IL-10 producing and IL-35 producing Tregs work in a co-
operative manner to maintain immune tolerance (136). 
1.2.2.4.3 Cytolysis  
Tregs possess cytotoxic activity to kill target cells. As shown by Gondek and 
colleagues this is through the secretion of granzymes A and B (137). It has been 
demonstrated this is in a perforin-dependent manner, with activated human 
Tregs able to eliminate various autologous immune cells (138). This suppressive 
mechanism has been shown to drive susceptibility to tumour growth. A mouse 
model of B16 melanoma adoptive transfer in granzyme B deficient recipients 
showed that WT Treg cells, but not granzyme B-/- or perforin-/- Treg cells 
prevented tumour clearance via the inhibition of anti-tumour NK and CD8+ T cell 
responses (139). Furthermore, engagement of Fas expressed on Tregs with 
FasL-bearing target cells results in the stimulation of a caspase-8 signalling 
pathway, capable of driving apoptosis of the target cell. Using cell lines, 
Janssens et al. observed that this mechanism could also kill antigen presenting 
B cells to down regulate immune responses (140). 
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1.2.2.4.4 Targeting dendritic cells 
Tregs also target DCs to alleviate effector immune responses. One of the most 
widely studied molecules involved is CTLA-4, which is highly expressed on 
Tregs. CTLA-4 binds to co-stimulatory molecules CD80/86, in direct competition 
with CD28 expressed on effector cells. CTLA-4 deficient mice develop 
spontaneous autoimmunity that can be abrogated by the transfer of WT Tregs. 
Studies also show that anti-CTLA-4 blocking antibodies are capable of 
abrogating Treg mediated suppression (100). Tregs can suppress DC activation 
further through expression of LAG-3, the CD4 homolog. LAG-3 is capable of 
binding MHC class II on DCs. This reduces binding of CD28 found on effector 
cells to MHC class II (141).   
 
1.4 Tumourgenesis  
1.4.1 Immunosurveillance  
Evidence arising from mouse and clinical observations show that the immune 
system plays an important role in surveying the body for transformed cells. Paul 
Ehrlich originally postulated that the host immune system could defend against 
nascent pre-malignant cells in the early 1900s. Sir Frank MacFarlane Burnet 
developed the theory of immunosurveillance further, hypothesising that antigens 
derived from tumours were capable of activating immune responses (142). This 
was following initial experiments by Foley in 1953, showing that tumours 
induced within mice by methylcholanthrene (MCA) were antigenic within the 
host (143).  
Advances in genetics then led to the generation of RAG KO mice in the 1990s. 
This made it possible to deplete NKT, B and T cells within mice while non-
lymphocyte linages remained. Shankaran and colleagues injected aged 
matched female RAG-2 deficient and WT mice with MCA, observing that RAG-2-
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/- mice developed tumours faster and had a higher tumour burden compared to 
control mice. This indicated a role for the adaptive immune system in chemically 
induced tumours (144). To investigate the development of spontaneous 
tumours, untreated RAG-2-/- and WT mice were evaluated for fifteen months. It 
was observed that 12/12 RAG-2-/- mice developed intestinal lesions within the 
intestine as well as in other locations. In contrast, no WT mice developed 
cancer. The authors also took a transplantation approach to investigate whether 
the immune system influenced the immunogenic phenotype of tumours. When 
RAG-2-/- mice received tumours derived from RAG-2-/- or WT mice, tumours 
grew progressively and with similar kinetics. WT mouse-derived tumours 
transplanted into WT immunocompentent hosts resulted in the formation of 
tumours in all recipients (17//17). However, it was observed that transplantation 
of RAG-2-/- derived tumours into WT recipients were rejected 40% of the time. 
The authors inferred that tumours developing in lymphocyte deficient animals 
are more immunogenic than those developing in immunocompetent hosts. The 
fact that fewer immunogenic tumours developed in the presence of an intact 
immune system implies that the anti-tumour response drives immunoselection of 
tumour cells that are capable of surviving (144). Links between the immune 
system and prevention of cancer development also became apparent through 
studies involving transplant patients and those suffering with AIDS. Both patient 
groups are comprised of immune compromised individuals and both groups also 
presented with higher rates of mainly virus-induced tumours (145).  
 
1.4.1.1 Immunoediting 
In 2002 the Schreiber group presented the three-step model of “cancer 
immunoediting” (146). The three steps are termed the three E’s of cancer 
immunoediting and are as follows: elimination, equilibrium and escape (146). 
Elimination describes the classical concept of cancer immunesurveillance, 
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where tumour cells are eliminated by the immune system. Early experiments 
identified that IFN-γ has a key role in this prevention. MCA tumours 
unresponsive to IFN-γ, due to a truncated chain in the IFN-γ receptor, showed 
enhanced tumourigenicity. Rapidly progressing tumours were formed compared 
to WT MCA tumours when transplanted into syngeneic recipients. However in 
SCID mice, which lack lymphocytes, both WT and IFN-γ insensitive tumours 
grew with similar growth characteristics, indicating that IFN-γ production by 
lymphocytes was important (147). In a follow up study, the same group 
evaluated the role of IFN-γ in the development of spontaneous tumours as 
opposed to transplanted tumours. Mice lacking the tumour suppressor gene p53 
were crossed with IFN-γ insensitive mice to create double KO animals. 
Compared to p53 single KO mice, double KO animals developed tumours 
significantly faster. Furthermore, unlike p53 single KO mice, double KO mice 
developed non-lymphoid tumours. Taken together the data demonstrated that 
IFN-γ does promote tumour surveillance (148). Other key immune molecules 
have been identified for being important for tumour surveillance including 
perforin and the TNF-related apoptosis-inducing ligand (TRAIL). Perforin is a 
cytolytic molecule, capable of making holes in target cells. Early studies showed 
that challenge with MCA in perforin-/- mice resulted in the formation of 2 - 3 times 
more tumours. Furthermore, ageing perforin-/- mice were found to spontaneously 
develop lymphomas at a much higher rate that WT mice.  
Activation of the innate arm of the immune system is also important for 
immunosurveillance. Cui et al. described the generation of a naturally occurring 
germline trait that resulted in a BALB/C mouse being able to resist the 
development of ascites after injection with the aggressive S180 sarcoma cell 
line (149). Further investigations revealed that mice with this trait were able to 
kill a range of both syngeneic and allogeneic tumours. When the trait was bred 
into nude mice, which lack a thymus, the enhanced resistance to tumour 
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development remained, suggesting that the innate immune response was 
responsible for the phenotype. In keeping with this finding, experiments where 
the apoptosis inducing molecule TRAIL, which is constitutively expressed on NK 
cells and dendritic cells as well as CD8+ T cells, is neutralised with mAbs, MCA 
tumour development is greatly increased (150). 
 
The equilibrium stage of immunoediting refers to a situation when some nascent 
cells have survived the elimination phase but are still being kept under control 
by the immune system. This is often termed immune mediated tumour 
dormancy. In a key paper, Koebel and colleagues investigated whether the 
equilibrium phase occurred during primary tumourigenesis (151). WT mice were 
injected with low dose MCA and monitored for tumour development. Mice that 
developed stable masses after approximately 200 days were then treated with 
mABs against immunological components. Results indicated a particular role for 
the adaptive immune system in maintaining tumour dormancy. Treatment with 
anti-, anti-CD8 and anti-IL12p40 caused progressively growing sarcomas at the 
injection site within mice that originally had stable tumours (151). In contrast 
monoclonal antibody treatment to deplete NK cells or inhibit TRAIL did not result 
in tumour outgrowth (151). The balance between anti-tumour effector cells such 
as CD4+/CD8+ T cells and numbers of suppressive cells such as Tregs is 
important for maintaining tumours in the equilibrium phase, with an increase in 
suppressive cells being linked to tumour escape (152).  
 
Ultimately the escape phase of immunoediting occurs when tumour cells 
proceed, unrestrained by the immune system and can form a clinically 
detectable mass. Studies have shown that tumour escape can be a direct result 
of alterations occurring in edited tumour targets themselves. In particular, loss of 
HLA class I antigens on tumour cells and other molecules in the antigen 
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presentation pathway such as TAP1 are frequently deficient in an effort to evade 
the immune system. Tumour cells can also upregulate molecules to promote 
proliferation and survival such as STAT-3 and BCL-2, respectively. Moreover, 
immune suppressive factors such as IDO, PDL-1 and CD39/CD73 can dampen 
effector immune responses and further recruit more immunosuppressive cells 
such as Tregs to the tumour microenvironment.  While tumour escape can occur 
naturally, it has been observed that immunotherapy treatments can also cause a 
selective pressure leading to tumour outgrowth (relapse).  
 
1.4.2 Colorectal cancer incidence 
CRC is the third most common cancer worldwide and second most common 
cause of cancer related death within the UK. Latest CRUK statistics show that 
over 41,000 new cases were reported in 2015 (153). While the 5-year survival 
rate for early-detected CRC is relatively promising (~90%), this dramatically 
reduces to less than 10% in patients with late stage metastatic disease. 
Recently a study has estimated that in 2018, across the European Union, CRC 
will have the second highest mortality rate of all cancers (154). It will account for 
approximately 180,000 deaths, mostly affecting the older generation (age 60+) 
(154). Interestingly studies suggest that CRC incidence is strongly related to diet 
and lifestyle with CRC mortality rates increasing faster than any other cancer 
type after migration to the Western world (155).  
 
1.4.3 Colorectal cancer aetiology  
Associated risk factors for CRC include increased age, obesity, alcohol, 
smoking, IBD and a poor diet, which includes an excess of red meat (156).  
Both sporadic and hereditary CRC exist. Hereditary CRC is associated with 
genetic conditions such as Lynch syndrome and Familial Adenomatous 
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Polyposis (FAP). However, sporadic CRC is most common, developing often 
from pre-existing adenomentous polyps through the accumulation of mutations 
arising in oncogenes and tumour suppressor genes.  
 
1.4.3.1 Hereditary CRC 
Heritable factors are associated with CRC development but only 5-10% are 
attributed to mutations within known CRC susceptibility genes. 
1.4.3.1.1 Lynch syndrome 
The pathologist Aldred Scott Warthin in the 1800s laid down the foundation for 
understanding the inherited cancer condition Lynch syndrome, providing the first 
comprehensive record of familiar clustering of cancer (157). However, it was not 
formally named until 1984 by Boland and Trancale (158). It is the most common 
form of hereditary CRC and is genetically heterogeneous. Most patients harbour 
pathogenic variants in one of four DNA mismatch repair (MMR) genes: MLH1, 
MSH2, MSH6 or PMS2. Patients can also display germline mutations in the 3’ 
end of EPCAM that can lead to gene silencing of MSH2 (157). As MMR genes 
are the post-replicative proof reading and editing machinery required to maintain 
genome integrity, inactivation leads to the accumulation of genetic mutations, 
driving microsatellite instability (MSI) and an increased risk of developing 
cancer. However, identification of Lynch syndrome can often be challenging as 
MMR protein deficiency can also occur within some sporadic forms of CRC. A 
recent study by Pai et al. investigated the expression of MMR proteins in non-
neoplastic intestinal mucosa obtained from colorectal surgical resection 
specimens from patients with Lynch syndrome-associated CRC and from non-
Lynch syndrome CRC patients (159). Results showed that MMR protein 
deficient non-neoplastic colonic crypts could be detected within Lynch patients 
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but could not be detected in those with sporadic MMR protein deficiency, 
suggesting a possible additional method for diagnosing Lynch syndrome (159). 
1.4.3.1.2 Familial adenomatous polyposis (FAP)  
FAP is an autosomal-dominant colorectal cancer syndrome, with patients 
presenting with hundreds or sometimes thousands of colonic adenomas. Onset 
is normally seen in early adolescence and carries a nearly 100% risk of 
developing CRC. If FAP is left untreated the average age for CRC development 
in 35-40 years, which is significantly younger than sporadic CRC (160). In 1991 
Groden et al. discovered that FAP develops due to a germline mutation in the 
adenomatous polyposis coli (APC) gene (161). The APC protein has many 
functions. It acts as a scaffolding protein, being part of a complex along with 
GSK3-β that is involved in cell migration and cell adhesion by regulating 
phosphorylation of the protein β-catenin. β-catenin is an intracellular protein that 
binds the adhesion molecule E-cadherin, linking it to the cell cytoskeleton. 
Under normal circumstances phosphorylated β-catenin is targeted for 
degradation by the proteasome. However, mutations in APC result in an excess 
of β-catenin within the cell cytoplasm, which binds to the TCF family of 
transcription factors through the wingless/integration 1 (WNT) signalling 
pathway (Figure 1.5) (160). This affects the expression of various genes 
associated with cell proliferation, differentiation, migration and apoptosis. In 
particular, it has been observed that cyclin D1, c-myc, matrilysin and caspases 
are altered (160). The cell cycle is influenced as APC prevents progression of 
cells from the G0/G1 phase to S phase. Furthermore, APC maintains cellular 
microtubules and preserves chromosomal stability. Consequently, mutations in 
APC result in uncontrolled cell proliferation as well as chromosomal aneuploidy 
to drive tumour development (160). There have been over 1000 APC mutations 
identified, many resulting in the production of a truncated APC protein (162). 
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Inability of the APC protein to function is seen as an initial step in CRC 
development and is often seen in sporadic cancer also.  
FAP is treated through endoscopy procedures to remove polyps but eventually 
prophylactic colectomy is required in most cases. However, many studies have 
observed that NSAID cyclooxygenase (COX) inhibitors can significantly inhibit 
the development of colorectal polyps within FAP patients (163). It is thought a 
regime of NSAIDs in conjunction with dietary supplements may be useful for 
FAP treatment, although further studies are required to confirm this (164).  
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Figure 1.5. Canonical Wnt Signalling.  
In the absence of Wnt engagement the protein destruction complex, consisting of APC, 
causes degradation of β-catenin via the ubiquitination/proteasome pathway. Upon Wnt 
engagement with Frizzled and the co-receptor LRP 5/6 dual phosphorylation by CK1 
and GSK3 occurs. The destruction protein complex is recruited to the plasma membrane 
along with the protein Dish. Dish inhibits GSK3 activity and induces the stabilisation of β-
catenin. β-catenin accumulates, translocating to the nucleus where it can bind with 
TCF/LEF transcription factors. This complex is then able to bind to the promoter region 
of genes such as MYC and cyclin D involved in cell proliferation and survival. During 
APC mutation in cancer the destruction complex is unable to function, resulting in β-
catenin translocation and continuous gene transcription. (Figure adapted from Komiya 
and Habas 2008 (165) 
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1.4.2 Sporadic CRC 
Sporadic CRC is a disease where pathogenesis is influenced by the local 
colonic environment as well as genetic background. It accounts for two thirds of 
all CRC seen in clinical practice and particular key mutations other than APC 
have been associated with sporadic cancer. KRAS is a proto-oncogene that 
encodes a GTPase, which acts downstream of the epidermal growth factor 
receptor (EGFR). Mutations in KRAS are evident in approximately 30-40% of 
CRCs and lead to a continuous active signalling that drives anti-apoptosis, while 
also promoting cell growth and survival. It has been observed through clinical 
trials that there is no benefit from neoadjuvant anti-EGFR chemotherapy 
(Cetuximab) within patients that have KRAS mutations. In contrast, treatment of 
patients harbouring WT KRAS with Cetuximab in addition to chemotherapy 
resulted in a significant increase in overall survival and progression free survival 
(166).   
Mutations in the Raf protein BRAF also often occur in CRC (up to 18% of 
CRCs). BRAF is one of the three RAF proteins found within mammals and 
activates MEK, which is directly upstream of ERK in the EGFR pathway (167). 
The most common mutation is BRAFV600E where a single nucleotide change has 
occurred resulting in constitutive BRAF signalling (168). This again leads to 
gene activation to drive cells survival, growth and differentiation. Interestingly 
BRAF mutations are more associated with females, tumours on the right side of 
the colon and have a distinct pattern of metastasis. Metastatic sites more often 
develop in the peritoneum and not as often in the lungs (169). A poorer survival 
prognosis is associated in metastatic CRC patients that have BRAF mutations, 
with most studies indicating a low 1-year median survival compared to a 2-3 
year median survival for patients with WT BRAF (169).  
The p53 tumour suppressor gene is the most commonly mutated gene in human 
cancers and mutated p53 is detected in up to 75% of CRCs. It functions in 
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response to stress such as DNA damage and actively causes the transcription 
of a myriad of genes which control cellular process involving cell cycle arrest, 
apoptosis and senescence (170). p53 upregulates the expression of the pro-
apoptotic markers Bcl-2 and FAS as well as cyclin-dependent kinases such as 
p21, which prevents transition of the cell cycle into S phase from G1 and can 
promote cells to become senescent. Upregulation of CDC2 by p53 also prevents 
the cellular process of mitosis (171). Therefore, mutated p53 is seen as a key 
driver of cancer cell development. 
 
1.4.3 Colorectal cancer development and staging 
Several layers, starting with the innermost mucosa then the submucosa, 
muscularis propria, subserosa and the serosa form the colon (Figure 1.6).  Upon 
surgical resection clinical pathologists will stage the tumour, which can have an 
impact on further treatments as well as indicating patient prognosis. Two 
classification systems for staging are currently used. Dukes’ staging, from A-D 
describes increased tumour infiltration into the colonic layers (Figure 1.2). TNM 
staging is also often used. T evaluates how deeply the tumour has penetrated 
the bowel lining. N indicates node involvement and M designates the 
appearance of any metastatic sites (172). The parameters for each stage are 
described in detail in Chapter 2. 
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Figure 1.6. Dukes’ staging of CRC.  
Image delineating the advancement of an adenocarcinoma though the colonic muscle 
layers in a cross-sectional schematic of the colon. Lymph node involvement and 
metastatic disease ultimately occurs at late Dukes’ C and D staged disease. <MOVED 
HERE> 
 
 
1.4.4 Consensus molecular subtypes of CRC 
Recently a new classification for CRC tumours has emerged. Guinney and 
colleagues created a general framework that compared the multiple strategies 
previously used to define common disease patterns in CRC (173). This enabled 
the group to elucidate the four consensus molecular subtypes of CRC, based on 
molecular patterns.  
Most tumours that are MSI positive fall into the CMS1 subtype. They are also 
characterised as having hyper-methylation, hyper-mutation and associated with 
the presence of BRAFV600E mutations. Furthermore, CMS1 tumours show high 
infiltration of immune cells such as CD8+ and CD4+ T cells and NK cells (174).  
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Tumours that show chromosomal instability develop through the traditional 
tumourigenesis pathway suggested by Fearon and Vogelstein (175), subdivided 
into three groups: CMS2, CMS3 and CMS4. CMS3 tumours are characterised 
as a metabolic subtype, being enriched for KRAS mutations and exhibiting 
metabolic reprogramming with activation of glutaminolysis and lipogenesis 
(174). CMS2 and CMS4 are both MSS and show low levels of hypermethylation. 
They can be distinguished as CMS2 tumours have increased upregulation of 
WNT signalling and expression of downstream targets. In contrast, CMS4 
tumours show activation of pathways in relation to epithelial-mesenchymal 
transition (EMT) such as the TGF-β pathway and overexpression of extracellular 
remodelling matrix proteins. Furthermore, CMS4 tumours have a pro-angiogenic 
influence on the microenvironment, predominately promoted by cancer 
associated fibroblasts (174). Interestingly CMS2 and CMS3 tumours have a low 
immune and inflammatory signature, showing poor immune cell infiltration and 
reduced expression of immunoregulatory cytokines. Furthermore, these tumours 
are most often PD-1 negative, together indicating the CMS2 and CMS3 tumours 
are less immunogenic (174). There is some crossover between subtypes with 
not all CRCs falling directly into one of the four subtypes described. It is thought 
that in this case the tumour may be at an intermediate stage. Nevertheless, it is 
believed that molecular characterisation of CRC tumours will advance effective 
drug discovery.	
 
1.4.5 Current treatments 
A multidisciplinary team will assess CRC patients to discuss treatment plans 
including whether the patient should receive neoadjuvant treatment such as 
chemotherapy or radiotherapy prior to surgical colectomy. Where possible, 
resection of the affected colon with curative intent is performed. However, 
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unfortunately 40-50% of patients still relapse and succumb to disease within a 5-
year period (176). This highlights the need for better treatments 
1.5 Tumour Antigens 
1.5.1 Classification of antigens 
Tumour antigens can be classified as either tumour specific antigens (TSAs) or 
tumour associated antigen (TAAs). TSAs are exclusively expressed on tumour 
cells while TAAs are expressed on both normal and cancerous tissue. A vast 
number of tumour antigens have been identified for various cancers. Most TSAs 
arise due to somatic and germline mutations while TAAs are in the form of 
antigens found on normal cells but overexpressed in cancer or altered during 
differentiation. One of the most well-known tumour antigens is HER2, an EGFR 
discovered by Robert Weinberg and colleagues (177). It is a TAA over 
expressed in breast, gastric, ovarian and CRC as well as others. It signals 
through several pathways, such as PI3K/Akt and Ras/Erk, associated with cell 
survival and proliferation. Approximately 25% of breast cancers are HER2 
positive and importantly HER2 overexpression is linked with poor survival in 
breast cancer patients regardless of lymph node involvement. The monoclonal 
antibody Trastuzumab (brand name Herceptin), which binds to HER2 has been 
approved as a first line treatment for HER2+ breast cancers since the 1990s with 
a 50%-80% response rate in patients (178). It is often given in combination with 
chemotherapy drugs such as docetaxel and paclitaxel.  Since 2012 pertuzumab 
(brand name Perjeta), which also binds HER2 has been approved for use in 
combination with trastuzumab and docetaxel for treatment of patients with 
HER2+ metastatic breast cancer (179). Following this, in 2017, the FDA 
approved the use of pertuzumab in combination with trastuzumab and 
chemotherapy as adjuvant treatment of patients with HER2+ early breast cancer 
at high risk of recurrence (180).  
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Genetic mutations can give rise to tumour antigens described as neo-antigens. 
Neo-antigens are observed most often in melanoma and lung cancer due to the 
high rate of exposure to carcinogens such as radiation and tobacco, which leads 
to DNA damage. In some cases, a high neo-antigen load can be beneficial as 
some of these antigens can stimulate the anti-tumour immune response. Rizvi 
and colleagues show that increased mutation and neo-antigen burden in non–
small cell lung cancer patients treated with the anti-PD-1 drug pembrolizumab, 
correlated with better objective response, durable clinical benefit, and 
progression-free survival (181). However, in some cases the immune system is 
unable to recognise neo-antigens or in many cases the tumour 
microenvironment can suppresses anti-tumour responses. Furthermore, 
developing treatments towards neo-antigens would be patient-specific and a 
laborious task. This makes it a challenging option as a large-scale cancer 
treatment strategy. 
 
Other promising targets for cancer therapy are the cancer testis (CT) antigens. 
In healthy adults, expression of CT antigens are restricted to male germ cells 
such as spermatocytes. However, ectopic CT expression can be detected within 
multiple cancers. Melanoma-associated antigen 1 (MAGE-1) was the first CT 
antigen discovered 20 years ago but other members such as GAGE, SSX and 
CT45 have been found to be over-expressed in cancerous tissues (182). Male 
germline cells are unable to express HLA molecules, rendering them incapable 
of displaying antigens on the cell surface. Studies have shown that CT antigens 
are expressed within the thymic medulla during T cell development. 
Nevertheless, cellular and humoral responses to CT antigens have been 
measured in cancer patients. CT antigens are thought of as neo-antigens when 
expressed within nascent cells and provide a promising target for therapies. 
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In our laboratory we focus on two antigens associated with CRC: 
Carcinoembryonic antigen (CEA) and 5T4.  
 
1.5.2 CEA 
Gold and Freedman originally extracted CEA from foetal intestinal tissue and 
from an adult CRC in 1965 (183). Initially it was believed that CEA was an 
oncofoetal antigen that was only overexpressed in cancerous tissue. Further 
studies disproved this, showing that CEA is expressed at low levels within the 
normal small and large intestine. Anhen and colleagues carried out a 
comprehensive study investigating the localisation and distribution of CEA. 
Results showed CEA expression within the small intestine was localised to the 
luminal surface of epithelial cells and could also be detected within goblet cells. 
Within the colon CEA was expressed in dense deposits at the apical surface of 
cells close to the lumen while higher CEA expression was found at the luminal 
border of cells within the crypt bases (184). The majority of CRCs overexpress 
CEA, however it can also be detected in lung, breast and ovarian malignancies. 
Within cancerous tissue CEA expression is approximately 60-fold higher 
compared to normal tissue (185). 
CEA is a highly glycosylated protein belonging to the immunoglobulin supergene 
family, functioning as a cell adhesion molecule. Some studies have also 
reported a role for CEA in trapping intestinal bacteria such as E.coli (186). CEA 
is anchored to the plasma membrane of epithelial cells but can also be shed 
from the cell surface into the circulation. Serum CEA levels are routinely used to 
monitor CRC patients for tumour recurrence after colectomy (187). In an early 
study by Wanebo et al. a positive correlation between the proportion of patients 
with high CEA serum levels and tumour stage was also observed (188).  
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Unfortunately there is no homologue for CEA within rodents; hence the first CEA 
transgenic mice (CEA-Tg) were established in 1991 to express human CEA in 
various tissues (189). CEA-Tg mice from the Zimmermann laboratory also 
importantly showed that the spatiotemporal pattern of CEA was similar to that 
seen in humans (190). Mice and humans develop tolerance to CEA, however 
vaccination studies show that this can be broken. This makes CEA an attractive 
target for immunotherapy. Nonetheless, as CEA is expressed on healthy tissue 
the safety and long-term implications of targeting CEA are not fully known. In a 
particular study by Bos and colleagues the safety of CEA-targeted 
immunotherapy within CEA-Tg mice was evaluated (191). The CEA-specific 
repertoire was reconstituted through adoptive transfer techniques. WT mice 
were challenged with the CRC cell line MC38 expressing CEA after inoculation 
with a CEA peptide loaded vaccine. While WT mice developed a CEA response, 
only a weak CD4+ T helper response could be detected in CEA-Tg animals. 
Furthermore transfer of CEA responding cells raised in WT mice failed to 
prevent tumour growth in CEA-Tg mice, suggesting that the CEA response is 
governed by peripheral tolerance as well as central tolerance (191). 
Nevertheless, irradiation of CEA-Tg recipients prior to adoptive transfer of WT 
CEA specific cells resulted in 35% of tumours being rejected, indicating that 
suppressive mechanisms to restrain CEA specific cells were in place. Using 
CD25 specific antibodies in combination with irradiation and CEA specific 
adoptive transfer the group showed that the majority of tumours could be 
cleared (191). However, it was observed that under the treatment regimes used 
in this study, mice developed colitis, showing symptoms of weight loss as well 
as colon shortening and thickening. Only CEA-Tg mice showed symptoms of 
experimental colitis, demonstrating the pathology was due to reactivity to normal 
intestinal CEA expression. In support of this, the colon showed increased 
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enteropathy compared to the small intestine where CEA expression is lower 
(191). Furthermore, transfer of Thy 1.1 donor CEA-specific cells into Th1.2 
recipients demonstrated CEA-specific cells were involved in generating colitis as 
donor cells were shown to infiltrate the intestinal epithelium. The authors do 
state that in this particular CEA-Tg mouse strain the expression of CEA is 10-
fold higher to that seen in humans and therefore may provide a worst-case 
scenario. Nevertheless, this study was one of the first to highlight severe colitis 
as a possible side effect of CEA targeted immunotherapy (191).  
Following this, a human study by the Rosenberg laboratory investigated the use 
of autologous T cells engineered to express a murine TCR against human CEA 
to treat three metastatic CRC patients (192). Transfer of engineered T cells 
resulted in lower CEA serum levels in all patients and one patient did show an 
objective response with tumour regression. However, as a side effect all three 
patients developed severe colitis and the authors discussed that this may pose 
a significant limitation of any treatment that uses CEA as a target (192). 
 
1.5.2.1 Blood anti-CEA responses 
The use of TAAs as immunotherapy targets relies on a natural existing pool of T 
cells able to recognise antigen epitopes. In 2000, a study by Nagorsen et al. 
measured blood derived responses to three tumour antigens and assessed 
whether reactive T cells could be detected in CRC patients (193). ELISpot 
technology evaluated the reactivity of PBMC from HLA-A2 positive patients to 
HLA-A2 restricted peptides from Ep-cam-1, HER-2 and CEA, using IFN-γ 
secretion to characterise a response. Spontaneous responses to all three 
antigens were observed in a proportion of metastatic CRC patients. In particular 
a significant response to CEA could be detected in 6/22 patients (193). This 
study was one of the first to identify IFN-γ specific CEA responses from the 
blood of CRC patients.  
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In our own laboratory, blood responses to CEA are also measured. In a study 
published in 2015 we reported that CRC patients harbouring blood-derived CEA 
specific IFN-γ responses prior to surgical colectomy had a poorer survival 
prognosis compared to non-responding patients (194). Intriguingly this finding 
was regardless of tumour stage. In contrast responses to the TAA 5T4 did not 
correlate with tumour recurrence. Furthermore, 5T4 responses provided a 
protective response as CEA-only responding patients had a worse prognosis 
than CEA/5T4 dual responding patients (194).   
 
1.5.3 5T4 
5T4 trophoblast glycoprotein was discovered during studies attempting to find 
surface molecules shared between a foetus and a tumour to promote survival in 
the mother and host, respectively. Hole and colleagues were able to show using 
monoclonal antibodies that 5T4 was 72 kD in size (195). While not expressed in 
most tissue, 5T4 was present within developing embryos on the 
syncytiotrophoblast, some extravillous cytotrophoblast and the amniotic 
epithelium (195). 5T4 upregulation occurs in many different cancers including 
CRC. Expression on tumours cells is associated with the process of epithelial-
mesenchymal transition (EMT) by impacting on the actin cytoskeleton and 
promoting epithelial cell motility (196). Furthermore, 5T4 is capable of 
modulating chemokine signalling, involved in the functional expression of 
CXCR4 on the tumour cell surface. CXCR4 and CXCL12 have been linked to 
promoting tumour spread in many cancers, attracting metastatic cells to distant 
organs such as the liver and lungs (197). Interestingly in the absence of 5T4, 
CCR7 upregulation can be seen. This leads to stimulation of signalling pathways 
involving the EGFR signalling pathway resulting in proliferation and anti-
apoptotic gene activation. It is thought that 5T4 potentiates the spread of 
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tumours while in its absence, CCR7 signalling promotes cell growth and survival 
at the primary site (197).  
5T4 has been evaluated as a potential therapeutic target for many years now. 
Originally 5T4 KO mice were used to evaluate how endogenous 5T4 influenced 
the immune system. Castro and colleagues showed that vaccination of 5T4 KO 
mice with an adenovirus encoding mouse 5T4 generates strong CD8+ and CD4+ 
IFN-γ responses which provide significant protection when challenged with 5T4 
expressing melanoma. In contrast, WT mice only developed low level CD8+ IFN-
γ production and were unable to control tumour growth (198). The group 
examined whether host Tregs could be supressing 5T4-specific responses by 
treating WT mice with a monoclonal antibody specific for folate receptor 4. 
Treatment halved Treg frequency and in combination with an MVA-5T4 
vaccination regime 5T4-sepecific IFN-γ responses increased and a modest 
reduction in tumour growth was observed within WT mice, indicating that local 
suppressive mechanisms could be contributing to low anti-5T4 T cell responses 
(198).  
Immunisation has been investigated with other viral vectors such as modified 
vaccinia Ankara (MVA) also. In a study by Mulryan et al. WT mice were 
challenged with autologous CT26 tumour cells expressing human 5T4, given 
MVA-5T4 either intravenous or intramuscular injection and followed up for 60 
days (199).  Results showed a decrease in the number of tumour nodules 
developing within the lungs of vaccinated animals compared to control groups, 
which was accompanied by a significant increase in overall survival (198).  
The aforementioned studies as well as others supported the clinical 
development of an MVA-5T4 vaccine termed Trovax. Initial clinical trials were 
promising for Trovax, indicating that it was well tolerated and was capable of 
promoting 5T4 cellular and humoral responses in prostate, colorectal and renal 
cancer. However, in a renal cancer phase III trial recruiting over 700 patients 
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Trovax was unable to meet its primary endpoint. No significant difference was 
observed between Trovax and placebo treated groups. It was however 
elucidated that some patient subgroups (high 5T4 antibody responders) may 
benefit from MVA-5T4 (200).  
Our own laboratory investigated the use of Trovax in a clinical trial aimed at 
disease-stable, metastatic CRC patients called “Trovax and cyclophosphamide 
treatment in colorectal cancer (TaCTiCC) (201). Results from the trial 
demonstrated that MVA-5T4 safely induced T cell and serological responses 
and significantly prolonged progression free survival (PFS). In one arm of the 
trial patients received Trovax in combination with low dose cyclophosphamide to 
reduce Treg numbers, in an attempt to remove possible suppressive 
mechanisms and boost 5T4-specific responses. However, while it was observed 
that cyclophosphamide did deplete Treg numbers, which was accompanied by 
an increase in prolonged PFS, combination treatment of Trovax and 
cyclophosphamide did not increase any immune response over Trovax alone 
(201). Interestingly cyclophosphamide treatment alone elicited a striking boost in 
anti-tumour immunity resulting in increased patient survival (202). 
 
1.6 T cell subsets in cancer 
Interactions between malignant cells and the immune system are complex, and 
as described above key for tumour development. Accordingly, Hanahan and 
Weinberg pronounced that the ability to avoid the immune system is a “hallmark 
of cancer” (203).  Various immune subsets are known to infiltrate tumours, some 
associated with driving tumour control and others facilitating tumour 
progression. Over all, many studies have shown that a high tumoural infiltrate of 
lymphocytes is associated with better patient survival. For example, meta-
analyses of breast cancer patients highlighted that in triple negative breast 
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cancer patients (TNBC) and Her-2+ patients, the presence of TILS is associated 
with improved prognosis. Mao and colleagues were able to show that CD8 
expressing lymphocytes were associated with better DFS while FoxP3+ cells 
correlated with poorer DFS (204). This finding was also seen in ovarian cancer 
with Hwang et al. carrying out meta-analysis of 10 studies and observing that 
both CD3+ and CD8+ cells confer an OS advantage to patients (205). In general 
a “pro-inflammatory” tumour microenvironment is associated with better clinical 
outcome.  
 
1.7 T cell subsets in CRC 
1.7.1 Th1 and cytotoxic T cells  
The immune infiltrate into CRCs also associates with survival prognosis. Meta-
analysis by Mei and colleagues of 9 CRC trials investigating the impact of 
inflammation found that the pooled HR ratio confirmed a high tumour infiltrating 
lymphocyte (TIL) density provided an OS benefit for patients (206). The group of 
Ĵerôme Galon has investigated TIL infiltration within CRC further. In particular, 
in 2005, immune infiltration analysis of 959 resected CRC samples revealed that 
the absence of metastasis correlated with the presence of effector memory T 
cells (207). Early metastatic disease can be defined by the presence of vascular 
emboli, lymphatic invasion, and perineural invasion (VELIPI) and carries a 
prognostic significance. After adjustment for TNM stage, VELIPI negative 
tumours were found to associate with better patient survival. Accordingly, 
VELIPI negative tumours also correlated with a strong immune cell infiltrate. 
Higher levels of CD8, granzyme B and granulysin were detected as well as a 
significant increase in Th1 markers such as T-bet, IRF-1 and IFN-γ compared to 
resected VELIPI positive tumours. Furthermore, flow cytometry using 410 
combinations of surface marks showed that CD3+ T cells were the most 
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prevalent immune cells infiltrating CRC tumours. This was accompanied by 
increases in CD4+ and CD8+ T cells in VELIPI negative tumours. Effector 
memory CD45RO+, CR7- CD28- CD27- T cells were also highly abundant. It was 
observed that the number of memory T cells was associated with lymph node 
(LN) involvement, with immunohistochemical analysis showing high CD45RO 
infiltration in VELIPI negative tumours and low numbers of CD45RO cells in 
VELIPI positive tumours. It was observed that CD45RO status was an 
independent prognostic factor for overall survival. Accordingly, 5-year survival 
was found to be 46.3% for high-density CD45RO tumours and 23.7% for 
CD45RO low-density tumours (207). 
Following this study the same group went on to demonstrate that the type, 
density and location of the immune cell infiltrate can influence clinical outcome 
regardless of CRC tumour stage; indicating that immunological data could 
possibly be a better prognostic tool than current histopathological methods 
(208). When evaluating the expression of genes related to immunity, a cluster of 
patients emerged with a clear Th1 phenotype. Within this cluster the expression 
levels of genes including T-bet, IRF-1, IFN-γ, CD3-z, CD8, granulysin, and 
granzyme B inversely correlated with tumor recurrence (208). Furthermore, in 
situ immune responses were analysed in the center of the tumour (CT) and at 
the invasive margin (IM). Results from three separate cohorts of CRC patients 
show that high CD3+ infiltration at either the CT or IM correlated with better DFS. 
Moreover, combined analysis of CT and IM regions increased the accuracy of 
DFS and OS prediction compared to single region analysis. Strikingly this 
correlation between high-density immune infiltration and increased survival 
remained regardless of the extent of tumour invasion and lymph node 
involvement. Furthermore, in corroboration with the previous findings, low levels 
of CD45RO T cells in both CT and IM regions results in an extremely poor 
prognosis, similar to that seen in patients harboring metastatic disease (208).  
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1.7.2 Th17  
A study by Tosilini and colleagues investigated T helper subpopulations (Th1, 
Th2, Th17 and Treg) in CRC tumours using gene expression analysis (209). 
Gene clusters associated with each subpopulation were identified and 
interestingly it was observed that patients with high expression of the Th17 
cluster had a very bad prognosis. In contrast Th1 cluster expression was 
associated with a good outcome as expected. Further analysis of the 
complementary effects of Th1 and Th17 immune reactions revealed that 
patients with a Th1lo/Th17lo phenotype still had a better 5-year survival than 
patients with Th1lo/TH17hi tumours (209). This indicates that Th17 cells are 
associated with tumour recurrence. In support of this, Th17 cells within the blood 
of CRC patients are increased compared to healthy donors and increase further 
with disease stage (210)  As mentioned previously Th17 cells are often involved 
in driving inflammation in conditions such as IBD. This in turn increases the risk 
of developing CRC. Mouse studies have investigated the role of IL-17A in the 
promotion of CRC. In particular, Chae et al. observed that in APCmin/+ mice, 
which spontaneously develop CRC, develop fewer tumours when IL-17A is 
ablated (211). This was accompanied by a reduction in proinflammatory 
cytokines and preservation of intestinal architecture, suggesting that IL-17A 
helps to drive spontaneous tumourigenesis via inflammatory processes (211). In 
support of this finding Hyan and colleagues observed a role for IL-17A in a 
model of colitis-associated cancer (CAC). CAC develops from IBD where 
chronic inflammation can create damage to induce mutations within tumour-
related genes. It was observed that after treatment of IL-17A KO and WT mice 
with azoxymethane (AOM) and DSS to induce tumour formation. Tumour 
incidence was lower within KO animals (212). Furthermore, where tumours did 
develop, they were fewer in number and smaller in size within IL-17A KO mice. 
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Ki67 staining revealed reduced proliferation of intestinal cells and tumour cells 
within IL-17 KO mice. This was accompanied by down regulation of cell cycle 
associated proteins cyclin D and cyclin E, as well as lower levels of β-catenin. 
Analysis of transcription factor expression also showed a reduction in STAT-3, 
which is a known tumour promoter. Together this data highlighted the close 
relationship between IL-17A, inflammation and CRC progression (212). 
Comparable results were also demonstrated in a mouse model of sporadic 
cancer. Grivennikov and colleagues used CPC-APC mice that develop tumours 
within the distal colon due to lack of the APC gene (213).  The group show that 
as within humans, IL-23 and IL-17A is increased within CPC-APC tumours. 
Removal of IL-23, the promoter of Th17 cells, diminished tumour frequency as 
well as reducing levels of STAT-3 expression and cell proliferation rates. Flow 
cytometry analysis revealed that IL-23 production in the tumour is linked to 
CD11b+ and F4/80+ cells such as tumour associated macrophages (TAM).  As 
discussed earlier, IL-23 can be secreted in response to recognition of the 
microbiota via PRRs. This study suggested that intestinal epithelial barrier 
deterioration could allow for the translocation of bacterial product to drive IL-23 
expression from myeloid cells in CPC-APC mice. Small sections of colon were 
clamped and then injected with 4kDa FITC dextran or LPS and the amount 
detected within the circulation after 1 hour was measured. Results indicate that 
increased 4kDa FITC and LPS passage occurred in CPC-APC mice compared 
to WT animals, indicating barrier dysfunction. In support of this, the expression 
of some TJ molecules was also reduced (213). These finding suggest that 
microbial products could promote a detrimental Th17 cell response that can 
encourage tumour progression. 
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1.7.3 Tregs 
The influence of Treg cells in CRC development has been somewhat 
controversial. Certain studies indicate a high FoxP3+ cell tumour infiltration is 
associated with better survival while others show the opposite. Ling and 
colleagues observed that CRC patients have a higher frequency of FoxP3+ cells 
within peripheral blood compared to healthy donors (8% vs 2.2% respectively) 
(214).  Furthermore, Treg tumour infiltration was significantly increased in 
relation to healthy background colonic tissue (214). Our laboratory supports 
these findings. In a detailed study investigating anti-tumour immune responses 
before and after surgery, it was observed that Tregs did impact on CEA and 5T4 
CD4+ T cell responses (215). In particular, after surgery an increased number of 
patients were able to respond to 5T4. Moreover, the magnitude of response was 
also increased. While analysing tumour recurrence it was observed that patients 
relapsing 12 months post-surgery were those found to have pre-operative 
responses that were Treg suppressed (215). In a follow up study, it was shown 
that 5T4 responses gradually declined with advanced disease while Treg 
numbers increased (216). This data implied that a high density of Tregs could 
detrimentally mask anti-tumour responses. The clinical trial TaCTiCC provided 
further evidence, showing that reduction of Treg cells with low dose 
cyclophosphamide resulted in improved IFN-γ responses, correlating with a 
significant delay in tumour progression (202).  
 
On the other hand, Salama and colleagues have reported that tumour infiltration 
with FoxP3+ cells resulted in significantly better survival in a study involving 967 
CRC patients (217). Frey et al. reported a similar result while investigating the 
prognostic significance of tumour Treg infiltration in MMR-proficient and deficient 
CRCs (218). The group showed that in two groups of MMR-proficient patients, a 
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high density of Tregs was associated with earlier pT stage and lymph node 
negative tumours. In MMR-deficient cases, high density FoxP3 was again more 
commonly found in tumours with no LN involvement and in those without 
vascular invasion (218). Upon analysis of 5-year survival, after adjustment for 
other well established prognostic factors it was observed that high Treg density 
correlated with better survival in MMR-proficient tumours (218).  
 
A review by Ladoire and colleagues discussed how CRC is a unique type of 
cancer, in that it develops in close proximity to the intestinal microbiota. 
Unsurprisingly, studies have shown that a large number of bacterial species are 
enriched within colorectal tumours. As mentioned previously, it is known that 
intestinal bacteria can stimulate the production of proinflammatory cytokines, 
which can lead to pro-angiogenic and tumour enhancing effects through 
activation of transcription factors such as NFκβ and STAT-3 (219). It has been 
suggested that T cells infiltrating CRC tumours may in fact be targeting microbial 
invasion instead of having direct anti-tumour effects. In an early mouse study by 
Erdman et al. it was observed that reducing bacterial inflammation could inhibit 
colon carcinogenesis (220). Rag-deficient mice orally inoculated with the enteric 
mouse pathogen Helicobacter hepaticus were found to develop intestinal 
inflammation with adenocarcinoma with muscle invasion within sixty days. In 
contrast WT animals did not develop an inflammatory or carcinogenic 
phenotype. Furthermore, the transfer of Tregs into Rag-deficient mice prior to 
inoculation prevented cancer development. This indicates that Treg control of 
bacterial induced inflammation can be beneficial in preventing CRC (220). In a 
more recent study evaluating Treg infiltration it was shown that both FoxP3hi and 
FoxP3lo Treg populations infiltrate CRC tumours (221). In particular, the 
abundance of FoxP3lo Tregs was associated with a better survival outcome than 
those patients with predominantly FoxP3hi infiltration. The authors suggest that 
	 61	
FoxP3hi cells could be preventing anti-tumour responses while FoxP3lo cells 
could have a role in suppressing inflammation derived from microbial infiltration 
(221). In support of this it was observed that high FoxP3lo T cell density was 
associated with the presence of the microbe Fusobacterium nucleatum, a gram-
negative anaerobe identified as having links with poor survival in CRC patients 
(222).   
 
1.8 Aims and Hypotheses  
Within this study two hypotheses were tested in an attempt to determine why 
CRC cancer patients with blood derived CEA specific responses have a poor 
survival outcome compared to non-responding patients (194): 
1. IL-17A and/or IL-17A/IFN-γ CEA-specific T cells exist within CRC patients 
and are involved in the poor survival prognosis associated with preoperative 
CEA-specific T cell responses. 
 
The following aims were used to test this hypothesis:  
• Evaluate the frequency of peripheral blood IFN-γ, IL-17A, and IL-
17A/IFN-γ CEA-specific and 5T4-specific responses in a cohort of 
preoperative CRC patients.  
• Determine the frequency and phenotype of T cells within the healthy 
bowel, tumour and peripheral blood of CEA-responding and non-
responding CRC patients.   
 
2. Patients harbouring CEA-specific IFN-γ responses have increased intestinal 
permeability leading to tumour progression through tumour associated 
inflammation. 
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The following aims were used to test this hypothesis:  
• Construct and optimise an Ussing chamber system to evaluate 
intestinal permeability. 
• Evaluate the intestinal permeability of colonic biopsies in a cohort of 
patients undergoing colonoscopy.  
• Measure peripheral blood CEA and 5T4 specific T cell responses 
and analyse with permeability observations.  
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Chapter 2. Materials and Methods 	
2.1 Materials 
All chemicals were purchased from Sigma Aldrich (unless stated otherwise). 
Phosphate buffered saline (PBS) pH7.2 was purchased from Gibco, Paisley, 
UK. Barnstead ultra filtered DNA & RNA free diH20 (ThermoFisher, UK) was 
used to prepare all buffers and reagents.  
2.1.1 Patient recruitment 
Blood and colonic samples were obtained from patients undergoing investigative 
colonoscopy procedures or colorectal surgery at The University Hospital of 
Wales. All subjects gave informed consent to take part in this ethically approved 
study (consent form can be seen in the Appendix). The Wales Research Ethics 
Committee granted ethical approval (reference number:15/WA/0291). Patient 
characteristics are summarised in Table 2.1 and Table 2.2 for surgical CRC 
patients and endoscopy patients respectively. 
2.1.2 Histopathological tumour grading 
Colorectal tumours used were analysed for overall size, invasive status and 
lymph node involvement, confirmed by consultant pathologists at the University 
Hospital of Wales. Each specimen was then graded. Dukes’ classification and 
TNM staging parameters are shown in Table 2.3 and 2.4 respectively. 
2.1.3 Healthy donors and age matched controls 
Peripheral blood was taken from members of the laboratory and age-matched 
healthy controls with no history or clinical evidence of malignancy. All donors 
were consented before obtaining samples. 
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Table 2.1. Surgical CRC patient characteristics where cultured CEA 
and 5T4 responses have been analysed (note that 1 patient had two 
tumours). 
 All Patients Male Female 
Number (%) 40  22 (55) 18 (45) 
    Age (Range) 67 (42-87) 65 (42-87) 70 (52-87) 
    Tumour Location (%) Caecum 5 (12.5) 3 (7.5) 
 Ascending 0 (0) 3 (7.5) 
 Hepatic Flexure  1 (2.5) 2 (5) 
 Transverse 2 (5) 2 (5) 
 Sigmoid 9 (22.5) 2 (5) 
) 
 Rectum 5 (12.5) 6 (15) 
    TNM Staging (%) T1 4 (10) 1 (2.5) 
 T2 1 (2.5) 1 (2.5) 
 T3 12 (30) 12 (30) 
 T4 6 (15) 4 (10) 
Lymph Node Spread (%) N0 11 (27.5) 12 (30) 
 N1 7 (17.5) 6 (15) 
 N2 4 (10) 1 (2.5) 
    Dukes’ Stage (%) A 4 (10) 2 (5) 
 B 7 (17.5) 10 (25) 
 C1 10 (25) 5 (12.5) 
 C2 1 (2.5) 0 (0) 
 D 1 (2.5) 1 (2.5) 
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Table 2.2. Endoscopy patient characteristics where cultured CEA 
and 5T4 responses or intestinal permeability was analysed. 
 All patients Male Female 
Number (%) 26 13 (50) 13 (50) 
Age (range) (29-73) (29-70) (52-73) 
Adenoma patient number (%) 9 3 (33.3%) 6 (66.6%) 
Age (Range) (52-68) 64 (61-67) 62.5 (52-68) 
Location of adenoma Caecum 1 2 
 Transverse 0 1 
 Sigmoid 1 2 
 Rectum 0 2 
 Unidentified 1 0 
    CRC Patient number 1 1 0 
Age  60 - - 
Tumour Location Rectum 1 0 
 
Table 2.3. Dukes’ staging parameters 
Grade Parameters 
Dukes’ A Invasion but not through the bowel wall. 
Dukes’ B Invasion through the bowel wall; no lymph node involvement. 
Dukes’ C1 Extending into muscularis propria; local lymph nodes involved. 
Dukes’ C2 Penetrating muscularis propria; local and apical lymph nodes involved 
Dukes’ D One or more metastatic sites 
 
Table 2.4. TNM staging parameters 
Grade Parameters 
T1 Tumour no more than 2 cm across (invades submucosa) 
T2 Tumour more than 2 cm but no more than 5cm across (invades muscularis 
propria) 
T3 Tumour greater that 5 cm across (invades serosa) 
T4 Tumour has grown into adjacent tissues 
N0 No spread to regional lymph nodes 
N1 1-3 regional lymph nodes involved 
N2 4 or more regional lymph nodes involved 
M0 No metastasis 
M1 Distant metastasis 
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2.1.4 Media  
R+ media  
RPMI-1640 media supplemented with 2 mM L-glutamine, 1 mM sodium 
pyruvate, 50 µg/ml penicillin and streptomycin (Gibco, Paisley, UK) was used for 
PBMC wash steps. 
R5 media  
RPMI-1640 media supplemented with 2 mM L-glutamine, 1 mM sodium 
pyruvate, 50 µg/ml penicillin, streptomycin (Gibco, Paisley, UK) and 5% human 
AB serum (Welsh Blood Service, Pontyclun, UK) was used for PBMC culture.  
R5 IL-2 media 
RPMI-1640 media supplemented with 2 mM L-glutamine, 1 mM sodium 
pyruvate, 50 µg/ml penicillin, streptomycin (Gibco, Paisley, UK), 5% human AB 
serum (Welsh Blood Service, Pontyclun, UK), 40IU IL-2 was used for PBMC 
feeds.  
CTL test plus serum free media 
CTL Test Plus supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 50 
µg/ml penicillin, streptomycin (Immunospot, Bonn, Germany) was used for 
PBMC culture in Chapter 5 only.  
CTL test plus serum free IL-2 media 
CTL Test Plus supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 50 
µg/ml penicillin, streptomycin and 40IU IL-2 (Immunospot, Bonn, Germany) was 
used for PBMC feeds in Chapter 5 only.  
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TIL extraction media 
RPMI-1640 supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 50 
µg/ml penicillin, streptomycin (Gibco, Paisley, UK), and gentamicin (Life 
Technologies, UK) and 2 µg/ml of Fungizone (Amphotericin B, Life 
Technologies, UK). 
TIL/CIL resting media 
RPMI-1640 supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 
50µg/ml of penicillin and streptomycin (Gibco, Paisley, UK), 10 µg/ml gentamicin 
(Life Technologies), 1 µg/ml of Fungizone (Amphotericin B, Life Technologies, 
UK) and 10% human AB serum (Welsh Blood Service, Pontyclun, UK). 
2.1.5 Peripheral blood mononuclear cell (PBMC) extraction and primary 
cell culture reagents: 
Lymphoprep  
20 ml lymphoprep (Axis-Shield, Dundee, Scotland, UK) was used to separate 
whole blood. 
Novocyte flow cytometer 
Used for absolute PBMC cell counts (ACEA Bioscience, Inc, San Diego, USA) 
Culture plate 
96 well U-bottom plates (Nunc, ThermoFisher Scientific, UK) were used for all 
PBMC cultures. 
Cell kine  
Sourced from Helvetica Healthcare, UK. 
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Antigens/Mitogens 
Tuberculin purified protein derivative (PPD; Statens Serum Institute, Denmark), 
Hemagglutinin (HA; kindly provided by Sir John Skehel, NIMR) and 
phytohemagglutinin (PHA; Sigma-Aldrich) were used as control 
antigens/mitogens. All were used at a concentration of 4 µg/ml. 
CEA and 5T4 antigens  
The CEA protein sequence AAA51967.1 was used to provide seventy 20 amino 
acid long peptides, each overlapping by 10 residues and covering the entire 
protein. Synthesized by GLBiochem (Shanghai, Shanghai, China) and with 
purity greater than 90%, these peptides were used to create two CEA “super 
pools” suspended in 20% dimethyl sulfoxide (DMSO). CEA peptide pool 1 (PP1) 
covered peptides 1 to 35 and CEA peptide pool 2 (PP2) covered peptides 36 to 
70 (Table 2.5). Forty-one peptides overlapping by 10 amino acids were also 
synthesized to cover the entire human 5T4 protein (GL Biochem, Shanghai, 
China). Two 5T4 “super pools” were created with PP1 covering peptides 1 to 20 
and PP2 covering peptides 21 to 41 (Table 2.6). All “super pools” were used at a 
final well concentration of 1.45 µg/ml/peptide 
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Table 2.5. CEA 20mer peptide sequences 
No Sequence No Sequence 
P1 MESPSAPPHRWCIPWQRLLL P36 NTTYLWWVNNQSLPVSPRLQ 
P2 WCIPWQRLLLTASLLTFWNP P37 QSLPVSPRLQLSNDNRTLTL 
P3 ASLLTFWNPPTTAKLTIES P38 LSNDNRTLTLLSVTRNDVGP 
P4 PTTAKLTIESTPFNVAEGKE P39 LSVTRNDVGPYECGIQNELS 
P5 TPFNVAEGKEVLLLVHNLPQ P40 YECGIQNELSVDHSDPVILN 
P6 VLLLVHNLPQHLFGYSWYKG P41 VDHSDPVILNVLYGPDDPTI 
P7 HLFGYSWYKGERVDGNRQII P42 VLYGPDDPTISPSYTYYRPG 
P8 ERVDGNRQIIGYVIGTQQAT P43 SPSYTYYRPGVNLSLSCHAA 
P9 GYVIGTQQATPGPAYSGREI P44 VNLSLSCHAASNPPAQYSWL 
P10 PGPAYSGREIIYPNASLLIQ P45 SNPPAQYSWLLIDGNIQQHTQ 
P11 IYPNASLLIQNIIQNDDTGFY P46 IDGNIQQHTQELFISNITEK 
P12 NIIQNDTGFYYTHVIKSDLV P47 ELFISNITEKNSGLYTCQAN 
P13 TLHVIKSDLVNEEATGQFRV P48 NSGLYTCQANNSASGHSRTT 
P14 NEEATGQFRVYPELPKPSIS P49 NSASGHSRTTVKTITVSAEL 
P15 YPELPKPSISSNNSKPVEDK P50 VKTITVSAELPKPSISSNNS 
P16 SNNSKPVEDKDAVAFTCEPE P51 PKPSISSNNSKPVEDKDAVA 
P17 DAVAFTCEPETQDATYLWWV P52 KPVEDKDAVAFTCEPEAQNT 
P18 TQDATYLWWVNNQSLPVSPR P53 FTCEPEAQNTTYLWWVNGQS 
P19 NNQSLPVSPRLQLSNGNRTL P54 TYLWWVNGQSLPVSPRLQLS 
P20 LQLSNGNRTLTLFNVTRNDT P55 LPVSPRLQLSNGNRTLTLFN 
P21 TLFNVTRNDTASYKCETQNP P56 NGNRTLTLFNVTRNDARAYV 
P22 ASYKCETQNPVSARRSDSVI P57 VTRNDARAYVCGIQNSVSAN 
P23 VSARRSDSVILNVLYGPDAP P58 CGIQNSVSANRSDPVTLDVL 
P24 LNVLYGPDAPTISPLNTSYR P59 RSDPVTLDVLYGPDTPIISP 
P25 TISPLNTSYRSGENLNLSCH P60 YGPDTPIISPPDSSYLSGAN 
P26 SGENLNLSCHAASNPPAQYS P61 PDSSYLSGANLNLSCHSASN 
P27 AASNPPAQYSWFVNGTFQQS P62 LNLSCHSASNPSPQYSWRIN 
P28 WFVNGTFQQSTQELFIPNIT P63 PSPQYSWRINGIPQQHTQVL 
P29 TQELFIPNITVNNSGSYTCQ P64 GIPQQHTQVLFIAKITPNNN 
P30 VNNSGSYTCQAHNSDTGLNR P65 FIAKITPNNNGTYACFVSNL 
P31 AHNSDTGLNRTTVTTITVYA P66 GTYACFVSNLATGRNNSIVK 
P32 TTVTTITVYAEPPKPFITSN P67 ATGRNNSIVKSITVSASGTS 
P33 EPPKPFITSNNSNPVEDEDA P68 SITVSASGTSPGLSAGATVG 
P34 NSNPVEDEDAVALTCEPEIQ P69 PGLSAGATVGIMIGVLVGVA 
P35 VALTCEPEIQNTTYLWWVNN P70 IMIGVLVGVALI 
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Table 2.6. 5T4 20mer peptide sequences 
No Sequence No Sequence 
P1 MPGGCSRGPAAGDGRLRLAR P22 GLRRLELASNHFLYLPRDVL 
P2 AGDGRLRLARLALVLLGWVS P23 HFLYLPRDVLAQLPSLRHLD 
P3 LALVLLGWVSSSSPTSSASS P24 AQLPSLRHLDLSNNSLVSLT 
P4 SSSPTSSASSFSSSAPFLAS P25 LSNNSLVSLTYVSFRNLTHL 
P5 FSSSAPFLASAVSAQPPLPD P26 YVSFRNLTHLESLHLEDNAL 
P6 AVSAQPPLPDQCPALCECSE P27 ESLHLEDNALKVLHNGTLAE 
P7 QCPALCECSEAARTVKCVNR P28 KVLHNGTLAELQGLPHIRVF 
P8 AARTVKCVNRNLTEVPTDLP P29 LQGLPHIRVFLDNNPWVCD 
P9 NLTEVPTDLPAYVRNLFLTG P30 LDNNPWVCDCHMADMVT 
P10 AYVRNLFLTGNQLAVLPAGA P31 HMADMVTWLKETEVVQGKDR 
P11 NQLAVLPAGAFARRPPLAEL P32 ETEVVQGKDRLTCAYPEKMR 
P12 FARRPPLAELAALNLSGSRL P33 LTCAYPEKMRNRVLLELNSA 
P13 AALNLSGSRLDEVRAGAFEH P34 NRVLLELNSADLDCDPILPP 
P14 DEVRAGAFEHLPSLRQLDLS P35 DLDCDPILPPSLQTSYVFLG 
P15 LPSLRQLDLSHNPLADLSPF P36 SLQTSYVFLGIVLALIGAIF 
P16 HNPLADLSPFAFSGSNASVS P37 IVLALIGAIFLLVLYLNRKG 
P17 AFSGSNASVSAPSPLVELIL P38 LLVLYLNRKGIKKWMHNIRD 
P18 APSPLVELILNHIVPPEDER P39 IKKWMHNIRDACRDHMEGYH 
P19 NHIVPPEDERQNRSFEGMVV P40 DACRDHMEGYHYRYEINADPR 
P20 QNRSFEGMVVAALLAGRALQ P41 YRYEINADPRLTNLSSNSDV 
P21 AALLAGRALQGLRRLELASN   
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2.1.6 FluoroSpot assay reagents 
FluoroSpot kit  
Human IFN-γ/IL-17 was sourced from MabTech, West Sussex, UK. 
FluoroSpot plates 
PVDF membrane plates (IPFL; Millipore). 
Plate reader 
Automated CTL-ImmunoSpot Reader (CTL, Bonn, Germany) equipped with 
filters for FITC (excitation 490 nm/emission 510 nm) and Cy3 (excitation 550 
nm/emission 570 nm). Double secreting cells were visualised and enumerated 
by a computerized overlay. 
2.1.7 Flow cytometry reagents 
All antibodies used for flow cytometry are shown in Table 2.7 (human) and 
Table 2.8 (mouse). 
Phorbol myristate acetate (PMA)/Ionomycin 
Stimulation of PBMC was carried out using PMA and ionomycin (Sigma Aldrich, 
UK) at final concentrations of 50 ng/ml and 500 ng/ml respectively for five hours 
in combination with Brefeldin A (Sigma Aldrich, UK) at 2 µg/ml to prevent 
cytokine release. 
FACS buffer 
PBS (Gibco, Paisley, UK) containing 2% foetal calf serum (FCS) and 5mM 
EDTA. 
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FACS fix/permeabilisation buffer 
Fixation/permeabilisation solution was sourced from eBioscience, UK. 
FACS permeabilisation buffer 
x10 permeabilization buffer (eBioscience, UK) was diluted 1:10 before use. 
FACS fix 
FACS buffer containing 2% paraformaldehyde (Sigma-Aldrich,UK). 
Flow cytometer 
Acquisition was carried out on the 8-colour BD FACSCanto II. 
 
Table 2.7. Details of flow cytometry human antibodies. 
Marker Conjugate Company Clone Final Concentration 
CD3 PerCPCy5.5 Biolegend UCHTI 5 µg/ml 
CD4 BV421 Biolegend OKT4 5 µg/ml 
CCR6 PeCy7 BD 11A9 1:20 
IFN-γ APC 
eFluor780 
eBioscience 4S.B3 1 µg/ml 
IL-17A APC eBioscience 64DEC17 1.7 µg/ml 
IL-10 PE Biolegend JES319F1 1.7 µg/ml 
FoxP3 FITC eBioscience PCH101 6.6 µg/ml 
 
Table 2.8. Details of flow cytometry mouse antibodies 
Marker Conjugate Company Clone Final Concentration 
CD4 FITC Biolegend  GK1.5 0.25 µg/ml 
CD8 BV421 Biolegend 53-6.7 0.5 µg/ml 
FoxP3 APC Invitrogen FJK-16s 1 µg/ml 
CD16/CD32 - ebioscience 93 5 µg/ml 
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2.1.8 Animal model reagents 
Male and female C57BL/6 FoxP3DTR (109) and Balb/C DREG mice (223) (bread 
in house) were housed in filter top cages in the specific pathogen free (SPF) 
Joint Biological Service Unit (Cardiff University). The age and sex of mice are 
stated throughout this thesis. All experiments were performed in the home cage. 
Mice were maintained at a constant temperature, with 12-hour light/dark cycle 
and had access to standard mouse chow and water ad libitium. All experiments 
performed were ethically approved in accordance with the Animal Scientific 
Procedures Act 1986, in compliance with UK Home Office regulations (project 
license 30/3428) and were carried out by individuals holding a UK personal 
licence.  
 
2.1.8.1 Dextran sodium sulphate (DSS) model 
DSS 
36,000-50,000 M.Wt DSS colitis grade (MP Biomedicals, UK) was prepared at 
3% w/v in drinking water.  
Occult blood test kits   
Kindly provided by Lee Parry (Biosciences, Cardiff University) and sourced from 
Beckman Coulter, UK Ltd. 
2.1.8.2 T-regulatory cell depletion mouse model 
Diphtheria toxin  
300µl intraperitoneal injection of diphtheria toxin in PBS (Native Antigen, UK) 
was given to animals giving a final concentration of 15 µg/kg. 
Red blood cell lysis buffer 
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Diluted 1:10 with sterile water before use and sourced from Biolegend, UK. 
2.1.9 Ussing chamber system materials and reagents 
Equipment components 
The Navicyte Ussing Chamber system and Ag/AgCl electrodes were purchased 
from Harvard Apparatus, UK and USA. EC825A volt/clamp boxes (Warner 
Instruments Inc, Connecticut, USA), Power-Lab 8/35 and Lab Chart software 
(AD Instruments, Oxford, UK) were used for data acquisition. Electrical cables 
were sourced from Maplin Electronics, Cardiff, UK.  The aluminium electrical 
manifold was kindly built by Mr Richard Charlton and Mr Liam Atkinson 
(Newcastle, UK). 
Gas cylinder 
During Ussing Chamber experiments a gas supply of 95% oxygen and 5% 
Carbon dioxide (BOC, UK) was used. 
Krebs buffers 
All Krebs buffers were pH 7.2. Buffer compositions are shown in Table 2.9. 
KCl saturated with Ag 
Sourced from Sigma Aldrich, UK. 
Permeability probes 
Lucifer yellow CH Di-lithium salt and 4kDa Fluorescein isothiocyanate-dextran 
(Sigma Aldrich, UK) were diluted in Krebs buffer. Concentrations used are 
described throughout.  
Reader 
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Clariostar plate reader (BMG, Labtech, Ortenberg, Germany) was used to 
measure fluorescence within Ussing samples. 
Forskolin  
Forskolin (Sigma Aldrich, UK) stock was made to 10 mM and diluted to give a 
working concentration of 333µM (15µl into 450µl Krebs buffer). 30µl of the 
working solution was added to give a final chamber concentration of 6.6µM. 
Bleach 
Household bleach (Tesco, Cardiff, UK) was used to chloride Ag/AgCl 
electrodes. 
Cleaner 
RBS 25 solution was sourced from Sigma Aldrich, UK to clean Ussing 
chambers. 
Sylguard plates 
Sylguard plates were made from a Dow Corning sylguard silicone and elastomer 
kit (Ellsworth Adhesives, East Kilbride, Scotland) by mixing the parts 10:1 
respectively, pouring into a petri dish and leaving to dry at room temperature for 
48 hours. 
Biopsy forceps 
EndowJaw oval fenestrated alligator non-spiked swing-jaw disposable biopsy 
forceps with a working length of 2300mm and minimal channel size of 2.8mm 
were used to obtain human colonic specimens (Olympus Medical Systems 
Corporation, Southend-on-Sea, UK). 
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Table 2.9. Details of Krebs buffers and concentrations. 
Buffer Concentration 
Krebs Stock 136 mM NaCl, 1.5 mM CaCl2*2H2O, 4.3 
mM KCl, 1.6 mM KH2PO4 , 27 mM 
NaHCO3, 1.4 mM MgSO4*7H2 
Glutamate Stock 114 mM Glutamate 
Sodium Pyruvate Stock 115 mM Sodium Pyruvate 
Glucose Stock 200 mM Glucose 
Mannitol Stock 200 mM Mannitol 
Transport Krebs 115.6mM NaCl, 1.3mM CaCl2*2H2O, 
3.7mM KCl, 1.4mM KH2PO4, 23 mM 
NaHCO3, 1.2 mM MgSO4*7H2 
Glucose Krebs 5.8 mM Sodium Pyruvate, 5.7 mM 
Glutamate, 10 mM Glucose 
Mannitol Krebs 5.8 mM Sodium Pyruvate, 5.7 mM 
Glutamate, 10 mM Mannitol 
 
2.1.10 Histology reagents 
Throughout this thesis, alcohol for histology was prepared using industrial 
methylated spirit (Fisher Scientific, UK). 
10% Neutral buffered formalin saline (NBFS) 
10% NBFS solution was sourced from Sigma Aldrich, UK. 
Agar embedding 
2% agar (Fisher, UK) was used to embed small colonic tissue samples 
Paraffin embedding 
A Shandon Tissue processor from ThermoFisher Scientific, UK was used to 
process samples for paraffin wax embedding. Processed samples were 
embedded into wax blocks using a Shandon Histocentre. The cycles used for 
samples are summarised in Table 2.10.  
Cold block 
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Paraffin blocks were kept on a Leica, Histocore Arcadia C cold block before 
cutting to allow for easier sectioning. 
Sectioning 
Mx35 Premier+ blades (Thermo Scientific, UK) were used for sectioning colonic 
tissue on a microtome (Microm HM325, Thermo Scientific, UK). 5µm thick 
sections were placed on superfrost glass slides (Thermo Fisher Scientific, UK). 
Haematoxylin 
Haematoxylin stain was sourced from Sigma Aldrich, UK.  
Eosin	
Eosin-Y stain was sourced from Sigma Aldrich, UK.  
DPX mounting medium 
Sourced from Raymond A. Lamb waxes and general laboratory suppliers, UK. 
Ammonia water solution 
A working solution of 2% Ammonium hydroxide (Fisher Scientific, UK) was 
made by mixing with distilled water. 
1% Acid alcohol solution 
1ml of hydrochloric acid (Fisher Scientific, UK) was mixed with 100ml 70% 
ethanol (Fisher Scientific, UK). 
CEA immunohistochemistry 
The Link 48 autostainer (Agilent Technologies LDA UK Limited, Stockport, UK) 
was used to stain CRC samples using and flex mouse monoclonal anti-CEA 
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antibody (Agilent Technologies LDA UK Limited, Stockport, UK) and envision 
flex high pH kit (Agilent Technologies LDA UK Limited, Stockport, UK). 
Histological analysis 
Slides were imaged using the digital Axio Scan.z1 slide scanner or Apotome 
microscope, both from Zeiss, Germany. 
 
 
Table 2.10. Shandon tissue processor cycles for colonic tissue 
samples 
Reagent Cycle Time (h) 
70% Methanol (v/v) 1:00 
90% Methanol 2:00 
100% Methanol 2:00 
100% Methanol 2:00 
100% Methanol 2:00 
100% Methanol 2:00 
Xylene 2:00 
Xylene 2:00 
Xylene 2:00 
Wax 2:00 
Wax 2:00 
Wax 2:00 
Wax 2:00 
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2.2 Methods  
2.2.1 Peripheral blood mononuclear ell (PBMC) extraction: 
Peripheral blood was taken and PBMC were isolated by slowly layering whole 
blood over lymphoprep. Samples were centrifuged for 20 min, 2000 RPM. 
Based on size and density, PBMC form a layer (Figure 2.1). The PBMC layer 
was removed using a pasteur pipette and washed twice with R+ media. Cells 
were then enumerated using a haemocytometer under a light microscope by 
mixing cells 1:1 with Trypan blue. In later experiments an absolute PBMC count 
was determined using the Novocyte flow cytometer. 
2.2.2 Primary cell cultures 
Cultures of freshly isolated PBMC were set up to detect low frequency tumour-
antigen specific responses. PBMC were seeded in a 96 well plate in R5 or CTL 
Test Plus Serum Free Media (Figure 2.2). On day 0 HA and PPD were added at 
a final concentration of 4 µg/ml and all peptide pools were added at a final 
concentration of 1.45 µg/ml/peptide. On day 3 PBMCs were fed with 10µl Cell 
Kine media and with 100µl fresh IL-2 media on days 6 and 9, resulting in a final 
concentration of 20 IU/ml IL-2/well. The culture plate was kept in sterile 
conditions at all times at 37°C for 14-15 days before re-stimulation. The wells on 
the edge of the plate were filled with PBS to prevent moisture loss from 
experimental wells 
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Figure 2 1. Isolation of PBMC from whole blood. 
20ml of peripheral blood was layered on top of 20ml lymphoprep. After centrifugation a 
distinct band of PBMC is formed between the lymphoprep and plasma, as shown above.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. PBMC plate layout.  
0.5x106 purified PBMC/well were seeded into a 96 well plate. Four replicate cell lines per 
condition were set up and PBMC stimulated with CEA, 5T4, control peptides or left un-
stimulated.  
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2.2.3 FluoroSpot assay 
A schematic of the FluoroSpot principle is shown in Figure 2.3. Membranes of a 
96-well low fluorescent PVDF plate were activated for 1 minute with 35% 
ethanol then washed five times with PBS. Membranes were coated with 80µl of 
an anti-IFN-γ (1-D1K) and anti-IL-17A (MT44.6) mix, each at a final 
concentration of 15 µg/ml. Plates were incubated at 4°C overnight then washed 
with PBS five times and blocked with 100µl culture media for at least 30 
minutes. After 14-15 days PBMC cultured in quadruplicate as shown in Figure 
2.2 were removed from the incubator and two identical lines were pooled 
together, before being washed three times with PBS (e.g. lines in row B were 
pooled with lines in row C and lines in row D were pooled with lines in row E. 
PBMC were re-suspended in 200µl culture media. 100µl was added into each 
FluoroSpot well to provide 5x106 PBMC/well. Peptide pools were added to one 
half of each culture condition for direct comparison of IFN-γ and IL-17 responses 
versus background.  Plates were incubated at 37°C, 5% CO2 for approximately 
42 hours. PBMC were discarded and plates washed five times with PBS. 
Primary detection antibodies were prepared by mixing anti-IFN-γ (7-B6-1-FS-
FITC, 1:200) and anti-IL17A (MT504-Biotin, 2 µg/mL) diluted in PBS containing 
0.1% bovine serum albumin (BSA), before adding 80µl to each well. The plate 
was incubated for two hours at room temperature then washed five times with 
PBS. Anti-FITC-490 and anti-SA-550 (1:200) were diluted in PBS containing 
0.1% BSA and 80µl of the mix added to each well. The plate was incubated for 
one hour in the dark at room temperature then washed five times with PBS. 
50µl/well of fluorescence enhancer was added for 15 minutes. Fluorescence 
enhancer was removed by firmly tapping the plate onto paper towels and then 
the plate was left to dry for 48 hours in the dark at room temperature before spot 
analysis. Cytokine producing PBMC were enumerated at the single cell level by 
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counting the number of spots/well using an automated plate reader. Positive 
IFN-γ, IL-17A and IFN-γ/IL17A responses were identified by a minimum of 50, 
25 and 10 spot-forming cells (SFC) per 5x105 cultured cells, respectively, and a 
minimum 50% increase above background. In Chapter 5 only, 1.25x105 
 
cells 
were plated into the FluoroSpot plate after culture.  
 
 
 
 
 
 
 
 
 
Figure 2.3. FluoroSpot assay principle.  
Well membranes are coated with capture antibodies to bind IFN-γ and IL-17A released 
from activated cells. Once cells are washed away, tagged detection antibodies bind to a 
different epitope of each analyte. Antibodies conjugated to fluorophores with non-
overlapping emission wavelengths bind to each detection antibody. Upon UV stimulation 
the fluorophores excite, allowing IFN-γ and IL-17A to be visualised simultaneously. 	
2.2.4 Collecting patient samples 
Samples of tumour and healthy bowel were obtained from theatre and dissected 
by a pathologist. Tissues were then transferred to the laboratory in warm TIL 
extraction media. 
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2.2.5 Preparation of single cell suspensions from human tissues 
Tumour and colon samples were minced into a fine pulp on a petri dish using a 
blade and then filtered through a 70µm cell strainer to isolate infiltrating cells. 
Cells were centrifuged twice in TIL extraction media at 2000 RPM for 10 minutes 
at room temperature. Supernatants were removed carefully using a stripette to 
prevent loosening of the cell pellet. Mechanical dissociation was used to obtain 
a single cell suspension. After washing, cells were left overnight to rest in the 
incubator suspended in TIL/CIL resting media.  
2.2.6 Preparation of murine splenocytes  
Single cell suspensions of spleens were prepared by filtering mashed tissue 
through a 70µm cell strainer with R+ media. 5ml red blood cell lysis buffer was 
added for 5 minutes to lyse red blood cells. 
2.2.7 Animal models  
2.2.7.1 DSS mouse model 
FoxP3DTR mice were given 50ml of 3% DSS in drinking water to induce intestinal 
inflammation. Mice were housed individually and a record of water consumption 
and weight as well as a stool sample was obtained daily. Fresh DSS water was 
supplied every three days. Animals were harvested when blood was observed 
within the stool and/or within the cage, this was typically from day 7 to day 9. 
2.2.7.2 Occult blood testing 
Murine stool samples were smeared onto filter paper treated with guaiac resin 
(≥0.05 mg). Hydrogen peroxide developer solution was then applied. In the 
presence of blood, the haem component of haemoglobin catalyses a reaction 
where hydrogen peroxide oxidises the guaiac resin, producing a blue-coloured 
quinone compound. 
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2.2.7.3 FoxP3DTR mouse model 
FoxP3DTR mice were injected Intraperitoneally with 300µl of diphtheria toxin (15 
µg/kg) three times a week (Monday, Wednesday and Friday) for up to 15 days. 
Mice were harvested with the onset of autoimmune symptoms (e.g. piloerection, 
scaly skin).  
2.2.8 Flow cytometry  
2.2.8.1 Antibody staining 
0.2-1x106 PBMC, colon infiltrating lymphocytes and TILs were seeded in 96-well 
plates and washed twice with 200µl sterile PBS. 3µl of aqua amine-reactive 
viability dye was added directly to the cell pellet to stain dead cells. Cells were 
incubated in the dark at room temperature for 15 minutes. Cold FACS buffer 
was used to wash cells three times. After the final wash, 30µl of FACS buffer 
was added to each well and anti-human surface antibodies added (Table 2.7). 
Cells were incubated in the dark 4°C for 15-20 minutes and then washed twice 
with 150µl FACS buffer. Cells were then incubated with 200µl of 
fixation/permeabilisation solution overnight. Cells were washed with 1x 
permeabilisation buffer and incubated with 30µl of 1x permeabilisation buffer 
containing 2% rat serum to block FC receptors for 15 minutes at 4°C. Without 
washing, anti-human antibodies used to stain intracellular markers/cytokines 
were added (Table 2.7) and incubated in the dark at 4°C for 30 minutes. Cells 
were next washed once with 1x permeabilisation buffer and fixed in FACS fix 
prior to acquisition.  
2.2.8.2 Murine antibody staining 
The same protocol as above was used. However anti-mouse antibodies detailed 
in Table 2.8 were used for staining and CD16/CD32 was used to block Fc 
receptors. 
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2.2.8.3 Activation for intracellular cytokines 
Cells were stimulated with PMA/ionomycin for five hours in combination with 
Brefeldin A before performing intracellular cytokine staining with the antibodies 
shown in Table 2.7. 
2.2.8.4 Flow cytometry analysis 
FlowJo V10.1 was used to analyse flow cytometry data. 
2.2.9 Ussing chamber experiments 
2.2.9.1 Buffers 
Krebs stock buffer and transport buffer were stored at 4°C for a maximum of 3 
weeks. Glutamate, sodium pyruvate, mannitol and glucose stock buffers were 
stored at 4°C for a maximum of 1 week. Glucose and mannitol Krebs buffers 
were freshly made on the day of Ussing experiments. 
2.2.9.2 Glass barrel micro-reference electrode 
Electrodes arrived in a “ready to use” state, previously being coated with AgCl. 
To ensure continued efficiency, electrodes were cleaned with dH2O after each 
experiment. The ceramic tip of the electrode was kept in 3M KCl or deionised 
water in between uses and never allowed to dry out. After experiments, old AgCl 
coating was removed from electrodes by gently rubbing with steel wool. 
Electrodes were cleaned with dH2O and immersed in household bleach for 24-
48 hours before the beginning of experiments to ensure efficient chloriding of 
the silver wire was achieved and washed with deionised water before being 
assembled.  
2.2.9.3 Electrode assembly 
Top and bottom sections of the electrode cap are matched sets. The glass 
barrel was removed and filled with 3M KCl electrolyte solution, saturated with Ag 
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using a polyethylene filling tube. When assembling voltage detecting electrodes 
a red O-ring was stretched over the bottom of the glass barrel prior to filling. 
Electrodes were inserted into glass barrels and the cap ends attached as shown 
in Figure 2.4A. Voltage detecting electrodes were secured in place on the 
chambers using a screw while current passing electrodes were placed into 
grooves located within each chamber half (Figure 2.4B).  
2.2.9.4 Chamber set-up 
Prior to experiments, chambers were assembled in the absence of tissue and 
filled with 3ml transport Krebs buffer. The four Ag/AgCl electrodes were inserted 
into each chamber and connected to an EC825A voltage/Clamp unit to monitor 
voltage (mV) and to pass current (µA). Offset electrode potential was nullified 
after a minimum 30-40 minute equilibration period and initial resistance caused 
by buffer and the presence of a blue x-ray film piece (used to reduce aperture 
size) was calculated as explained in Chapter 4. Cumulative blue film and fluid 
resistance values were subtracted from tissue resistance values during analysis. 
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Figure 2.4. Ussing Chamber Electrodes and Chambers.  
(A) Assembled electrode diagram. (B) Single chamber set up. Placements of voltage 
and current electrodes are shown along with the positioning of tissue (depicted as a pink 
box) and gas ports. (C) Birds eye view of chamber set up. Voltage electrodes are 
positioned at a 45° angle to be closest to the tissue while current electrodes are situated 
within small grooves found inside each half of the chamber. 
 
2.2.9.5 Mouse tissue preparation 
Prior to tissue collection transport Krebs, glucose Krebs and mannitol Krebs 
were bubbled with 95% O2, 5% CO2 for no less than 30 minutes and pH set to 
7.3. Mice were culled by increased exposure to CO2 and death confirmed by 
cervical dislocation before being dissected along the ventral midline to expose 
the abdomen. The gastrointestinal tract from the stomach to the rectum was 
carefully removed and the colonic region separated by dissecting directly below 
the cecum. Colonic samples were immediately flushed with 20ml ice-cold 
B C 
A 
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transport Krebs buffer to remove waste products. Under 5x magnification colon 
samples were pinned down on to cold sylguard plates and opened longitudinally 
using micro-dissecting scissors. A piece of blue x-ray film punctured with a hole 
(aperture of 7.1 mm2) was placed directly onto the mucosal surface and the 
chosen section dissected from the remainder of the colon. Using the blue X-ray 
film, sections were mounted mucosal side up onto six pins located on the inner 
surface of the Ussing chamber. A second piece of blue x-ray film, corresponding 
in size to the first, is placed on top to “sandwich” the tissue in place, preventing 
leakage. Once mounted the chamber halves are closed and secured in place 
with metal circlips. Transport buffer is added to each side of the chamber and 
chambers transported to the laboratory on ice for electrode addition. All samples 
were transported to the lab within 30 minutes.  
2.2.9.6 Human biopsy preparation  
Prior to tissue collection transport Krebs, glucose Krebs and mannitol Krebs 
were bubbled with 95%O2, 5% CO2 for no less than 30 minutes and pH set to 
7.3. Qualified clinicians carrying out endoscopy procedures obtained biopsy 
samples using non-spiked forceps to avoid tissue damage. Up to six biopsy 
samples per patient were obtained and placed immediately in ice-cold transport 
Krebs buffer for transport to the laboratory. Under 5X magnification mucosal and 
serosal surfaces were identified and samples mounted mucosal side up into 
Ussing chambers. Biopsies were sandwiched between two pieces of blue x-ray 
film possessing identical holes giving an exposed tissue area of 0.79 mm2.  
2.2.9.7 Equilibration of tissue 
Once tissue was mounted, residual transport buffer was removed using an 
electric vacuum pump. Serosal compartments were filled with 1.5ml 10 mM cold 
glucose Krebs buffer to provide the tissue with an energy source and mucosal 
compartments filled with 1.5ml cold 10 mM mannitol Krebs buffer to maintain 
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osmotic balance without effecting glucose mediated Na+ transport. Buffers were 
added at a quick but steady pace to avoid dislodging the tissue. Electrodes were 
inserted at this time to monitor and achieve steady state potential difference 
(PD) values. Chambers were kept at 37°C using a circulating water bath and 
continuously oxygenated with 95% O2, 5%CO2 to aid tissue viability and provide 
buffer circulation. Buffers were renewed after 20 minutes and 30 minutes to 
remove auto-fluorescent molecules before measurements began.  
2.2.9.8 Electrical measurements  
The spontaneous tissue potential difference (PD) was measured continuously 
throughout experiments via the two voltage detecting Ag/AgCl electrodes. 
Experiments were performed in open circuit conditions where every five minutes 
short current pulses of 1.5, -1.5, 3 and -3µA with duration of 235ms were sent 
across the tissue via two Ag/AgCl current passing electrodes. Current 
stimulation was generated from an EC825A voltage/clamp unit via the 
PowerLab A/D D/A board controlled by a protocol developed in-house using 
LabChart software. The response of the tissue to current was measured at 
every stimulation event and the mean voltage response of four recordings was 
calculated. Resistance of the tissue at each five-minute recording was 
calculated using a linear least-squares fit model based on Ohm’s Law which 
describes the relationship between voltage (V) current (I) and Resistance (R) as 
R=V/I. From the slope of the line resistance was calculated and PD was equal to 
the intersection of the Y-axis as shown in Figure 2.5. Short circuit current (Isc) 
can be calculated by PD/R. Note that electrical resistance takes into account 
both trancellular and paracellular passage (Figure 2.6).  
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Figure 2.5. The principle of Ohm’s law. 
Ohm’s law states that the flow of electric current is proportional to voltage and inversely 
proportional to resistance. Epithelial resistance can be calculated as the slope of the 
line. 
 
2.2.9.9 Permeability Probe Studies 
4kDa FITC-dextran and Lucifer yellow (457 daltons) were used as probes for 
measuring paracellular transport. Once tissue had equilibrated for 30 min and 
had a steady PD value, mannitol-Krebs buffer from the mucosal chamber was 
replaced with 150µl 4kDa FITC-dextran or Lucifer yellow to give a final chamber 
concentration of 500 µg/ml and 250 µg/ml respectively.  At 60 and/or 120 
minutes paired mucosal and serosal samples (150µl) were taken and 
fluorescence analysed on a plate reader. Concentrations of 4kDa FITC-dextran 
and Lucifer yellow were determined based on a standard curve generated from 
known concentrations to identify paracellular passage (Figure 2.6).  
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Figure 2.6. Electrical current and paracellular probe passage involved in Ussing 
experiments.  
Current pulses are able to travel across the epithelial barrier through paracellular and 
transcellular routes. Epithelial cells act as both a conductor and a resistor to the current. 
TJ structures also give resistance to electrical current as well as to paracellular probe 
passage. 
 
2.2.10 Immunohistochemistry  
2.2.10.1 Tissue preparation 
The full mouse colon was opened longitudinally and flattened out, mucosal side 
facing up. The tissue was wrapped around a large pair of forceps to create a 
“gut roll”. This was pinned in place with a 23G needle and fixed in 10% NBFS 
buffer. Harvested spleen samples were also fixed using 10% NBFS. For 
samples ran in Ussing Chambers, 10% NBFS was added directly to chambers 
upon completion of Ussing experiments. Tissue was removed 2 days later and 
placed in universals containing 10% NBFS. A day later the 10% NBFS was 
replaced with 70% ethanol. Small sections of mouse tissue and human biopsies 
were agar embedded to ensure correct orientation of the tissue for sectioning 
(Figure 2.7). Samples were processed using a Shandon tissue processor, going 
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through automatic serial cycles of methanol to dehydrate the tissue in order to 
remove water from the specimen and allow the infiltration of wax. Cycles of 
xylene were used to clear the sample of methanol, as both methanol and water 
are immiscible in wax. Samples were then embedded into paraffin blocks. 5µm 
sections were cut using a microtome and placed onto glass slides for staining.  
2.2.10.2 Haematoxylin and eosin Staining 
Tissues were rehydrated by emersion in 100% xylene, 100% ethanol, 90% 
ethanol and deionized water.  Slides were then stained with Harris haematoxylin 
to observe the cell nucleus and counterstained with eosin to observe cellular 
cytoplasm. Both stains together provided a view of the colonic structure. Tissues 
were then dehydrated through a series of ethanol and xylene steps before finally 
DPX and a coverslip was placed on top to protect tissue staining. Details of 
staining steps and timings are detailed in Table 2.11. 
2.2.10.3 CEA staining 
The University Hospital of Wales pathology department kindly stained tumour 
sections from CRC patients. Tissue was stained using a programmed protocol 
on the Link 48 autostainer. Antigen retrieval was carried out using a high pH 
buffer solution for 40 min, followed by a 20 min cool down period. Sections were 
then stained with the flex mouse monoclonal anti-CEA antibody followed by the 
envision flex high pH kit, which contains a peroxidase block, HRP, DAB 
chromagen and buffer, wash buffer and haematoxylin. Slides were imaged using 
the digital Axio Scan.z1 slide scanner. 
2.2.11 Statistical analysis 
Prism 5 (GraphPad) was used for all parametric and non-parametric statistical 
analyses. Normal distribution was tested using the D’Agostino and Pearson 
omnibus normality test. A P-value ≤ 0.05 was considered statistically significant. 
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Figure 2.7. Agar embedding of small colonic samples. The tip of a 5ml syringe was 
removed and filled with approximately 1ml warm 2% agar. Human biopsy samples and 
small murine colonic samples were inserted upright and kept in place until the agar 
solidified. This kept small sections in the correct orientation for sectioning to visualise 
colonic crypts.  
 
Table 2.11. Haematoxylin and eosin staining protocol 
Step  
1. Deparaffinise sections with three changes of xylene (2-3 minutes each) 
2. Re-hydrate in two changes of absolute alcohol (3 minutes each) 
3. 90% alcohol and then 70% alcohol (2 minutes each) 
4. Wash briefly in distilled water 
5. Stain with Harris haematoxylin for 8 minutes 
6. Wash in running tap water for 5 minutes 
7. Differentiate in 1% acid alcohol for 30 seconds 
8. Wash in running tap water for 1 minute 
9. Blue slides in 0.2% ammonia water for 1 minute 
10. Wash under running tap water for 5 minutes 
11 Rinse in 95% alcohol, 10 dips 
Counter stain in eosin for 2 minutes 
12. Dehydrate through 95% alcohol (15 dips), 2 changes of absolute alcohol (2-3 
minutes each) 
13. Clear in three changes of xylene (5 minutes each) 
14. Mount with DPX 
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Chapter 3. T cell Responses to Carcinoembryonic antigen 
(CEA) in pre-operative CRC Patients. 
3.1 Introduction 
The immune system plays an important role in the control of CRC. In particular, 
IFN-γ producing CD4+ T-lymphocytes, which recognise tumour antigens, are 
critically involved in anti-tumour immunity. Studies report that an influx of Th1 
cells into CRC tumours is linked with favourable patient outcome (208, 224). Our 
own laboratory has identified peripheral blood-derived IFN-γ responses to the 
TAA 5T4. In pre-operative CRC patients, 5T4 IFN-γ specific responses correlate 
positively with patient survival (194, 201, 215). Conversely, we have discovered 
that a specific IFN-γ response towards the TAA CEA correlates with poor patient 
survival (194) (Figure 3.1A). This unexpected association is present regardless 
of tumour stage (Figure 3.1B) (194). Furthermore, individuals with both 5T4 and 
CEA specific responses had better survival than those responding to CEA 
alone, confirming a response to 5T4 is advantageous (194). Both TAAs are 
highly up-regulated in CRC, 5T4 being an oncofelatal antigen not widely 
expressed in healthy adult tissue. It can be detected in certain tissues with low 
expression such as the glomeruli in the kidney, villi of the small intestine and 
bladder epithelium (195). However, CEA is an auto antigen expressed in normal 
intestinal epithelium, falling into the “over expressed in cancer” category of 
tumour antigens (225). CEA is up-regulated in other adenocarcinomas such as 
breast and lung, making it an attractive target for immunotherapy (226, 227). 
However, the data from our laboratory clearly show there is a clinical 
significance of mounting a tumour-selective versus an auto-antigen-specific T 
cell response. This opens up a debate about the potential risks therapies aiming 
to target CEA may have. Furthermore, this observation raises the question of: 
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why do CEA specific T cell responses correlate with a detrimental outcome in 
the first place?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 3.1. CRC cancer patients secreting IFN-γ in response to CEA are at a 
greater risk of tumour recurrence.  
PBMC were taken prior to patients undergoing colectomy for CRC and IFN-γ CEA-
specific T cell responses measured by ELISpot. (A) The presence of a CEA response 
correlated with tumour recurrence over a 5 year time period before and (B) after 
stratifying patients by tumour stage. This data was generated by Dr Gareth Betts and 
analysed by Dr Martin Scurr (194). 
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Th17 cells were first described in mice in 2005 and are characterised by IL-17A 
production (228). High numbers reside within the colon. They are induced by the 
presence of intestinal microbes, capable of adhering to intestinal epithelial cells, 
such as SFB (229). While important for defence against fungal and bacterial 
pathogens, studies suggest Th17 cells are involved in tumour development, 
particularly in the progression of CRC (230). Increased Th17 infiltration is seen 
within stage II and further advanced CRC tumours (210) (231). Tosilini and 
colleagues have carried out gene expression analysis in three separate cohorts 
of CRC patients. Results from this have clearly shown that a high intra-tumoral 
infiltration of Th17 cells, in combination with low levels of Th1 cells, is 
associated with shorter disease-free survival (209). The presence of Th17 cells 
in other intestinal diseases such as CD and UC has also been documented. IBD 
patients show elevated IL-17A levels within mucosal tissue and sera compared 
to healthy controls. This also increases with disease severity (80). IBD and 
inflammation has long been linked to CRC development, with an increase in 
CRC incidence occurring within IBD patients (232, 233). Inflammatory mediators 
such as IL-6 and TNF-α are known to have pro-tumourigenic properties, due to 
their ability to activate oncogene associated transcription factors (234). Also 
implicated in promoting tumour progression is IL-17A, capable of activating the 
transcription factor STAT-3. This activation can lead to increased tumour cell 
survival, proliferation and invasion, as well as promoting immune-suppression 
(235, 236). Moreover, persistent STAT-3 activation can provide a proliferative 
advantage to myeloid cells within the tumour microenvironment to promote pro-
oncogenic inflammation (237) (238). Another key feature of tumour development 
is the formation of new blood vessels. Liu and colleagues show that IL-17A can 
play a role in shaping the tumour vasculature, promoting angiogenesis via 
VEGF and PGE2 production (239), again aiding in tumour development. Based 
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on this collective knowledge of Th17 cells, I aimed to generate a data set 
investigating CEA specific IL-17A producing cells.  
 
I hypothesised that CEA specific IL-17A and/or IFN-γ/IL-17A dual producing 
cells could be responsible for overcoming beneficial IFN-γ responses within 
CRC patients, ultimately leading to tumour recurrence. This Chapter focuses on 
i) evaluating IFN-γ and IL-17A secretion in response to CEA and 5T4 in a cohort 
of CRC patients, and ii) phenotyping CD4+ T cells subsets isolated from primary 
tumours of CEA responding and non-responding patients. 
 
3.2. Results 
3.2.1 CEA and 5T4 specific IFN-γ and IL-17A responses measured by the 
FluoroSpot assay 
The FluoroSpot technique is built on the widely used ELISpot assay, employed 
to measure the frequency of cytokine-secreting cells. However, unlike ELISpot, 
FluoroSpot allows for the detection of up to three cytokines in the same assay 
and from the same single cell. PBMC from patients or healthy donors were 
cultured for two-weeks with CEA or 5T4 peptide pools to expand antigen 
specific cells. The recall response to antigens was then measured using the 
FluoroSpot technology (full method described in Chapter 2). In doing so, it was 
possible to determine whether cells specific for CEA produced IFN-γ and/or IL-
17A. Responses to 5T4 were also measured to determine if they were similar or 
different to those produced against CEA. Figures 3.2 and 3.3 show 
representative examples of patients who responded to CEA and 5T4 peptide 
pools respectively. Green spots indicate IFN-γ secretion and red spots show IL-
17A. A computerised overly is used to visualise IFN-γ/IL-17A dual producing 
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cells, shown in yellow. Responses to control antigens haemagglutinin (HA) and 
purified protein derivative (PPD) were also measured (Figure 3.4).  
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Figure 3.2. Examples of IFN-γ, IL-17A and IFN-γ/IL-17A dual secretion after 
stimulation with CEA peptide pools. 
5x105 PBMC were stimulated with CEA PP1, incubated for 2 weeks and re-stimulated (+ 
antigen) or not (- antigen) with CEA PP1 again, before detection of cytokine release. 
Green spots represent IFN-γ release and red spots IL-17A. Yellow spots indicate IFN-
γ/IL-17A dual secretion. 
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Figure 3.3. Examples of IFN-γ, IL-17A and dual IFN-γ/IL-17A secretion after 
stimulation with 5T4 peptide pools. 
5x105 PBMC were stimulated with the indicated 5T4 peptide pools, incubated for 2 
weeks and re-stimulated (+ antigen) or not (- antigen) with the same antigen, before 
detection of cytokine release. Green spots represent IFN-γ release and red spots IL-
17A. Yellow spots indicate IFN-γ/IL-17A dual secretion. 
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Figure 3.4. Examples of IFN-γ, IL-17A and dual IFN-γ/IL-17A secretion after 
stimulation with control antigens HA, PPD and PHA.  
5x105 PBMC were stimulated with (A) HA, (B) PPD or (C) PHA, incubated for 2 weeks 
and re-stimulated (+ antigen) or not (- antigen) with the same antigen, before detection 
of cytokine release. Green spots represent IFN-γ release and red spots IL-17A. Yellow 
spots indicate IFN-γ/IL-17A dual secretion. 
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3.2.2 CEA and 5T4 specific IFN-γ and IL17A responses in pre-op CRC 
patients and healthy donors 
A cohort of patients (n=40) was used to investigate whether CEA-specific IL-17A 
producing cells could be responsible for the poor survival outcome seen within 
CEA responding patients. Complementary to previous studies in our laboratory it 
was observed that healthy donors and CRC patients produced CEA-specific and 
5T4-specific responses (Figure 3.5). In this new cohort of patients there was no 
difference observed between percentages of healthy donors producing IFN-γ in 
response to CEA or to 5T4 (Figure 3.6A and Figure 3.7A respectively). 
Conversely, a higher percentage of healthy donors produced an IL-17A CEA 
response compared to an IL-17A 5T4 response (Figure 3.6B and Figure 3.7B, 
respectively). This indicates that under non-pathological conditions CEA is a 
potent promoter of IL-17A. There was however, no increase in the percentage of 
CRC patients secreting CEA-specific IL-17A in comparison to the healthy 
donors (Figure 3.6B). Furthermore, CRC patients also secreted IL-17A in 
response to 5T4 as well as CEA (Figure 3.7B). This data suggests that CEA 
responding patients are not more likely to generate IL-17A producing cells than 
healthy donors or patients responding to 5T4. 
 
CEA-specific IFN-γ responses were seen within a similar percentage of CRC 
patients across disease stage (~60%) (Figure 3.6A). The magnitude of the IFN-γ 
response (calculated from the combined response to PP1 and PP2) towards 
CEA and 5T4 are shown Figure 3.8A and 3.8B respectively. Interestingly, the 
magnitude of response is lower in Dukes C patients compared to healthy 
controls (Figure 8C and Figure 8D.) This supports previous findings in our 
laboratory, showing that 5T4 IFN-γ responses decline in advanced CRC (216). 
Such results indicate that while CRC patients maintain an IFN-γ response to 
CEA, the total magnitude of that response is reduced in CRC. At present it is 
	 103	
unclear why Dukes B patients do not show a reduced magnitude of response 
compared to HD. There was no association observed between CEA-specific IL-
17A response magnitude and disease stage (Figure 3.8E). Moreover, CEA 
responses were not increased compared to 5T4-specific IL-17A secretion. 
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Figure 3.5. Percentage of CRC patients with a CEA and 5T4 response is similar to 
that seen within our previous study (Scurr et al 2015). 
(A) Percentage of IFN-γ CEA specific and (B) IFN-γ 5T4 specific responders. n= 55 
patients in previous study vs n= 40 in current study. Fishers exact test was used for 
comparison. 
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Figure 3.6. CEA responses are present within healthy donors and CRC patients.  
Percentage of individuals secreting (A) IFN-γ or (B) IL-17A in response to CEA. CRC 
patients were grouped based on Dukes stage. Fishers exact test was used for 
comparisons. 
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Figure 3.7 The percentage of IFN-γ secreting 5T4 responding patients declines 
with advanced disease. 
The percentage of patients responding to 5T4, secreting either (A) IFN-γ or (B) IL-17A. 
CRC patients were grouped based on Dukes stage. Fishers exact test was used for 
comparisons. 
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Figure 3.8. Magnitude of IFN-γ but not IL-17A CEA and 5T4 responses decline in 
CRC patients.  
(A) Total magnitude of IFN-γ responses to CEA and (B) 5T4. Patients grouped based on 
Dukes stage. (C) CEA and (D) 5T4 IFN-γ response magnitude of HD and Dukes C 
patients. (E) and (F) show total magnitude of IL-17A responses towards CEA and 5T4 
respectively. Error bars show mean +/- SEM. Mann Whitney tests were used to test for 
statistical differences between groups. 
C 
B 
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Overall it was found that cells producing IFN-γ in response to CEA and 5T4 
were more frequent than IL-17A or IFN-γ/IL-17A dual producing cells (Figure 
3.9). Furthermore, the magnitude of IFN-γ responses was always higher 
compared to IL-17A (Figure 3.10). This was also true for HD (Figure 3.11). This 
suggests that greater IL-17A responses are not outweighing beneficial IFN-γ 
responses to drive tumour recurrence in CEA responding patients. In fact, IL-
17A was only secreted in response to CEA when IFN-γ was also made. PBMC 
from twenty-six patients produced IFN-γ with seventeen also secreting IL-17A in 
response to CEA. No solitary IL-17A response was detected in CRC patients or 
in HD (Figure 3.9A and C). In response to 5T4, only one patient secreted IL-17A 
alone (Figure 3.9B). The total magnitude of IFN-γ and IL-17A secretion between 
CEA and 5T4 antigens (Figure 3.12A and 3.12B, respectively) was also the 
same. This indicates that neither antigen is superior at activating an immune 
response. Taken together these data demonstrate that CEA and 5T4 are similar 
in their ability to stimulate IL-17A production, which is low in magnitude and 
secreted in conjunction with IFN-γ.  
 
Previous studies indicate that low affinity CEA-specific T cells are present within 
the normal T cell repertoire (240, 241). These data highlight that CEA and 5T4 
specific cells are capable of secreting both IFN-γ and IL-17A. However, 
collectively these data also suggest that IL-17A secreted by CEA-specific cells 
in the blood does not reflect the increase in tumour occurrence in patients 
identified previously as IFN-γ CEA-responders from blood samples. 
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3.2.3 CEA-specific responses, CEA tumour cell expression and CEA serum 
levels  
CEA is an adhesion molecule, implicated as a marker of tumour progression as 
it is shed from the tumour surface (187). Accordingly, in CRC, high levels of 
serum derived CEA is linked to advanced disease (242). Studies performed in 
mice also showed that systemic CEA protein results in increased liver 
metastases (187).  We aimed to investigate whether CEA-specific PBMC 
responses were a result of high soluble CEA within serum, possibly indicating 
micro-metastasis not detectable at the time of diagnosis. Serum CEA was 
measured before primary tumour surgical resection and at least six months after 
surgery to address whether this had any correlation with IFN-γ or IL-17A CEA-
specific responses. However, no association between high levels of serum CEA 
and generation of CEA-specific responses either before (Figure 3.13A), or after 
surgical resection (Figure 3.13B) were found.  
Also investigated was tumour cell CEA expression itself to determine if this 
correlated with the presence of CEA-specific T cells in the blood. Seven tumours 
were selected at random, with six showing positive staining for CEA (Figure 
3.14A). However, only two patients with CEA+ tumours mounted a CEA-specific 
T cell response (Figure 3.14B). This indicates that the presence of CEA alone 
either soluble in serum or expressed on the tumour surface does not dictate 
development of a measurable antigen-specific T cell response. 
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Figure 3.9. An IL-17A CEA or 5T4 specific response occurs alongside an IFN-γ 
response.  
(A) The number of patients secreting IFN-γ alone, IL-17A alone or combinational 
responses towards CEA and (B) 5T4. (C) The number of HD secreting IFN-γ alone, IL-
17A alone or combinational responses towards CEA and (D) 5T4. IFN-γ and IL-17A 
indicates two separate cell populations secreting each cytokine concurrently. IFN-γ/IL-
17A indicates secretion is from the same population. 
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Figure 3.10. CEA specific and 5T4 specific IFN-γ responses are higher in 
magnitude than IL-17A in CRC patients. 
(A) Total magnitude of responses to CEA and (B) 5T4, calculated by combining 
responses specific for peptide pools 1 and 2. Error bars indicate mean +/- SEM. Kruskal-
Wallis test was used for comparisons. (C) CEA specific and (D) 5T4 specific IFN-γ, IL-
17A and IFN-γ/IL-17A responses for individual patients. One line represents one patient. 
(E) Responses specific to control antigens HA and (F) PPD. 
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Figure 3.11. CEA specific and 5T4 specific IFN-γ responses are higher in 
magnitude than IL-17A in HD. 
(A) Total magnitude of responses to CEA and (B) 5T4, calculated by combining 
responses specific for peptide pools 1 and 2. Error bars indicate mean +/- SEM. Kruskal-
Wallis test was used for comparisons. (C) CEA specific and (D) 5T4 specific IFN-γ, IL-
17A and IFN-γ/IL-17A responses for individual HDs. One line represents one patient. (E) 
Responses specific to control antigens HA and (F) PPD. 
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Figure 3.12. There is no difference in magnitude of response towards CEA and 
5T4.  
(A) IFN-γ response towards CEA and 5T4, calculated by combining peptide pools 1 and 
2. (B) IL-17A response to CEA and 5T4. Error bars indicate mean +/- SEM. 
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Figure 3.13. Serum CEA levels do not correlate with a CEA specific PBMC 
response. 
(A) Serum CEA level before and (B) after surgical colectomy. Post surgical samples 
were obtained a minimum of 6 months after the procedure. Responder indicates the 
presence of an IFN-γ, IL-17A or dual response. Error bars indicate mean +/- SEM. 
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Figure 3.14. CEA expression can be detected on tumours but does not correlate 
with the presence of a PBMC response.  
(A) Immunohistochemistry staining of CRC tissue. Brown stain shows CEA expression. 
Nuclear stain is blue. Tissues from the appendix and from a known negative colon 
sample were used as controls. (B) The number of responding or non-responding CRC 
patients with CEA+ or CEA- tumours.  
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3.2.4 The presence of CEA specific responses in blood correlates with 
lower percentages of T-lymphocyte subsets 
 
Infiltration of CD3+ T-lymphocytes into tumours has been shown to correlate with 
better patient survival in many cancers, including breast, ovarian, prostate and 
colorectal. However, the combination of T cell subsets present is also important. 
As mentioned previously, Tosilini et al showed that within CRC tumours high 
infiltration of Th17 cells, in combination with low Th1 cells has a negative impact 
on patient survival (209). However, only expression of genes associated with T 
cell subsets was assessed and not cytokine secreting cells. In this current study 
CD3+CD4+ cells from PBMC, healthy colon and TILs were phenotyped from 
CEA responding and non-responding patients to investigate infiltrating T cell 
subsets. This made it possible to determine if presence of an IFN-γ and/or IL-
17A CEA-specific response measured in blood reflects a difference in the 
tumour immune cell profile.  
Using PMA/ionomycin stimulation and the staining panel shown in Table 2.7 in 
Chapter 2, the frequency and phenotype of CD4+ T-helper subsets was 
identified. Representative gating strategies for PBMC, healthy colon and TILs 
are shown in Figure 3.15 and Figure 3.16. Analysis showed that CRC patients 
with a CEA response (IFN-γ or IL17A) had significantly lower frequencies of 
CD4+ IFN-γ+, FoxP3+ and CCR6+ TILs compared to CEA non-responders (Figure 
3.17C, F and I respectively). Representative FACS plots of reduced marker 
expression are shown in Figure 3.18A, B and C. A reduced frequency in the 
Th17 cell associated chemokine receptor CCR6 was also found within the 
healthy colon and PBMC fractions of CEA responding patients (Figure 3.17G 
and 3.17H). Interestingly no reduction in IFN-γ+, FoxP3+ or CCR6+ T cell subset 
frequency was found between 5T4 responders and non-responders (Figure 
3.19). There was also no difference in frequencies of IL17A+ CD4+ or IL10 + 
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CD4+ T cells in any compartment between CEA or 5T4 responders and non-
responders (Figure 3.20A-L).  
This data shows there is no increase in IL-17A-producing cells (Th17 cells) 
within CEA responding patients compared to non-responders. Therefore, an 
increase in Th17 cells is unlikely to be the cause of poor patient survival within 
CEA responding patients. The data also shows that a CEA-specific response is 
linked with low immune cell infiltrated tumours. This suggests that tumours from 
CEA responsive patients may be poorly immunogenic and/or more aggressive 
than tumours from CEA non-responsive patients. 
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Figure 3.15. Representative gating strategy used to analyse CD3+ CD4+ PBMCs. 
Patient PBMCs were isolated and stained using the panel shown in Table 2.7 in Chapter 
2. (A) Lymphocytes were gated based on granularity and size using side scatter (SSC) 
and forward scatter (FSC). (B) Gating on FSC area and height identified single cells. (C) 
Live cells were selected by the ability to exclude Aqua live/dead dye. (D) CD3+ CD4+ 
cells were then selected prior to cytokine expression analysis. (E) Fluorescence minus 
one (FMOs) was used to set gates showing cytokine secretion. (F) Representative 
gating of IFN-γ secretion by unstimulated PBMC. (G-K) Shows the same gating strategy 
for PMA/Ionomycin with Brefeldin-A stimulated cells. 
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Figure 3.16. Representative gating strategy used to analyse CD3+ CD4+ colon cells 
and TILs.  
Healthy colon infiltrating lymphocytes and TILs were isolated and stained using the 
panel shown in Table 2.7 in Chapter 2. The gating strategy was the same as shown in 
Figure 3.14. FMOs were used in the majority of cases when enough cells were 
available. Where cell numbers were too low, gates were applied based on comparison 
with un-stimulated cells. (A-D) Representative plots of IFN-γ release from un-stimulated 
and stimulated CD3+ CD4+ cells from healthy colon. (E) Backgating of CD4+ IFN-γ+ colon 
cells. (F-I) Representative plots of IFN-γ release from un-stimulated and stimulated 
CD3+ CD4+ cells from TILs. (J) Backgating of CD4+ IFN-γ+ TILs. 
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Figure 3.17. CEA responding patients have lower percentages of CCR6+, FoxP3+ 
and IFN-γ+ T lymphocytes.  
(A-C) Percentage of IFN-γ secreting, (D-F) FoxP3+ and (G-I) CCR6+ CD3+ CD4+ cells 
from PBMC, healthy colon or TILs, isolated from CEA responders and non-responders 
after stimulation with PMA/Ionomycin. Error bars indicate mean +/- SEM. Unpaired two-
tailed students T-test used to test for significant differences. 
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Figure 3.18. Representative FACS plots showing reduced expression of IFN-γ, 
FoxP3 and CCR6 in CEA responding patients. TILs were gated as described in 
Figure 15. CEA non-responder and responder (A) IFN-γ secretion, (B) FoxP3 and (C) 
CCR6 expression. Un-stimulated cells were used to apply gates where cell number was 
too low for FMO).
B 
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Figure 3.19. No difference was found between CD3+CD4+ cells from 5T4 
responders and non-responders. 
(A-C) Percentage of IFN-γ secreting, (D-F) FoxP3+ and (G-I) CCR6+ CD3+ CD4+ cells 
from PBMC, healthy colon or TILs, isolated from 5T4 responders and non-responders. 
Error bars indicate mean +/- SEM. Unpaired two-tailed students T-test used to test for 
significant difference. 
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Figure 3.20. IL-17A and IL-10 secretion showed no difference between CEA or 5T4 
responders or non-responders.  
(A-C) Percentage of IL-17A+ CD3+, CD4+ and (D-F) IL10+ CD3+, CD4+ PBMC, colon 
cells and TILs from CEA non-responders and responders. (G-I) Percentage of IL-17A+ 
CD3+, CD4+ and (J-L) IL10+ CD3+, CD4+ PBMC, colon cells and TILs from 5T4 non-
responders and responders. Error bars indicate mean +/- SEM. Unpaired two-tailed 
students T-test used to test for significant differences. 
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3.3 Discussion 
CEA is over-expressed in many adenocarcinomas, widely investigated as a 
potential therapeutic marker since its discovery in 1965 (183). Mice do not 
express the CEA protein. Therefore CEA transgenic (Tg) mice, displaying 
similar CEA expression patterns to that found within humans, were generated 
for use in animal studies (189). Vaccination work in Tg mice has demonstrated 
that tolerance can be broken to produce protective immune responses against 
CEA-tumour expressing cells (240). Human studies have also demonstrated an 
ability to stimulate CEA-specific T cell responses, after immunisation with CEA-
loaded vaccines (243). However, what is not clear from these studies is the 
association between CEA-specific responses and long-term survival of patients. 
Studies from our laboratory have shown that CEA-specific T cell responses 
actually correlate with tumour recurrence in CRC patients.  
 
This Chapter focused on whether IL-17A played a role in promoting the poor 
survival prognosis seen within CEA responding patients (194). Using FluoroSpot 
technology we have established for the first time that IL-17A CEA-specific 
responses can be detected. However, the percentage of IL-17A responding 
patients did not increase compared to healthy donors. Furthermore, the 
magnitude of IL-17A responses did not increase compared to IFN-γ secretion. 
Nor did IL-17A CEA responses differ from 5T4 responses. Collectively these 
data demonstrate that CEA-specific IL-17A is not the main factor in peripheral 
blood influencing poor outcome within CEA responding patients. Other 
explanations therefore must account for the increased tumour recurrence 
observed.  
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This study indicates that tumours from IFN-γ/IL-17A CEA-specific responsive 
patients may be less immunogenic. Significant decreases in IFN-γ+, FoxP3+ and 
CCR6+ T cell populations were detected, compared to tumours from non-
responsive patients. Low immunogenicity of tumours is often attributed to 
selective pressures elicited by immune responses within the host themselves 
and has been shown to be a major factor in the failure of the immune system to 
cause tumour regression (244). Recently, increased knowledge of genomic and 
transcriptomic patterns has resulted in a consensus molecular classification 
system (CMS) to characterise CRC tumours. Based on biological and gene-
expression most tumours can be classified into four subtypes (CMS1- CMS4) 
(174). We suggest that tumours from CEA responsive patients are microsatellite 
stable, expressing low levels of neopeptides available to stimulate immune 
responses. Concurrent with this we suggest the tumours are of a chromosomal 
instable subtype, CMS2 or CMS3, which lack TILs and immunoregulatory 
cytokines. CMS2 and CMS3 tumours are also typically PDL-1 negative, 
suggesting they are poorly immunogenic (174, 245). A study by Spragner and 
colleagues however has pointed out that in melanoma tumours the density of 
antigen does not dictate the presence of a tumour response and that batf-3 
linage dendritic cells, which were not investigated in this study, are key to 
generating T cell responses (246). With this in mind, it would be advantageous 
to investigate the molecular signature of tumours from CEA-specific responsive 
patients. 
 
A key fact about CRC, which one must take into account, is that tumours 
develop in close proximity to intestinal micro-biota. The field of host–microbe 
mutualism and its relationship with intestinal disease is becoming of great 
interest. Recent studies indicate that the micro-biota is dysregulated in CRC 
patients compared to healthy controls (247). This is also the case in IBD 
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patients (248, 249) Furthermore the presence or absence of bacterial strains 
have correlated with differences in response to immunotherapy. In particular 
Daillere et al (2016) have shown that bacterial species Enterococcus hirae and 
Barnesiella intestinihominis can alter the immune landscape of the tumour 
microenvironment to reduce regulatory T cells and stimulate cognate antitumor 
cytotoxic T lymphocyte responses (250). As a result, this correlated with better 
efficacy during treatment with the anti-cancer immunomodulatory agent 
cyclophosphamide. 
 
On the other hand, it is possible that micro-biota can stimulate immune 
responses, driving intestinal inflammation, which could aid tumour development. 
There is strong evidence that aspirin and other nonsteroidal anti-inflammatory 
drugs help to prevent the growth of polyps and cancer in the colon, findings 
which support a role for inflammation in disease pathogenesis (251). A study by 
Grivennikov et al has shown that IL-23 and IL-17A levels are increased in a CRC 
mouse model and within patients. IL-23 is secreted in response to stimulation of 
toll-like receptors (TLRs) on myeloid cells, activated by bacterial products 
derived from the microbiota. IL-23 is then capable of acting on downstream 
cells, including lymphocytes, contributing to an inflammatory signature 
comprising of IL-17, IL-6, and IL-22. Such cytokines and other inflammatory 
molecules (TNF-α) have been shown to promote activation of pro-oncogenic 
genes, capable of stimulating tumour cell survival and proliferation (234). 
Associated with intestinal inflammation is loss of epithelial barrier function, 
shown by reduced tight junctional protein and surface mucin expression (252). 
Disruption of the epithelial barrier can lead to further translocation of microbes 
and microbial products from the intestinal lumen. This can result in further IL-23 
secretion and downstream effects, resulting in a continuous cycle of 
inflammation (213) (253). Loss of the tight junctional protein claudin-3, 
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responsible for maintaining barrier function in the colon has been shown to 
induce IL-6 and STAT-3 signalling. The authors of this study observed increased 
STAT-3 activation was associated with CRC malignancy in mice and also 
correlated with CRC progression in humans (254). Together this data implies 
there is an important role for intestinal barrier function in CRC development. 
 
CEA is a glycoprotein, expressed on the normal intestinal epithelium at low 
levels as well being up-regulated in adenocarcinomas. It is possible that a 
dysfunctional epithelial barrier may allow cross reactivity of CEA-specific T cells 
to luminal microbial products; generating local inflammation. In turn, 
inflammation and CEA-specific T cells could drive further barrier deterioration 
and provide a pro-tumorigenic niche for tumour cells to survive and proliferate. 
As CEA specific IL-17A secreting cells were found not to be the cause of poor 
survival within CEA responding patients, we next hypothesised that CEA 
responsive patients had increased intestinal mucosal permeability. In support of 
this hypothesis, IL-17A has been shown in some studies to actually promote 
mucosal barrier function and in its absence there is an increase in epithelial 
injury and compromised barrier function (255, 256). It is possible the reduction in 
Th17 cells seen within CEA responding patients (lower CCR6+ T cell infiltration) 
could have a role in tumourigenesis though lack of epithelial barrier 
maintenance. Investigations into epithelial barrier function are discussed in 
Chapter 4 and Chapter 5. 
 
3.4 Conclusion 
In this chapter it has been shown that CEA and 5T4 TAAs are capable of 
stimulating IFN-γ and IL-17A responses from PBMC obtained from CRC 
patients. However, it has been concluded that blood CEA-specific IL-17A 
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secreting cells are not responsible for the increased tumour recurrence seen 
within CEA responding patients, identified in the laboratory’s previous study. 
However, a response to CEA could be used as a biomarker for monitoring 
disease as CEA responders may have less immunogenic tumours, indicating 
tumour recurrence would be more likely.  
An investigation into epithelial barrier function playing a role in the correlation 
seen within CEA-specific responses and tumour recurrence is discussed in the 
remainder of this thesis.  
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Chapter 4. Optimisation of the Ussing Chamber system 	
4.1 Introduction 
The Ussing Chamber system was originally developed by Danish biologist Hans 
Ussing in the 1950’s to understand the phenomenon of active Na+ transport 
(257). At the heart of the system lies the chambers, with a perfusion system, 
electrodes, an amplifier and a data acquisition system performing supporting 
roles (Figure 4.1). 	
The chambers support epithelial tissue or cell monolayers in such a way that 
each side of the membrane is isolated and faces a separate chamber-half. The 
chambers are then filled with a physiologically relevant solution, such as Krebs 
buffer. This configuration allows for adjustments to either side of the tissue 
membrane with complete control. The initial work performed by Hans Ussing 
led to the two-membrane hypothesis for epithelial transport, where the apical 
membrane is permeable to Na+ and the basolateral permeable to K+ (258). This 
paradigm served as the foundation for our present models of transepithelial 
transport. In later years it was discovered that primary active transport via the 
Na+/K+ ATPase pump is capable of transporting Na+ ions out of the cell in 
exchange for K+. It is this mechanism which provides absorption of Na+, 
establishing an electrochemical gradient for secondary active transport of other 
ions and water absorption (259). Together these studies unravelled a 
fundamental physiological cellular process. 
 
Ussing chambers have also been utilised in the investigation of diseases, 
including cystic fibrosis. The CFTR receptor, found on the apical membrane, is 
defective within patients. As seen by Ussing measurements this leads to 
increased Cl- secretion and Na+ absorption within epithelial cells, located in the 
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intestine and airways (260, 261). This abnormal ion movement causes an 
inability to effectively absorb nutrients from the gut. Moreover, it results in a 
reduction of airway surface liquid and excess mucus production. This affects 
sterility of the airways, leading to susceptibility to infection and the development 
of inflammation (262).  
 
While Ussing can be used to monitor ionic movements, the system is also able 
to evaluate permeability of tissues via electrical and fluorescent probe flux 
measurements. Various methods to measure permeability exist, with tracer 
molecules including Cr-EDTA (263), polyethylene glycols (PEGs) (264, 265) and 
fluorescently labelled dextran (256, 266) often used to monitor passage across 
epithelial tissue. In more recent studies, 4kDa FITC-dextran is frequently used in 
vivo, where animals are orally administered dextran and levels in blood plasma 
are measured four hours later (267). However, the passage of tracer molecules 
in vivo fails to provide information on precise locations of increased permeability. 
Other factors including gastrointestinal motility, surface area and mucosal blood 
flow differences may also lead to inaccuracy of measurements. The ex-vivo 
Ussing system aims to remove some of these limitations, by investigating 
permeability of isolated tissue sections under consistent environmental 
conditions and with the same exposed surface area. The epithelial barrier is 
semi-permeable, with charge and size selectivity limiting the passage of liquids, 
ions and larger solutes. By using both tracer molecule and electrical 
measurements, explained within this chapter, Ussing takes into account both 
ionic and paracellular permeability, often referred to as the pore and leak 
pathways (268). This gives a robust insight into the overall permeability of tissue 
specimens. Increased 4kDa FITC-dextran passage can be seen across the gut 
during colonic enteropathy. Studies show that inflammatory molecules TNF-α 
and IFN-γ have key roles in modifying tight junctional (TJ) protein complexes, 
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found between epithelial cells, through myosin light chain kinase expression 
(269). Down regulation of TJ “sealing” proteins such as claudins 3, 5, 8 and 
JAM-A, as well as up-regulation of the pore forming claudin-2 are associated 
with increased permeability (27, 270-274). Furthermore over expression of the 
tight junctional protein occludin was found to prevent increased permeability 
within Madin-Darby canine kidney (MDCK) cell monolayers (10). There was no 
increased permeability seen within occludin-/- mice (275), however it may be 
important for cell adhesion (276). Human studies of intestinal tissue from IBD 
patients also show TJ differences between inflamed tissues compared to 
healthy samples, as reviewed by Landy and colleagues (277). Complementary 
to these findings, Ussing chamber analysis has demonstrated that IBD patients 
have increased intestinal permeability, shown both by electrical and probe flux 
measurements (278, 279). It is clear from these studies that distribution and 
composition of TJ proteins impacts intestinal barrier function, which can be 
measured using the Ussing chamber system. 
 
Current data from our laboratory indicates that CRC patients responding to the 
tumour-associated antigen CEA have a poorer survival prognosis than non-
responding patients (194). The majority of CRCs overexpress the CEA protein 
but it can also be detected at low levels on the surface of healthy intestinal 
mucosa (280). Soler and colleagues have previously shown that the 
permeability of colonic tissue in CRC is increased compared to healthy 
specimens (281). Furthermore, mouse models have suggested barrier defects 
could aid in tumour progression through generation of an inflammatory 
environment (213, 253). Based on this information and as mentioned in Chapter 
3, I hypothesised that CEA responding patients have reduced intestinal barrier 
function. This could allow cross reactivity of CEA-specific T cells to luminal 
microbial products, possibly creating an inflammatory environment. In turn, 
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inflammation could drive further barrier deterioration and provide a pro-
tumorigenic niche for tumour cells to thrive. This could explain why a CEA-
specific T cell response is associated with tumour recurrence. To address 
measuring intestinal permeability I aimed to successfully construct an Ussing 
chamber system within our laboratory. This chapter describes the design of our 
Ussing system, optimisation of the method and validation of the technique in two 
mouse models of intestinal inflammation.  
 
4.2: Results  
4.2.1 Ussing System Design 
I first set out to assemble an Ussing chamber system selecting each element 
individually for the purpose of this study, thereby creating a system unique to 
our laboratory.  
The Navicyte Ussing design was used. It accommodates six individual Ussing 
chambers, providing analysis of six tissue samples simultaneously (Figure 
4.2A). The chambers themselves are a modified version designed by Grass and 
Sweetana in 1988 (282) (Figure 4.2B and 4.2C). The chambers consist of two 
halves with the intestinal tissue specimen mounted as a semi-permeable 
membrane in-between (Figure 4.2D).  
During electrical evaluation of intestinal integrity, the three main building blocks 
of electricity are required: voltage, current and resistance. Each Ussing chamber 
is therefore equipped with four Ag/AgCl electrodes to obtain electrical readings 
(Figure 4.2B and Figure 4.2C). The Ag/AgCl electrode is stable at various 
temperatures and pH levels. Also the use of glass barrels with a ceramic 
junction at the end of the electrode renders the use of agar bridges obsolete. 
Electrodes are connected to an EC825A voltage/clamp box to monitor both 
voltage and current  (Figure 4.2E).  
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Figure 4.1. The Ussing chamber system. 
Image of laboratory bench showing Ussing chambers and all other supporting equipment required for permeability experiments.
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Figure 4.2. Design of the Ussing chamber system. 
(A) Navicyte Ussing system unit supporting six chambers with custom made electrical 
manifold. (B) Individual Ussing chamber with voltage and current Ag/AgCl electrodes. 
(C) Birds-eye view of individual Ussing chamber showing electrode and gas inserts. (D) 
Chamber halves showing metal pins used to secure tissue. Gas flow direction to stir 
buffer is depicted by arrows. (E) Amplifying EC825A voltage clamp box containing a volt 
and amp meter to record voltage and current respectively. External timer is selected to 
connect to computer software. 
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 4.2.2 Electrical Resistance Measurements and Optimisation of Software 
Columnar epithelial cells that line the intestine are polarised structures, with 
cations and anions being transported across apical and basal membranes at 
different rates (32, 283). The separation of charged ions across the phospholipid 
bi-layer creates a membrane potential at each side of the epithelium. This 
polarisation is a fundamental property of epithelial cells and is essential for the 
absorption of electrolytes, water and salt. By inserting the Ag/AgCl electrodes at 
the apical and basal membranes each potential can be detected and the overall 
spontaneous tissue voltage across the epithelium determined. This value is 
termed the potential difference (PD), measured in volts and is displayed on the 
EC825A volt/clamp box. The PD is an indicator of tissue viability and essential 
for all Ussing chamber experiments (284).   
Electrical resistance of tissue is often used as a measurement of gut integrity, 
with low electrical resistance indicating tissue is leaky. An open circuit current 
clamping technique was used for all experiments. PD was continuously 
measured and small square current pulses of 1.5, -1.5, 3 and -3 µA were 
delivered across the specimen. Injections of external current pulses charge the 
apical and serosal membranes towards depolarisation and hyperpolarisation 
resulting in a change of tissue PD. Voltage electrodes sense this change in PD 
and it can be visualised using computer software. An overview of the electrical 
circuit can be seen in Figure 4.3.  
 
Initially murine colonic samples were clamped at particular current amplitudes 
manually and the effect on tissue voltage was measured using the EC825A 
volt/clamp box. This provided expected values that could be used validate the 
values obtained using our new computer-controlled stimulation. As shown 
previously by Asa Keita and colleagues, current stimulation pulses with the 
magnitudes chosen were sufficient to detect a voltage response from small 
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tissue samples (285). However, the number of current pulses to be delivered 
across the tissue was tested (Figure 4.4A, B and C). As pulses resulted in 
almost identical tissue response peaks, a repeat of four current pulses at each 
magnitude was selected. This allowed for a mean voltage response to be 
calculated and reduced tissue exposure to unnecessary current pulses. The 
stimulation protocol was created and delivered across the tissue at five-minute 
intervals during a total of 90-minute experimental periods (Figure 4.4D). 
Stimulation traces were assessed before every experiment as damage to 
electrodes, air bubbles, or blockages can result in excess noise within the 
system leading to abnormal stimulation peaks (Figure 4.4E).  
Electrical resistance measurements are based on Ohm’s law (Figure 4.5A). 
Using a linear least squares fit analysis, the paired relationship between voltage 
and current was used to calculate electrical resistance of colonic tissue, 
measured in Ω/cm2 at the time of current stimulation (Figure 4.5B).  
 
4.2.3 Temperature  
The six Ussing chambers sit within a black heating unit that is connected via 
tubing to a circulating water bath, maintained at 45°C. Due to heat loss through 
the system this higher temperature is required to ensure chambers are kept at a 
constant 37°C.  
 
4.2.4 Optimising Ag/AgCl electrodes 
Ag/AgCl electrodes function as a redox electrode with an equilibrium existing 
between the silver (Ag) metal and its low soluble salt and the anion of that salt 
(AgCl). The electrode maintenance protocol had to be optimised for this study 
as the purchased pre-chlorided electrodes began to show drifting potential 
difference values over time in the absence of tissue. This made it impossible to 
	 140	
“zero” offset potential prior to the start of experiments. Various methods for re-
chloriding, including electroplating, were investigated. The best method to 
achieve stable electrodes was removing the old AgCl coating using steel wool, 
wiping the silver wire with deionised water and 70% ethanol to remove oils and 
immersing in sodium hyperchlorite (NaCIO). By exposing the Ag wire to OCl-, 
spontaneous oxidation occurs creating a coat of AgCl on the metal surface.  
Electrode glass barrels were filled with an electrolyte solution of 3M KCl, 
saturated with Ag. However, efficient electrolyte solution filing technique is 
imperative as small air bubbles located within the glass barrel leads to electrical 
noise within the system (Figure 4.4E). To achieve good filling technique, 
electrolyte solution was dispensed into a small bottle containing a holder for a 
thin plastic tube. The tube is inserted to the end of the glass barrel where the 
ceramic junction is located. Using constant pressure so electrolyte solution flows 
continually the barrel is filled as the tube is slowly withdrawn. By tapping lightly 
against the ceramic junction during this process air bubbles are dislodged. KCl 
salt, formed when exposed to air can be deposited at the opening of the glass 
barrel. It must be carefully removed and not descend to the ceramic junction as 
this can cause blockages, leading to interference or obstruction of electrical 
readings.  
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Figure 4.3. Schematic of the electrical circuit used in the Ussing chamber system. 
Computer controlled current pulses are sent from the EC825A volt/clamp box amplifier via current electrode I1 through the mucosal chamber-half (indicated 
by arrows), across tissue apical and basal membranes and through the serosal chamber-half. Current electrode I2 connecting back to the EC825A volt/clamp 
box completes the circuit. Voltage electrodes V1 and V2, connected to the EC825A amplifier box and computer software continuously monitor voltage at the 
apical and basal tissue membranes.
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Figure 4.4 A stimulation protocol of four pulses was adequate to determine tissue resistance. 
Current pulse traces using four (A), eight (B) or twelve (C) current stimulations. (D) Chosen current pulse stimulation event protocol. (E) Current pulse trace 
showing air bubbles within electrodes causing electrical noise.
E 
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4.3.5 Optimisation of Chambers for small tissue samples 
Chambers had to be optimised to accommodate small mouse tissues, as the 
standard chamber aperture size is 9mm diameter. To do so, X-ray film was cut 
into square pieces, large enough to cover all six chamber pins. In the centre of 
each, a 3mm hole was punched to reduce the tissue area exposed (Figure 
4.5C). The x-ray film was made so that each square had a matching 
counterpart. Initial experiments showed this was necessary as samples had to 
be mounted in-between two x-ray film squares, securing tissue in place to 
prevent leakage.  
4.3.6 Optimisation of dissection technique and handling of tissue  
Tissue viability is key to obtaining accurate measurements and can be 
determined by the steady state PD value (284). This value generally is negative 
due to the active transport of ions at the apical and serosal membranes (284) 
(286). Preliminary experiments using untreated FoxP3DTR mice resulted in 
positive PD values (Figure 4.6A). Multiple investigations were made to ascertain 
why (Table 4.1). Ultimately it was found that the mucosal surface of the colonic 
tissue was more delicate and prone to damage. I therefore optimised my 
dissection technique and tissue handling when mounting samples into 
chambers. An overview is shown in Figure 4.6B and 4.6C and a detailed 
description in Chapter 2. Improved handling resulted in tissue displaying a 
negative PD (Figure 4.6D). Furthermore, responses to the chloride secretion 
enhancer Forskolin (287), as seen by a drop in PD (Figure 4.6D) and low 4kDa 
FITC passage (Figure 4.6E) were seen. Only samples showing a PD value of 
0.5 mV or less at the beginning of experiments and a response to Forskolin 
were included within analyses.  
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Figure 4.5. Calculation of electrical resistance. 
Linear least fit squares analysis based on Ohm’s law (A) used to plot current stimulation 
against tissue voltage (B). Linear regression is equal to resistance. The y-intercept 
equals the PD value of tissue and Isc can be calculated by PD/R. (C) X-ray films with a 
hole size of 3mm were placed over chamber pins to reduce exposed tissue area. 
 
Voltage (mV)
-4 -2 2 4
-10
-8
-6
-4
-2
2
4
Current (µA)
R = 1750 Ω PD = -2.25 mV Isc =  1.28 µA
Tissue 
X-ray film 
Chamber half 
	 146	
-3 -2 -1 0 1 2 3
500
1000
1500
2000
2500
4 
kD
a 
FI
TC
-D
ex
tra
n 
(n
g/
m
l)
PD (mV)
20 40 60 80 100 120
-4
-3
-2
-1
0
1
CH1
CH2
CH3
CH4
CH5
CH6
Time (min)
PD
 (m
V)
20 40 60 80 100 120
-1
0
1
2
3
4
CH1
CH2
CH3
CH4
CH5
CH6
Time
PD
 (m
V)
Forskolin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Optimised dissection and mounting technique gives rise to negative 
PD values, indicative of healthy tissue. 
(A) Positive PD values of tissue before dissection optimisation. (B) The colon is 
dissected as indicated by dashed lines and (C) flushed out before being opened 
longitudinally with micro dissection scissors. X-ray film is used to select colonic regions. 
(D) Negative PD values after optimisation showing tissue responds to Forskolin at 60 
minutes. (E) Tissue with a negative PD value shows little or no 4kDa FITC-dextran 
passage. Black triangles indicate tissue not responsive to Forskolin. 
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Table 4.1. Alterations to Ussing experiments investigated to obtain 
reliable electrical readings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Variable investigated 
1. Fresh buffers immediately before experiment 
2. Chloriding of electrodes in bleach 
3. Glass barrel ceramic tips cleaned with hot water 
4. Tissue orientation altered 
5. Method of culling (CO2 Vs cervical dislocation) 
6. Buffer pH 
7. Dissection technique to avoid touching the mucosal surface 
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4.3.7 Regional variation in electrical resistance 
To assess baseline permeability distal, mid and proximal sections of colon were 
harvested from untreated FoxP3DTR mice. Results show the proximal region of 
the colon has the highest electrical resistance and the mid section the lowest 
(mean=41.12Ω/cm2 and 26.34 Ω/cm2 respectively) (Figure 4.7A). This 
difference was stable throughout experiments (Figure 4.7B and 4.7C). Although 
not significant, this trend was also detected in Balb/C DEREG mice (Figure 
4.7D). These data validate use of the Ussing system to measure electrical 
resistance of mouse tissue and demonstrate the natural variability in 
permeability along the colon. Variations are suggested by embryological origins 
of hind vs midgut (288), different patterns of disease distribution seen in IBD, 
variability in drug absorption and expression patterns of TJ proteins (23, 289, 
290). This was taken into consideration for future Ussing experiments. Distinct 
regional variations of colonic permeability have not been well defined previously. 
4.3.8 Optimisation of FITC-dextran and Lucifer yellow 
As mentioned previously the diffusion of fluorescent probes across tissue is 
often used as a measurement of intestinal permeability. 4kDa FITC-dextran and 
Lucifer yellow (457 daltons) were titrated to ascertain optimal mucosal chamber 
starting concentrations. Initial experiments showed that in healthy mice 4kDa 
FITC-dextran, at 0.5 mg/ml, was only detectable after 120 minutes (Figure 
4.8A). High concentrations of either 0.5 mg/ml or 1 mg/ml 4kDa FITC-dextran 
were used to saturate the mucosal chamber in future experiments. Lucifer  
yellow passage could be detected in all tissue samples, showing its usefulness 
as a positive control (Figure 4.8B) with 250 µg/ml and 125 µg/ml starting 
concentrations showing the most passage to the serosal chamber (Figure 4.8B). 
However, since the 125 µg/ml starting concentration was detected using the mid 
section of the colon, previously shown to be most leaky (Figure 4.7A), a starting 
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concentration of 250 µg/ml lucifer yellow was chosen to ensure good passage 
through all tissue regions.  
 
4.3.9 Gas supply 
A constant supply of carbogen (95% oxygen, 5% CO2) must be supplied to each 
Ussing chamber in order to maintain tissue viability. Loss of oxygen leads to 
quicker deterioration of tissue resistance (Figure 4.9A and 4.9B). Consistent 
with this was increased passage of Lucifer yellow in both proximal and distal 
colonic regions investigated (Figure 4.9C).  
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Figure 4.7 Baseline electrical resistance identifies regions permeability  
differences. 
(A) Electrical resistance of matched distal, mid and proximal colonic regions from 
untreated FoxP3DTR mice. Electrical resistance at (B) twenty minutes and (C) sixty 
minutes during experiments. (D) Electrical resistance of distal, mid and proximal colonic 
sections from untreated DEREG mice. Unpaired students T test used to test for 
significant differences. Error bars show +/- SEM. 
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Figure 4.8. Lucifer yellow passage across colonic epithelium is higher than 4kDa 
FITC-dextran passage. 
(A) Serosal 4kDa FITC-Dextran concentration with various starting mucosal 
concentrations after 1 hour using mid and proximal colonic regions. (B) Lucifer yellow 
serosal chamber concentration after 1 hour with various starting concentrations. 62.5 
µg/ml and 7.8 µg/ml, 125 µg/ml and 15.6 µg/ml, 250 µg/ml and 31.25 µg/ml starting 
concentrations were used for proximal, mid and distal colon sections respectively. Error 
bars show SEM. 
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Figure 4.9. Loss of oxygen reduces electrical resistance and increases 
paracellular permeability.  
Electrical resistance of (A) proximal and (B) distal colonic regions with or without an 
oxygen supply. (C) Lucifer yellow serosal chamber-half concentration after one hour. 
Linear regression comparison of electrical resistance slopes tested for significant 
differences. 
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4.3.10 Dextran sodium sulphate (DSS) mouse model  
DSS is an irritant, widely used to induce intestinal inflammation as a model of 
IBD (291, 292). It has been shown that under inflammatory conditions colonic 
permeability is increased, due to inflammatory molecules altering TJ proteins 
(269). Therefore the DSS model was used as a positive control to evaluate if the 
Ussing system was capable of detecting increased permeability in inflamed 
tissue. Using the 3% DSS treatment schedule described in Chapter 2, a 
reduction in mouse weight was seen within nine days (Figure 4.10A). Upon 
harvest, treated mice were also found to have a shortened colon length (Figure 
4.10B) and positive occult blood test results compared to untreated animals 
(Figure 4.10C). Furthermore histological analysis revealed gross abnormalities 
of the intestinal architecture along with increased cellular infiltration, indicative of 
inflammation (Figure 4.10D). Ussing analysis showed a decrease in electrical 
resistance (Figure 4.10E) and an increase of 4kDa FITC-dextran flux (Figure 
4.10F) across the proximal region of the intestinal epithelium. Together this data 
shows that our Ussing system was capable of identifying alterations in gut 
integrity under inflammatory conditions.  
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Figure 4.10. 3% Dextran Sodium Sulphate causes intestinal inflammation and 
increase intestinal permeability. 
(A) Body weight and (B) colon length of 3% DSS treated and untreated 10 week old 
female Fop3DTR/DTR mice. (C) Hemoccult blood testing of stool samples. (D) 
Haematoxylin & eosin staining of colonic gut rolls. Asterisks and arrows indicate 
increased immune cell infiltration and disrupted crypt structure respectively. (E) 
Electrical resistance of proximal colon and (F) 4kDa FITC-dextran passage.  Mucosal 
starting concentration was 0.5 mg/ml. n=4 treated vs 8 untreated. Error bars show SEM. 
Mann Whitney test used to test for significant differences.  
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4.3.11 Depletion of T-regulatory cells leads to increase intestinal 
permeability  
Depletion of Tregs causes the development of autoimmune symptoms, including 
colitis, which as shown by Mottet and colleagues can be rescued in adoptive 
transfer models (293). Using FoxP3DTR mice described by Kim et al. (109), 
treatment with diphtheria toxin (DTx) depleted the FoxP3+ Treg population 
(Figure 4.11A). DTx Treated mice did develop autoimmune symptoms such as 
scaly skin seen around the eyes (Figure 4.12B), listless behaviour, extreme 
splenomegaly (Figure 4.11C) and began to lose weight after two-weeks of 
treatment (Figure 4.11D). Colon length was not altered by T-reg depletion 
(Figure 4.11E). However, histological analysis showed architectural differences 
between DTx treated and untreated mice, constant with enteropathy (Figure 
4.11F).  
 
Over a 90-minute experimental period, electrical resistance of mid and proximal 
colonic sections from DTx mice was lower and declined more rapidly than 
colonic sections from untreated animals (Figure 4.12A and 4.12C). Regardless, 
all samples did respond to Forskolin addition and had a negative PD. Although 
not significant, paracellular flux of 4kDa FITC-dextran was higher within treated 
mice (Figure 4.12B and 4.12D). These data suggest that T-regs cells play a role 
in maintaining gut integrity within the intestine. Furthermore it validated that our 
Ussing system could detect permeability differences within this mouse model. 
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Figure 4.11. Depletion of T-regulatory cells causes autoimmunity. 
Splenocytes were harvested from mice and stained with the panel of antibodies show in 
Table 3.1 in Chapter 2. Lymphocytes were identified by size and granularity using side 
scatter (SSC) and forward scatter (FSC), respectively. Live cells were selected based on 
the ability to exclude aqua stain. CD4+ cells were gated and then FoxP3 expression 
analysed. (A) Gating strategy of splenocytes harvested from untreated and (B) DTx 
treated mice to identify CD4+ FoxP3+ cells. (C) Image of mice showing autoimmune eye 
symptom, indicated by asterisk. (D) Image showing splenomegaly in T-reg deplete mice. 
50ml falcon tube diameter is 34mm. (E) Percentage body weight of mice. (F) Colon 
lengths of mice. (G) H&E staining of distal colonic sections from treated and untreated 
animals. Asterisks and arrows indicate increased immune cell infiltration and disrupted 
crypt structure respectively n=3 treated vs 3 untreated. Error bars show SEM. 
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Figure 4.12. T-regulatory cell depleted mice show increased intestinal 
permeability. 
(A) Electrical resistance and (B) 4kDa FITC-dextran passage of mid colonic sections 
from 14 week old female FoxP3DTR mice. (C) Electrical resistance and (D) 4kDa FITC-
dextran passage of proximal colonic sections. Mucosal starting concentration was 1 
mg/ml. An ANOVA was used to test for significant differences between linear regression 
slopes. n=3 treated vs 3 untreated. Error bars show SEM. 
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4.4 Discussion 
It is accepted that intestinal inflammation is a risk factor associated with CRC 
development. Accordingly the risk of CRC in IBD patients is 1.5-2 times greater 
than the general population (294). IBD patients also exhibit increased intestinal 
permeability and it is thought barrier breakdown enhances disease. It was 
hypothesised that the unfavourable outcome identified in CRC patients 
responding to the TAA CEA was due to increased intestinal permeability, which 
in theory could result in a pro-tumorigenic environment (194). This chapter has 
focused on the design, optimisation and validation of the Ussing chamber 
system as a tool for measuring gut integrity. 
The Navicyte system was chosen over classic Ussing designs as this increased 
analysis from one tissue sample per experiment to six (286). This increase in 
sample number was beneficial as a major limitation of Ussing experiments is 
tissue viability, resulting in samples being disregarded. Wallon and colleagues 
show that tissue samples displaying a negative PD value have lower rates of 
paracellular transport as well as stable levels of lactate and ATP (284). By 
optimising dissection and mounting techniques tissue sample health was greatly 
improved. I also measured tissue viability using the compound Forskolin. An 
adenylate cyclase agonist, Forskolin increases cAMP and activation of PKA, 
leading to CFTR stimulation to promote Cl- secretion (287, 295). This causes a 
decline in PD values. As this process requires energy only healthy tissue are 
able to respond. By measuring both baseline PD and responses to Forskolin we 
could be confident that only viable tissue samples were included within our 
analysis.  
 
After electrode optimisation it was possible to re-use Ag/AgCl electrodes to 
nullify offset potential differences and achieve stability over 90-mintute 
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experimental periods. The chloriding method used (immersion in household 
bleach) may however be harsh as the Ag wire often breaks from the electrode 
cap. An investigation into electroplating electrodes was attempted but 
unsuccessful. It may therefore be worth exploring electroplating options further 
in an effort to make the electrodes longer lasting.  
 
Validation of the custom-made Ussing system was achieved using mouse 
models. DSS treatment, which causes enteropathy, is widely used as animals 
develop features similar to those seen within IBD patients. We therefore used 
DSS treatment as a positive control to identify leaky epithelium using our Ussing 
system. The exact mechanism of DSS action is not fully understood. However, 
Laroui and colleagues suggest that DSS binds to medium chain fatty acids 
within the gut, allowing the formation of lipid nanoparticles. Nanoparticles can 
bind to the membrane of colonocytes and once inside can stimulate 
inflammatory signalling pathways (296). Multiple repeated cycles of DSS 
treatment followed by water results in chronic intestinal inflammation (291, 297) 
but unnecessary for this study since one cycle of 3% DSS treatment induced 
acute intestinal inflammation. The permeability of the proximal region of the 
colon was analysed as it had the highest electrical resistance in healthy animals. 
Furthermore, unlike the mid colonic region, the proximal region could be clearly 
identified even though colon length was reduced. Both electrical resistance and 
4kDa FITC-dextran passage data confirmed that the Ussing system could 
identify increased permeability within DSS treated mice.  
 
A mouse model of intestinal inflammation driven by Treg depletion was also 
used to validate the Ussing system. Tregs are a major component of the 
immune system. They are critical for maintaining immune homeostasis and 
reducing inflammation (298). Furthermore, they promote tolerance towards 
	 161	
commensal micro-biota and food antigens within the intestine to maintain a 
healthy intestinal environment (298-300). Transfer of naïve CD4+ T cells into 
Rag-/- mice results in T cell-driven colitis (301). However, transfer of CD4+ CD25+ 
Tregs prevent disease development (293). Treg depletion is a valuable model 
for investigating colonic permeability using the new Ussing system. Upon DTx 
treatment of FoxP3DTR mice, depletion of the FoxP3+ Treg population was 
achieved and colonic inflammation developed. I report here for the first-time 
increased permeability within Treg depleted mice, measured directly using an 
Ussing chamber system. These data confirm the robustness of the system as a 
tool for measuring permeability. 
 
4.5 Conclusion 
The unforeseen complex assembly of the Ussing chamber system did slow the 
initial momentum of this project. Nonetheless, I did successfully construct and 
optimise an Ussing chamber system, which has proved capable of effectively 
measuring gut integrity. This technique was therefore used to measure intestinal 
permeability of human tissue, described in Chapter 5. 
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Chapter 5. Human Permeability Studies 	
5.1 Introduction 
There is a link between inflammation and the development of CRC, highlighted 
by increased tumour incidence within IBD patients. Furthermore, studies have 
identified an association with the use of non-steroidal anti-inflammatory drugs 
(NSAIDs) and a reduced risk of developing CRC. In particular, the Cancer 
Prevention Programme (CAPP2) investigated the role of aspirin within Lynch 
syndrome patients, which extended to 43 different centres covering 16 countries 
(302). Patients were randomly assigned to receive 600mg of aspirin daily or 
placebo comprising 30g resistant starch for 2-4 years. Results showed that with 
a group mean follow up of 55.7 months, patients receiving aspirin had up to a 
60% risk reduction in developing cancer compared to the placebo group (302). 
Similar findings have been observed for sporadic CRC as reported in a meta-
analysis study by Algra and colleagues (303). Appropriately, inflammation has 
been recognised as one of the  “hallmarks of cancer” (203).  
Unlike most cancers, CRC develops next to a wide range of microbial species. 
Moreover, the microbiota can influence the anti-tumour immune response. This 
appears to be a complex process, with an on-going debate on the beneficial and 
detrimental aspects of microbial invasion. Differences in microbial composition 
have been identified in CRC patients compared to healthy controls. However, as 
of yet a clear signature that unifies “CRC microbiota” across studies has not 
been identified. Nevertheless, particular bacterial species have been recognised 
as having the ability to promote intestinal inflammation that can aid in tumour 
progression. For example, two back-to-back recently published studies identify 
Escherichia coli and Bacteroides fragilis as being pro-carcinogenic through 
initiation of an inflammatory cascade by targeting colonic epithelial cells (304, 
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305). Biofilms predominately containing E.coli and B.fragilis were identified 
within FAP patients, the genetic condition associated with heredity CRC. Both 
can also be found in sporadic CRC patients (304). Strong experimental 
evidence exists to support the carcinogenic potential of E. coli and B..fragilis. 
E.coli containing the polyketide synthase (pks) genotoxic island encodes genes 
for the bacterial toxin colibactin. This toxin has been shown in vitro and in vivo to 
induce DNA damage in host cells, as well as promoting tumourigenesis in a 
CRC mouse model (304). Meanwhile, B.fragilis toxin (BFT) can act as a 
metalloproteinase to affect epithelial cell TJ structures (306). This signalling 
process, which relies on an unidentified epithelial cell receptor, results in 
cleavage of E-cadherin. This causes impaired barrier integrity and the activation 
of pathways associated with tumour progression such as Wnt/b-catenin 
signalling (305, 306). Interestingly, when co-colonised with E.coli and B.fragilis 
azoxymethane (AOM) treated mice showed increased tumourigenesis 
compared to mono-colonised animals, indicating that a synergistic effect is 
required for tumour development (304). This change in microbial composition 
also correlated with higher levels of epithelial cell DNA damage within AOM 
treated mice. Furthermore, bacterial induced IL-17 immune responses were 
found to play a role in tumour development. While not sufficient alone to drive 
tumourigenesis, it was observed that AOM treated IL-17 deficient mice co-
colonised with E.coli and B.fragilis did not develop tumours (304). Such findings 
corroborate with the observations of Grivennikov and colleagues (213).  Using 
APCF/WT mice that develop tumours primarily in the distal colon, marked 
upregulation of IL-17A and IL-23 was detected. However, ablation of either 
cytokine diminished tumour growth. Furthermore, short-term treatment with 
broad-spectrum antibiotics depleted the microbiota, leading to reduced IL-23 
and IL-17A, as well as STAT-3 activation in cancer cells (213). Using an in vivo 
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FITC-dextran passage approach, an increase in intestinal permeability was also 
observed within APCF/WT mice. This was associated with penetration of microbial 
products such as LPS, shown to associate with tumour associated 
macrophages (TAMs) located in tumour tissue (213). Based on this evidence it 
is possible that reduced epithelial barrier function aids tumour development 
through bacterial induced inflammation. 
As mentioned previously our laboratory observed that CRC patients responding 
to the TAA CEA were found to have a poorer prognosis than non-responding 
patients (194). Reasons to explain this observation were explored. 
CEA is expressed on normal healthy gastrointestinal tissue and it has been 
shown that cytokines such as IFN-γ and TNF-α can act on barrier function, 
causing increased permeability in a myosin light chain kinase dependant 
manner (269). Therefore, activation of IFN-γ producing auto-reactive CEA T 
cells could potentially play a role in altering gut epithelial barrier function. Based 
on this and the evidence suggesting that impaired barrier function can assist 
tumour-associated inflammation, we hypothesised that CEA responding patients 
have increased colonic mucosal permeability. This could lead to the 
translocation of microbes or their products into the lamina propria, creating an 
inflammatory setting capable of aiding tumour progression, and hence earlier 
tumour relapse compared to non-responding patients. 
To address this hypothesis the Ussing chamber was employed to investigate the 
permeability of human biopsy samples obtained from patients undergoing 
colonoscopy procedures.  
 
In this chapter I aimed to (i) obtain baseline readings from healthy biopsy 
samples, (ii) examine any alterations in gut permeability upon adenoma 
formation and (iii) investigate if CEA blood responses correlated with increased 
intestinal permeability. 
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5.2 Results 
5.2.1 Human biopsy samples remained viable within Ussing chambers for 
up to 90 minutes. 
To determine the permeability of human colonic tissue, Ussing chambers were 
modified to support biopsy samples, approximately 1-1.5 mm in diameter. 
Biopsies were mounted into chambers in between two pieces of x-ray film with a 
1 mm hole to reduce the exposed tissue area to 0.79 mm2 (Figure 5.1A). Unlike 
mouse tissue, which was full thickness when mounted, biopsy samples 
consisted of the epithelial and sub-mucosal layers of the colon only. 
Nevertheless, by applying the same techniques it was observed that biopsy 
samples could remain viable during 90-minute experimental periods. Overall, 
82% of all biopsy samples ran in Ussing chambers were viable and included in 
analyses. Figure 5.1 shows representative images of a viable biopsy sample, 
demonstrating consistent electrical resistance (Figure 5.1B) and a PD response 
to Forskolin at 60 minutes (Figure 5.1C). Furthermore, the Forskolin-induced 
drop in PD is mirrored by an increase in short circuit current (Isc), indicating 
increased ion movement as a result of CFTR activation (Figure 5.1D). From use 
of the animal models described in Chapter 4, it was found that passage of 4kDa 
FITC dextran across the colon was minimal in healthy mice and on some 
occasions no passage was detected at all. Due to this, a second paracellular 
probe called Lucifer yellow was used to investigate paracellular flux across 
biopsy tissues. Only 457Da in size, Lucifer yellow was able to translocate the 
tissue barrier, leading to a more sensitive measurement of paracellular passage 
in healthy samples. Moreover, Lucifer yellow passage correlated with tissue 
electrical resistance measurements in biopsy samples obtained from both the 
right (Figure 5.1E) and left side of the colon (Figure 5.1F).  
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5.2.2 Baseline Ussing measurements show regional variation in colonic 
biopsies 
Tumours can develop within any region of the colon. However, cancers arising 
in the right side of the colon (caecum/ascending) often have different 
characteristics than left sided cancers (descending/sigmoid). The clinical 
relevance of tumour location is still debated however some studies suggest that 
right and left sided CRCs should be treated as distinct biological entities. In 
contrast, it has been proposed that tumour location is secondary to other tumour 
and host factors such as the tumour microenvironment. 
In Chapter 4 it was demonstrated that regional variation in intestinal permeability 
existed within the mouse colon (Figure 4.8). With this in mind, and the 
suggestion that tumour location associates with particular disease 
characteristics, patients found to have no macroscopic disease during 
colonoscopy examination had three biopsies taken from the right and left side of 
the colon. This was to evaluate baseline permeability within healthy individuals. 
The average electrical resistance of right and left biopsies was calculated as 
well as the flux of Lucifer yellow. A difference in intestinal permeability between 
the left and right colon was observed. Left sided biopsies had lower electrical 
resistance (Figure 5.2A) and higher Lucifer yellow passage (Figure 5.2B), 
indicating the left side of the colon is more permeable than the right.  
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Figure 5.1. Human biopsy samples remained viable within Ussing chambers for up 
to 90 minutes.  
(A) Image of colonic biopsy mounted in Ussing chamber. (B) Resistance, (C) PD and (D) 
Isc of viable biopsy sample. Flux of the fluorescent probe Lucifer yellow correlates with 
tissue electrical resistance in both the (E) right and (F) left side of the colon. A 
Spearmans’ test was used to test for a significant correlation. 
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Figure 5.2. Baseline Ussing measurements show regional variation in healthy 
colonic biopsies. 
(A) Baseline electrical resistance at 20 minutes of biopsy samples taken from the right 
and left colon. A significant difference between groups was tested for using an unpaired 
two-tailed students T test. (B) Lucifer yellow flux across right and left colonic biopsies at 
20 minutes. A Mann Whitney test was used to test for statistically significant differences. 
Error bars show SEM. 
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5.2.3 Adenoma lesion biopsies show increased permeability  
Adenomatous polyps (adenomas) are benign growths that develop within the 
intestine but have the potential to become cancerous over an extended period of 
time. Therefore, if an adenoma is detected it is most often removed by 
clinicians. Figure 5.3A and 5.3B show colonoscopy images of an adenoma and 
an adenocarcinoma (CRC tumour) from patients in this study. I sought to 
evaluate whether adenoma formation was a result of individuals having a 
permeable gut. I hypothesised that a permeable gut would acquire more genetic 
mutations as a result of bacterial-driven inflammation, leading to adenoma 
formation. I also hypothesised that adenoma formation itself would result in a 
local leaky environment at the lesion site. Upon colonoscopy examination, right 
and left sided biopsy samples were obtained from adenoma patients, taken from 
sites greater than 5 cm away from the adenoma itself. Biopsy permeability was 
then measured using the Ussing system. As a control, “lesion” samples within 1 
cm of an adenoma were obtained where possible. Tumour biopsies obtained 
from a single CRC patient were also included within the lesion sub-group. 
Results showed that samples obtained greater than 5 cm away from the 
adenoma site were not more permeable than biopsy samples from healthy 
patients. Surprisingly it was observed that left sided biopsies from adenoma 
patients actually had a statistically significant higher electrical resistance (Figure 
5.3C) and a lower mean passage of Lucifer yellow (Figure 5.3D) than left sided 
samples from healthy individuals. In contrast to what was hypothesised, this 
indicates increased epithelial integrity within left colon background tissue of 
adenoma patients. Due to this, the regional variation in colonic permeability 
detected within healthy individuals (Figure 5.2) disappears within adenoma 
patients (Figure 5.3E).  
Biopsy samples obtained from adenoma lesion sites (within 1 cm) had a 
significantly lower electrical resistance, as did tumour biopsies, compared to 
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healthy samples which indicates increased permeability (Figure 5.3C). However, 
while lesion site Lucifer yellow passage was relatively high (mean = 16.83 
µg/ml/h/cm2), similar flux was also observed for some healthy left sided biopsy 
samples (mean = 15.2 µg/ml/h/cm2) (Figure 5.3D). To investigate further, 
histological analysis of biopsy samples post-Ussing was carried out where 
possible. Background tissue (greater than 5 cm from adenoma) and tissue from 
a lesion site from the same adenoma patient was compared, with no dramatic 
histological differences in epithelial architecture observed. Only a small increase 
in immune cell infiltrate could be seen, along with some possible deterioration of 
the epithelial layer (Figure 5.3G). However, this was very subtle compared to the 
inflammation-induced damage observed within the mouse models used in 
Chapter 4 (Figure 4.11D). Blood derived CEA-specific T cell responses were 
also measured. Interestingly, adenoma patients had a higher magnitude CEA-
specific IFN-γ T cell response compared to healthy controls (Figure 5.3F).  
These data show that very mild tissue damage does occur near the site of 
adenoma development. While mouse and human tissue is not directly 
comparable, inflamed mouse intestine (shown in Chapter 4) was permeable to 
4kD FITC dextran probe. However, lesion human biopsy samples did not show 
increased flux of the smaller sized Lucifer yellow probe in comparison to healthy 
biopsies. This suggests that any tissue damage that may have formed near the 
site of adenoma formation now has normalised compared to the damage 
caused by DSS treatment or Treg depletion in mice. However, the fall in 
electrical resistance within lesion samples compared to healthy biopsies 
suggests that the passage of small molecules/ions is still affected. The increase 
in epithelial integrity of background tissue from adenoma patients compared to 
healthy controls also argues against the hypothesis that patients who develop 
adenomas do so as a result of having a more permeable intestine than healthy 
individuals.  
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However a study by Laukoetter and colleagues suggests that epithelial cell 
proliferation could play a role in decreasing tissue injury (27). The authors show 
that JAM-A-/- mice have increased susceptibility to DSS treatment compared to 
untreated JAM-A-/- animals. However, colonic disease was not as severe when 
compared to DSS treated WT mice. The group were able to demonstrate that 
JAM-A-/- mice have higher levels of Ki67+ epithelial cells compared to WT 
animals. This high percentage of Ki67+ cells remained during DSS treatment of 
JAM-A-/- mice but a decrease was seen during treatment of WT animals. Such 
findings suggest that enhanced cell proliferation could result in rapid repair of 
epithelial defects (27). Its possible that the increased gut integrity of background 
tissue detected in adenoma patients is a consequence of a feedback 
mechanism resulting in barrier tightening in response to adenoma formation, 
potentially through enhanced epithelial cell proliferation. 
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Figure 5.3. Lesion biopsies show increased permeability but tissue obtained >5cm 
from the adenoma site does not. 
(A) Representative image of an adenoma and (B) adenocarcinoma. (C) Electrical 
resistance and (D) Lucifer yellow flux of biopsy samples from the right and left colon of 
healthy patients and adenoma patients (AP). Biopsy samples from lesion sites are also 
shown. A one-way anova was used to test for significant differences between right, left 
healthy samples and lesion sites. An unpaired students T test was used to test for 
statistical significance between healthy and AP left biopsies (E) Paired electrical 
resistance between right and left colonic biopsy samples from adenoma patients. (F) 
CEA-specific IFN-γ+ T cell response in healthy and AP patients. Significant differences 
tested for using A Mann Whitney test. (G) H and E staining of healthy background tissue 
(>5cm from adenoma) and tissue obtained from a lesion (<1cm of an adenoma). 
Asterisk and arrow indicate increased immune cell infiltration and epithelial damage, 
respectively. Error bars show SEM. 
A	 B	
E	
C	 D	
F	
G	
	 173	
5.2.4 CEA responses and permeability 
As shown by our laboratory, CEA-specific T cell responses in CRC patients 
reflected in a poor 5-year outcome for patients (194). To address the hypothesis 
that patients harbouring CEA-specific IFN-γ T cell responses have increased 
intestinal permeability biopsy samples were obtained and run on the Ussing 
system. Peripheral blood was also taken from patients where possible and CEA-
specific responses were measured using the FluoroSpot technique (described in 
Chapter 2). Results showed that all patients in this cohort had an IFN-γ T cell 
response to CEA. However, there was variation in the magnitude of response 
that patients produced (Figure 5.4A). Detection of a CEA T cell response in all 
patients is due to an unavoidable change of culture medium used for FluoroSpot 
assays compared to that used in Chapter 3. Side by side comparison showed 
that T cell responses to the same peptide pools were detected when using 
either media. However, due to better growth factor conditions that support T cell 
responses, the magnitude of T cell response in some cases was increased by 
up to 10% when using the new media (see appendix). This resulted in “low and 
high” responding patients as opposed to responding and non-responding 
patients as seen in Chapter 3. Patients were split based on the magnitude of 
CEA response generated. A low T cell response was defined as a FluoroSpot 
spot forming cell count (SFC) lower than the group median. A high T cell 
response was defined as a SFC greater than the group median. Low and high T 
cell response was then correlated with the electrical resistance and Lucifer 
yellow flux of colonic biopsies. In healthy patients it was found that a higher 
CEA-specific IFN-γ T cell response significantly correlated with decreased 
electrical resistance in the right side of the colon (Figure 5.4B). This was 
mirrored by an increase in Lucifer yellow flux (P=0.0571) (Figure 5.4C). 
Interestingly, this finding was not observed in the left side of the colon (Figure 
5.4D and 5.4E). Also evaluated was the correlation between CEA-specific IL-
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17A and IL-17/IFN-γ dual T cell responses and intestinal permeability (Figures 
5.5 and 5.6, respectively). No associations in either the right or left side of the 
colon were observed. As a comparison 5T4-specific responses, which were 
shown not to be associated with a poor prognosis in CRC were also measured. 
This made it possible to evaluate if increased permeability was due to T cell 
responses to a tumour antigen or whether it particularly correlated with CEA-
specific T cell IFN-γ responses. Figures 5.7B-5.7E show that no association 
between high or low magnitude 5T4-specific IFN-γ T cell response and intestinal 
permeability were observed. This was also true when permeability was 
correlated with IL-17A (Figure 5.8B-5.8D) and IL-17A/IFN-γ dual 5T4-specific T 
cell responses (Figure 5.9B-5.9D).  
Together these data suggest that CEA-specific IFN-γ T cell responses are 
specifically linked with decreased epithelial integrity in the right side of the colon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 175	
IFN
-γ
0
100
200
300
400
C
EA
 IF
N
-γ
 S
FC
/5
x1
05
 
cu
ltu
re
d 
PB
M
C
<m
ed
ian
 S
FC
> m
ed
ian
 S
FC
0
5
10
15
R
es
is
ta
nc
e 
(Ω
/cm
2 )
<m
ed
ian
 S
FC
> m
ed
ian
 S
FC
0
10
20
30
Lu
ci
fe
r y
el
lo
w
 (µ
g/
m
l//
h/
cm
2 )
Right colon
Right colon Left colon
Left colon
<m
ed
ian
 S
FC
> m
ed
ian
 S
FC
0
5
10
15
0.0571P =
Lu
ci
fe
r y
el
lo
w
 (µ
g/
m
l//
h/
cm
2 )
<m
ed
ian
 S
FC
> m
ed
ian
 S
FC
0
5
10
15
20
0.0159
*
P =
R
es
is
ta
nc
e 
(Ω
/cm
2 )
IFN
-γ
0
100
200
300
400
C
EA
 IF
N
-γ
 S
FC
/5
x1
05
 
cu
ltu
re
d 
PB
M
C
<m
ed
ian
 S
FC
> m
ed
ian
 S
FC
0
5
10
15
R
es
is
ta
nc
e 
(Ω
/cm
2 )
<m
ed
ian
 S
FC
> m
ed
ian
 S
FC
0
10
20
30
Lu
ci
fe
r y
el
lo
w
 (µ
g/
m
l//
h/
cm
2 )
Right colon
Right colon Left colon
Left colon
<m
ed
ian
 S
FC
> m
ed
ian
 S
FC
0
5
10
15
0.0571P =
Lu
ci
fe
r y
el
lo
w
 (µ
g/
m
l//
h/
cm
2 )
<m
ed
ian
 S
FC
> m
ed
ian
 S
FC
0
5
10
15
20
0.0159
*
P =
R
es
is
ta
nc
e 
(Ω
/cm
2 )
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Higher magnitude CEA-specific IFN-γ T cell responses correlate with 
increased intestinal permeability in the right side of the colon but not the left. 
Electrical resistance and Lucifer yellow passage of colonic biopsies was measured. 
Patients were then divided based on magnitude of CEA response, defined as having a 
FluoroSpot IFN-γ SFC higher or lower than the group median. (A) Magnitude of IFN-γ 
responses from all patients. (B) Right and (D) left colon electrical resistance. (C) Right 
colon and (E) left colon Lucifer yellow passage. Data shown is at 20 minutes. Mann 
Whitney test used to test for statistically significant differences. Error bars show SEM. 
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Figure 5.5 CEA-specific IL-17A T cell responses do not correlate with intestinal 
permeability.  
Electrical resistance and Lucifer yellow passage of colonic biopsies was measured. 
Patients were then divided based on magnitude of CEA response, defined as having a 
FluoroSpot IL-17A SFC higher or lower than the group median. (A) Magnitude of IL-17A 
responses from all patients. (B) Right and (D) left colon electrical resistance. (C) Right 
colon and (E) left colon Lucifer yellow passage. Data shown is at 20 minutes. Error bars 
show SEM. 
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Figure 5.6. CEA-specific IFN-γ/IL-17A dual T cell responses do not correlate with 
intestinal permeability. 
Electrical resistance and Lucifer yellow passage of colonic biopsies was measured. 
Patients were then divided based on CEA magnitude of response, defined as having a 
FluoroSpot IFN-γ/IL-17A SFC higher or lower than the group median. (A) Magnitude of 
IFN-γ/IL-17A responses from all patients. (B) Right and (D) left colon electrical 
resistance. (C) Right colon and (E) left colon Lucifer yellow passage. Data shown is at 
20 minutes. Error bars show SEM. 
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Figure 5.7 5T4-specific IFN-γ T cell responses do not correlate with intestinal 
permeability.  
Electrical resistance and Lucifer yellow passage of colonic biopsies was measured. 
Patients were then divided based on 5T4 magnitude of response, defined as having a 
FluoroSpot IFN-γ SFC higher or lower than the group median. (A) Magnitude of IFN-γ 
responses from all patients. (B) Right and (D) left colon electrical resistance. (C) Right 
colon and (E) left colon Lucifer yellow passage. Data shown is at 20 minutes. Error bars 
show SEM. 
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Figure 5.8. 5T4-specific IL-17A T cell responses do not correlate with intestinal 
permeability.  
Electrical resistance and Lucifer yellow passage of colonic biopsies was measured. 
Patients were then divided based on 5T4 magnitude of response, defined as having a 
FluoroSpot IL-17A SFC higher or lower than the group median. (A) Magnitude of IL-17A 
responses from all patients. (B) Right and (D) left colon electrical resistance. (C) Right 
colon and (E) left colon Lucifer yellow passage. Data shown is at 20 minutes. Error bars 
show SEM. 
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Figure 5.9. 5T4-specific IFN-γ/IL-17A dual T cell responses do not correlate with 
intestinal permeability.  
Electrical resistance and Lucifer yellow passage of colonic biopsies was measured. 
Patients were then divided based on 5T4 magnitude of response, defined as having a 
FluoroSpot IFN-γ/IL-17A SFC higher or lower than the group median. (A) Magnitude of 
IFN-γ/IL-17A responses from all patients. (B) Right and (D) left colon electrical 
resistance. (C) Right colon and (E) left colon Lucifer yellow passage. Data shown is at 
20 minutes. Error bars show SEM. 
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5.3 Discussion  
This chapter focused on whether CEA blood responses correlated with 
increased intestinal permeability. Firstly, it was established that human colonic 
biopsy permeability could be measured within the Ussing chamber system. 
Acquiring biopsy samples was extremely beneficial, as historically surgical 
samples would have been used. Logistically surgical samples are difficult to 
work with; as tissue viability is often sub-optimal by the time it reaches the 
laboratory from theatre. Furthermore, surgical specimens require dissection of 
the colonic muscle layer prior to mounting. In contrast, biopsy samples can be 
transported directly to the laboratory and mounted immediately. Moreover, as 
patients often receive repeat colonoscopies there are opportunities to obtain 
samples on more than one occasion from the same patient. However, one 
drawback of biopsy samples is that the small tissue size can sometimes induce 
edge damage, which may not be present in larger samples. Edge damage can 
create a shunt pathway, providing a lower resistance pathway for current to 
travel. This can lead to an underestimation of the true tissue electrical 
resistance. Nevertheless, biopsy samples do provide a good tissue source for 
Ussing experiments. 
 
There has been conflicting data regarding the prognostic impact of right versus 
left sided tumours. Most studies indicate a poorer prognosis for right-sided CRC 
(307) (308, 309). However, Weiss et al found no difference in outcome based on 
tumour site and Warschkow and colleagues observed a better survival for 
patients with right-sided tumours (310) (311). What is clear however is that left 
and right tumours do have characteristic differences. For example right-sided 
tumours are associated more often with increased age, female gender and are 
poorly differentiated (307). Furthermore, primary tumour location has been 
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linked with clinical outcome during treatment. For example, in RAS wild-type 
CRC, cetuximab treatment was associated with a poorer survival outcome in 
patients with right-sided tumours than left sided. (312). In this study it was 
observed that intestinal permeability between the right and left colon of healthy 
patients also differed. The left side of the colon is more permeable that the right. 
Interestingly, tumour occurrence is also more common in the left (sigmoid = 23% 
for males and 20% for females) colonic region that the right (caecum = 12% for 
males and 17% for females) according to Cancer Research UK statistics (313).  
When permeability was correlated with CEA T cell response it was observed 
that magnitude of CEA-specific IFN-γ T cell response only associated with 
increased intestinal permeability in the right side of the colon, not the left. This 
data supports our hypothesis that CEA responding patients have increased 
mucosal permeability compared to non-responding patients. A high magnitude 
CEA response under normal circumstances appears to be somewhat 
insignificant, as this association with increased permeability was observed in 
healthy patients who had no indication of colonic disease. However, in the case 
where a tumour has developed this natural increase in intestinal permeability 
within the right colon may contribute to tumour progression through bacterial 
driven inflammation (Figure 5.10). Our data investigating adenoma patients also 
supports this idea, as those with a lesion displayed a higher magnitude CEA-
specific IFN-γ T cell response than healthy controls, suggesting that damage to 
the epithelial barrier may enhance CEA responses, perhaps through cross-
reactivity to microbes.  
 
Since CEA is highly upregulated in cancer it has been suggested as a target for 
immunotherapy and for use in vaccination. However, while studies have shown 
that immune tolerance to CEA can be broken, the long-term effects of this are 
unknown. Both mouse and human studies have provided evidence that 
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stimulation of anti-CEA immune responses can reduce tumour size however as 
a consequence very severe colitis ensues (191, 192). This supports our findings 
that CEA responses are linked with increased intestinal permeability and 
therefore may be detrimental in the case of CRC patients. Based on our data, 
CEA T cell blood responses should be considered a risk factor for poor 
prognosis in CRC, with data obtained using the Ussing system suggesting that 
this may be due to intestinal epithelial barrier dysfunction, at least within the 
right side of the colon. 
 
5.4 Conclusion 
 
The Ussing Chamber system was successfully modified to accommodate small 
human colonic biopsy samples and intestinal permeability could be evaluated. A 
blood CEA specific T cell response appears to associate with increased right-
sided intestinal permeability.  
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Figure 5.10. Schematic showing the hypothesis that increased intestinal 
permeability helps drive bacterial induced inflammation, aiding tumour 
progression in CEA responding patients.  
Cancerous cells develop due to genetic mutations within colonic epithelial cells, resulting 
in disruption of the epithelial barrier locally at the tumour site. This results in 
translocation of microbes, which are detected by myeloid cells within the lamina propria 
via TLRs, driving the release of inflammatory products such as IL-1, IL-6 and IL-23 that 
can activate T helper cells. IL-23 activation of Th17 cells in particular can drive STAT-3 
production in tumour cells through the release of IL-17 and IL-22 to aid survival and 
proliferation. Auto-reactive CEA specific T cells in the lamina propria contribute to the 
inflammatory setting as IFN-γ released can act directly on TJ proteins in-between 
epithelial cells, further increasing mucosal permeability and bacterial translocation. 
Consistent inflammation can drive further CEA T cell activation, increase the chance of 
developing additional genetic mutations, more epithelial barrier dysfunction and 
ultimately promote tumour progression. Figure adapted from Gallimore and Godkin, 
2013 (253). 
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Chapter 6. Final Discussion  	
6.1 Introduction  	
This thesis has investigated the role of auto-reactive T cells in CRC, a disease 
where typically treatment consists of a surgical colectomy with curative intent. 
However, unfortunately up to 50% of patients will relapse within a 5-year period 
(176). A better understanding of CRC development and progression is key to 
the generation of superior treatments for patients.  
 
Current dogma suggests that IFN-γ producing T cells are beneficial for CRC 
patient outcome. However, the clinical consequences of such a response with 
respect to long-term outcome is not properly understood. In a study carried out 
by our laboratory blood derived IFN-γ responses to two well-known tumour 
antigens, 5T4 and CEA, were evaluated in a cohort of CRC patients prior to 
surgical colectomy (194). As expected, results showed that disease recurrence 
was most associated with late stage III disease. However, surprisingly the 
presence of a CEA-specific IFN-γ response identified patients with a statistically 
significant increased risk of tumour recurrence irrespective of tumour stage. In 
contrast, a 5T4 response alone did not reflect outcome, but did provide a 
protective affect within patients also harbouring a CEA response. The major 
focus of the work within this thesis centred around two hypotheses to determine 
why IFN-γ responses towards CEA correlate with earlier tumour recurrence. 
 
My first hypothesis stated that IL-17A and/or IL-17A/IFN-γ dual producing CEA-
specific T cells existed within CRC patients and contributed to tumour relapse. 
Results from Chapter 3 showed that CEA-specific IL-17A and IL-17A/IFN-γ T 
cell responses were present within healthy donors and CRC patients. However, 
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the magnitude of CEA-specific IL-17A response was constantly lower than CEA-
specific IFN-γ responses. Furthermore CEA-specific IL-17A secretion was 
always accompanied by CEA-specific IFN-γ release. IL-17A/IFN-γ dual 
responses towards CEA were also rarely detected. Together this indicates that 
CEA-specific IL-17A is not the main factor influencing patient outcome. 
Interestingly it was observed that tumours from CEA responding patients have a 
lower immune cell infiltrate compared to non-responding patients. High immune 
cell infiltration, particularly the presence of CD3+ T cells, is associated with 
better patient survival in CRC (208). Therefore lack of T cell infiltration could 
allow for earlier relapse in CEA responding patients.  
 
My second hypothesis stated that patients harbouring CEA-specific T cell IFN-γ 
responses had increased intestinal permeability, which could lead to tumour 
progression through bacterial driven inflammation. Importantly, data supporting 
this hypothesis emerged from experiments using the Ussing chamber system, 
which I recently established within our laboratory. A high magnitude CEA-
specific IFN-γ T cell response was associated with increased permeability within 
the right colon. To better explain this finding further investigations should be 
carried out. Firstly due to the regional differences in intestinal permeability 
detected, the distribution of CEA expression throughout the colon should be 
explored using immunohistochemistry. Thus far the localisation of CEA has 
been determined in the small intestine and the colon with results showing high 
luminal expression at both sites (184). However, the pattern of CEA expression 
along the length of the colon is yet to be defined. In our initial data set showing 
that an IFN-γ CEA response correlated with earlier relapse, tumour location was 
shown to not be an associated factor (194). However, in this study increased 
intestinal permeability is linked with CEA responses in the right colon but not the 
left. Interestingly baseline permeability Ussing measurements showed that the 
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left colon is more permeable compared to the right. It may be possible that this 
increase in baseline permeability makes it more difficult to extrapolate a positive 
correlation between CEA response and increased permeability in the left colon. 
If a correlation does exist it may be subtle, making it difficult to observe with 
Ussing measurements on a low number of patients. Increasing the size of this 
cohort should confirm if IFN-γ T cell CEA responses only correlate with 
increased permeability of the right colon or not. 
Reduced epithelial integrity is associated with a change in TJ protein 
composition in-between epithelial cells. Inflammation is linked with the down 
regulation of “sealing” TJ proteins and increased barrier permeability (19). 
Through the use of cell lines, mouse models and patient samples, Ahmad et al 
recently investigated the role of the TJ protein claudin-3 in CRC (254). The 
group were able to show that claudin-3 is the most abundant cell adhesion 
molecule in the normal colon but there is a significant loss of expression in 
colonic tumours. It was also observed that claudin-3 deficient mice had 
dedifferentiated colonic epithelium as well increased mucosal leakage compared 
to WT animals, indicating a role for claudin-3 in promoting intestinal barrier 
function. Moreover, claudin-3 deficiency resulted in increased susceptibility to 
AOM/DSS induced colon carcinogenesis, with 33% of mice developing invasive 
tumours while WT mice developed none. Loss of claudin-3 was also shown to 
induce the Wnt/β-catenin signalling pathway to aid in tumour progression (254). 
CRC patient samples also revealed that claudin-3 expression had a prognostic 
significance, with greater claudin-3 expression correlating with better patient OS 
(254). It’s clear from such observations that TJ proteins play a major role in gut 
homeostasis. Within our cohort of endoscopy patients it is unknown if there is a 
correlation between TJ composition and CEA response. Therefore exploring the 
expression of TJ proteins at various colonic regions and within CEA high and 
low responding patients would be extremely advantageous.   
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6.2 Microbial influence in colorectal cancer 
The influence of the microbiota in intestinal disease is a rapidly expanding field. 
Studies have identified a dramatic alteration in microbial composition between 
CRC patients and healthy controls (314) (315). It is believed this is in part due to 
the substantial change in diet, which has occurred over the last few decades in 
the western world. Dietary behaviour can influence microbial composition, which 
in turn can affects susceptibility to intestinal disease (316, 317). With the colon 
exhibiting the highest bacterial density of the GI tract a potential role for the 
microbiota in CRC progression should therefore be considered. Throughout this 
thesis it has been suggested that translocation of microbes across the epithelial 
barrier could aid in tumour development. Some studies support this theory, 
showing that specific bacterial species are linked with tumourigenesis (222, 304, 
305). However, there is now evidence to suggest that bacterial species can 
impact the effectiveness of cancer therapy also. This makes microbial 
composition a crucial factor to consider not only for understanding tumour 
progression but also for developing better treatment strategies for CRC patients. 
 
In particular, the group of Laurence Zitvogel showed that treatment with the drug 
cyclophosphamide, a prominent alkylating anticancer agent, alters the intestinal 
microbial composition and promotes the translocation of distinct gram+ bacteria 
across the gut. This was associated with the generation of better anti-tumour 
immune responses in a mouse model (318). Moreover, tumour-bearing germ-
free and antibiotic treated mice had reduced anti-tumour responses and any 
beneficial effects of cyclophosphamide were diminished, suggesting that the 
microbiota are of great importance. In a follow up study it was shown that oral 
gavage of mice with a particular Gram+ bacterial strain called Enterococcus 
hirae (clone 13144) could restore cyclophosphamide-mediated anti-tumour 
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effects (250). The group stated that E.hirae had translocated across the gut 
epithelium, identified by cultivation of the mesenteric lymph nodes (mLN) of 
colonised mice on agar plates, followed by mass spectrometry to identify the 
presence of bacterial species. While results implied that E.hirae had 
translocated the epithelium, it is not unreasonable to suggest that E.hirae 
detected within the mLN is in fact a result of antigen presenting cells such as 
DCs sampling the intestinal luminal environment, consuming E.hirae and 
migrating to lymphoid tissue as opposed to direct translocation. In scenarios 
such as this the Ussing chamber system can be a valuable tool. Preliminary 
data from our laboratory based on one experiment suggests that E.hirae is able 
to translocate across the intestinal barrier after 20 minutes of being in contact 
with the intestinal mucosal surface (see appendix). Such findings highlight a 
useful future use for the Ussing chamber system, potentially investigating the 
direct impact of particular bacterial species on barrier integrity during disease. 
Findings from our laboratory also support the observations that 
cyclophosphamide can promote anti-tumour responses. Data emerged from our 
clinical trial (TaCTiCC) showing that cyclophosphamide treatment was able to 
reduce Treg numbers within CRC patients, which led to the expansion of 
effector T cells producing IFN-γ and granzyme-B. Furthermore, 
cyclophosphamide-treated patients demonstrating the most enhanced IFN-
γ/granzyme-B tumor-specific T-cell responses exhibited a significant delay in 
tumor progression (202). As mentioned previously CRC patients have a high 
risk of tumour recurrence, with up to 50% of patients relapsing within 5-years 
post-surgery. It is possible that alterations in microbial composition and/or 
intestinal permeability occur after surgical colectomy. Using the Ussing chamber 
system intestinal permeability before surgery could be measured. Following this, 
permeability measurements at various time points after surgery (e.g. every year) 
may make it possible to ascertain whether intestinal permeability changes occur 
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over time, and whether this increases the risk of tumour recurrence. The impact 
of therapies such as cyclophosphamide on barrier function within post-operative 
patients could also be assessed. Further to this, it would be interesting to 
determine if the effectiveness of cancer therapy is altered as a consequence of 
having increased baseline intestinal permeability, such as that seen within 
individuals harbouring a high CEA response. 
 
Not many studies exist where intestinal permeability has been successfully 
restored. However Yi et al recently reported that administration of the 
antimicrobial peptide (AMP) Cathelicidin-WA (CWA) provides enhanced barrier 
function in the intestine. Intraperitoneal injection of CWA into piglets 
experiencing post-weaning diarrhoea resulted in reduced pro-inflammatory 
cytokines such as IL-6 and IL-8, compared to control animals. Moreover, 
symptoms of disease were also reduced. Furthermore, it was also shown that 
CWA treatment was associated with the upregulation of TJ proteins ZO-1 and 
occludin, known to have a key role in barrier integrity. Moreover, in vitro 
experiments using IPEC-J2 cell monolayers, a porcine epithelial cell line, 
showed that treatment with CWA ameliorated LPS induced reductions in 
electrical resistance (319). In a follow-up study it was shown that CWA 
treatment could also attenuate intestinal colitis driven by enterohemorrhagic 
Escherichia coli (320). Additionally, there were differences in microbial 
composition between animals treated with CWA versus those treated with the 
standard antibiotic enrofloxacin. This change was accompanied by restoration of 
SCFA levels to that observed in control animals. Such observations indicate that 
CWA treatment exhibits different effects on the bacterial community and can 
help to restore gut homeostasis. While the area of modulating intestinal barrier 
function is still in its infancy, studies such as this indicate that barrier function 
potentially could be promoted during inflammatory disease. Potentially 
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treatments to enhance intestinal function alongside cancer therapies may be 
beneficial for patients.  
 
6.3 Concluding remarks 
Superior treatments for CRC are required and immune based therapies could 
potentially be life saving for patients. However, one of the major difficulties is 
developing agents that are useful for the majority of patients. For this reason the 
development of treatments that target non-mutated self-antigens is very 
attractive. On the other-hand the long-term effects of unleashing such immune 
responses is still largely unknown. As shown in this thesis immune responses to 
particular targets, such as CEA, may be detrimental. The consequences of 
immune based therapies must therefore be fully understood to ensure the most 
effective targets are selected. 																							
	 192	
APPENDIX  
Appendix Figure 1. Magnitude of cytokine responses in FluoroSpot assays 
when using  CTL Test Plus Serum Free media or R5 Media for culture. n=1. 
Error bars show SEM. Note that HA was not tested in CTL Test Plus Serum 
Free Media. 
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Appendix Figure 2. E.Hirae translocation across sigmoid biopsy tissue 
mounted in Ussing chambers. (A) Staining of E.hirae with the fluorescent dye 
SYBR-Green. 1 billion E.Hirae were added to the mucosal chamber and (B) 
shows the percentage of E.Hirae detected in the serosal chamber at various 
time points. (C) The number of E.Hirae/µl detected in serosal samples. (D) 
FACS plots of mucosal and serosal samples at 0, 20, 40, 60, 90 and 960 
minutes. 																																									
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  or	  not	  you	  wish	  to	  take	  part.	  The	  person	  running	  this	  study	  is	  
Professor	  Andrew	  Godkin	  who	  looks	  after	  patients	  with	  diseases	  of	  the	  colon	  in	  Cardiff	  and	  
Vale	  University	  Health	  Board	  and	  undertakes	  research	  with	  scientific	  colleagues	  from	  Cardiff	  
University.	  	  
	  
3.	  What	  is	  the	  purpose	  of	  the	  study?	  	  
The	  purpose	  of	  the	  study	  is	  to	  study	  the	  role	  of	  white	  blood	  cells	  (leucocytes)	  and	  the	  way	  
they	  work	  in	  differing	  diseases	  of	  the	  colon	  and	  in	  people	  without	  disease	  of	  the	  colon.	  
We	  request	  samples	  from	  four	  different	  groups,	  one	  of	  which	  you	  fall	  into:	  
	  
Group	  1	  –	  Samples	  of	  blood	  from	  healthy	  people	  without	  diseases	  of	  the	  colon	  
Group	  2	  –	  Samples	  of	  blood	  and	  normal	  colon	  from	  patients	  undergoing	  surgery	  of	  the	  colon	  
Group	  3	  –	  Samples	  of	  blood,	  normal	  colon	  and	  tumour	  from	  patients	  undergoing	  surgery	  for	  
cancer	  of	  the	  colon	  
Group	  4	  –	  Samples	  of	  blood	  and	  bowel	  from	  patients	  undergoing	  gastointestinal	  endoscopy	  
for	  clinical	  reasons	  
	  
4.	  Why	  have	  I	  been	  invited?	  	  
You	  have	  been	  invited	  to	  take	  part	  as	  a	  member	  of	  Group	  [insert	  group]……………..	  
	  
5.	  Do	  I	  have	  to	  take	  part?	  	  
It	  is	  up	  to	  you	  to	  decide.	  We	  will	  describe	  the	  study	  and	  go	  through	  this	  information	  sheet,	  
which	  we	  will	  then	  give	  to	  you.	  We	  will	  then	  ask	  you	  to	  sign	  a	  consent	  form	  to	  show	  you	  
have	  agreed	  to	  take	  part.	  You	  are	  free	  to	  withdraw	  at	  any	  time,	  without	  giving	  a	  reason.	  This	  
will	  not	  affect	  the	  standard	  of	  care	  you	  receive.	  
6.	  What	  will	  happen	  to	  me	  if	  I	  take	  part?	  
For	  all	  Groups	  –	  You	  will	  be	  told	  by	  the	  surgeon	  or	  physician	  who	  is	  looking	  after	  your	  clinical	  
care	  about	  the	  study	  and	  asked	  if	  you	  are	  interested	  in	  taking	  part.	  If	  you	  are	  interested	  and	  
agree	  to	  take	  part	  in	  the	  study,	  samples	  will	  be	  taken	  by	  staff	  involved	  in	  your	  clinical	  care	  
and	  will	  be	  passed	  to	  the	  research	  team	  at	  Cardiff	  University.	  When	  the	  research	  group	  get	  
your	  sample,	  it	  will	  have	  no	  details	  that	  can	  identify	  you	  with	  it,	  only	  a	  code	  number.	  The	  
master	  copy	  with	  your	  identification	  details	  will	  stay	  with	  the	  chief	  investigator	  in	  a	  locked	  
office,	  and	  will	  not	  be	  disclosed	  to	  the	  researchers.	  Where	  useful	  to	  understand	  the	  
pathology,	  clinical	  outcomes	  may	  be	  recorded.	  We	  will	  allocate	  a	  code	  number	  to	  each	  
person	  so	  that	  the	  clinicians	  can	  provide	  this	  additional	  information	  (e.g.	  on	  the	  outcome	  of	  
your	  surgery	  if	  you	  are	  having	  an	  operation)	  at	  a	  later	  date.	  The	  data	  on	  each	  subject	  will	  be	  
retained	  for	  10	  years.	  
Group	  1	  -­‐	  If	  you	  agree	  to	  participate,	  we	  will	  take	  a	  sample	  of	  your	  blood	  (3-­‐5	  teaspoonfuls)	  
and	  use	  it	  to	  identify	  white	  blood	  cells	  and	  to	  perform	  studies	  in	  the	  laboratory	  on	  how	  they	  
work.	  
	  Group	  2	  -­‐	  If	  you	  agree	  to	  participate,	  we	  will	  take	  a	  sample	  from	  the	  normal	  part	  of	  your	  
colon	  or	  bowel	  when	  it	  is	  removed	  during	  surgery	  and	  look	  at	  how	  the	  wall	  of	  the	  bowel	  
works.	  This	  material	  would	  normally	  be	  disposed	  of	  after	  surgery.	  We	  would	  also	  like	  to	  take	  
a	  sample	  of	  your	  blood	  (3-­‐5	  teaspoonfuls),	  both	  the	  bowel	  and	  the	  blood	  sample	  will	  be	  
used	  to	  look	  at	  how	  the	  white	  cells	  work.	  	  
Group	  3	  -­‐	  If	  you	  agree	  to	  participate,	  we	  will	  take	  a	  sample	  from	  part	  of	  the	  tumour	  in	  your	  
colon	  and	  the	  normal	  part	  of	  colon	  when	  it	  is	  removed	  during	  surgery.	  This	  material	  would	  
normally	  be	  disposed	  of	  after	  surgery.	  We	  would	  also	  take	  a	  sample	  of	  your	  blood	  (3-­‐5	  
teaspoonfuls),	  both	  the	  normal	  bowel/tumour	  and	  the	  blood	  sample	  will	  be	  used	  to	  look	  at	  
how	  the	  white	  cells	  work.	  	  
Group	  4	  -­‐	  If	  you	  agree	  to	  take	  part,	  we	  will	  take	  two	  or	  three	  additional	  biopsies	  when	  you	  
undergo	  your	  routine	  clinical	  endoscopy.	  We	  would	  also	  like	  to	  take	  a	  sample	  of	  your	  blood	  
(3-­‐5	  teaspoonfuls),	  both	  the	  bowel	  and	  the	  blood	  sample	  will	  be	  used	  to	  look	  at	  how	  the	  
white	  cells	  work.	  	  
It	  is	  possible	  you	  may	  be	  approached	  for	  an	  additional	  blood	  sample	  after	  4-­‐8	  weeks;	  you	  
would	  be	  asked	  for	  repeat	  consent.	  
7.	  What	  are	  the	  possible	  disadvantages	  and	  risks	  of	  taking	  part?	  
For	  Groups	  1-­‐3	  there	  are	  no	  disadvantages	  or	  risks	  in	  taking	  part	  (other	  than	  a	  small	  bruise	  
from	  the	  blood	  test)	  
For	  Group	  4	  there	  is	  a	  risk	  in	  having	  additional	  biopsy	  samples	  taken	  for	  research.	  In	  the	  
course	  of	  over	  25	  years	  of	  performing	  endoscopies,	  in	  over	  10	  000	  patients,	  and	  taking	  
1000s	  of	  biopsies,	  the	  chief	  investigator	  is	  yet	  to	  witness	  a	  significant	  problem.	  Guidelines	  
from	  the	  British	  Society	  of	  Gastroenterology	  in	  2006	  stated	  that	  an	  endoscopic	  biopsy	  is	  
rarely	  complicated	  by	  significant	  bleeding.	  In	  theory,	  bleeding	  may	  occur.	  
	  
8.	  What	  are	  the	  possible	  benefits	  of	  taking	  part?	  
Taking	  part	  in	  this	  study	  will	  not	  help	  you	  but	  the	  information	  we	  get	  from	  this	  study	  will	  
help	  to	  improve	  our	  understanding	  of	  the	  role	  of	  white	  blood	  cells	  in	  the	  body,	  and	  how	  
they	  react	  to	  different	  diseases.	  
	  
Part	  2	  
	  
1.	  Will	  my	  taking	  part	  in	  the	  study	  be	  kept	  confidential?	  	  	  
Yes.	  We	  will	  follow	  ethical	  and	  legal	  practice	  and	  all	  information	  about	  you	  will	  be	  handled	  
in	  confidence.	  The	  data	  that	  is	  sent	  outside	  the	  clinical	  team	  will	  be	  anonymised	  so	  that	  the	  
research	  team	  will	  not	  have	  access	  to	  your	  information	  
	  
2.	  What	  will	  happen	  to	  my	  samples?	  
The	  samples	  are	  transferred	  to	  the	  laboratory	  where	  they	  are	  prepared	  for	  experiments.	  
These	  include	  looking	  at	  how	  white	  blood	  cells	  and	  other	  cells,	  and	  compounds	  such	  as	  
proteins	  function	  in	  different	  tissues.	  
	  
3.	  What	  will	  happen	  if	  I	  don’t	  want	  to	  carry	  on	  with	  the	  study?	  	  
You	  can	  decide	  to	  withdraw	  from	  the	  study	  at	  any	  point.	  If	  you	  want	  to	  withdraw	  you	  can	  
contact	  the	  research	  team	  and	  make	  that	  request.	  If	  any	  samplesare	  stored	  they	  can	  
destroyed	  at	  your	  request.	  If	  the	  results	  from	  experiments	  with	  your	  sample	  have	  been	  
included	  in	  an	  analysis,	  it	  will	  not	  be	  possible	  to	  withdraw	  it	  retrospectively.	  
	  4.	  What	  if	  there	  is	  a	  problem?	  	  
If	  you	  have	  any	  concerns	  about	  the	  conduct	  of	  this	  study,	  you	  should	  ask	  to	  speak	  to	  the	  
Chief	  Investigator	  who	  will	  do	  his	  best	  to	  answer	  your	  questions	  (029	  20687129).	  If	  you	  
remain	  unhappy	  and	  wish	  to	  raise	  a	  formal	  concern	  then	  you	  should	  contact	  Cardiff	  
University	  Research	  and	  Innovation	  Service	  via	  the	  governance	  officer	  (029	  20879131).	  
If	  you	  have	  a	  concern	  about	  the	  clinical	  care	  you	  have	  received,	  you	  can	  do	  this	  through	  the	  
Cardiff	  and	  Vale	  Concerns	  Team	  (029	  21847391).	  	  
	  
5.	  Future	  research	  	  
With	  your	  consent,	  we	  might	  store	  the	  sample/s	  you	  have	  given	  us	  for	  use	  in	  future	  
research,	  we	  do	  not	  yet	  know	  what	  the	  research	  might	  involve	  but	  it	  may	  include	  
collaborators	  abroad	  or	  working	  for	  a	  commercial	  company.	  The	  stored	  samples	  may	  
include	  serum	  and	  cells	  including	  the	  genetic	  material	  in	  the	  cell	  i.e.	  DNA.	  This	  will	  be	  done	  
in	  accordance	  with	  the	  Human	  Tissue	  Act	  which	  lays	  down	  requirements	  for	  the	  storage	  and	  
use	  of	  all	  samples.	  No	  identifiable	  personal	  information	  will	  be	  stored	  with	  the	  sample.	  If	  
you	  wish,	  you	  can	  agree	  for	  the	  sample	  to	  be	  used	  for	  the	  current	  project	  but	  not	  for	  future	  
research.	  If	  so,	  you	  should	  not	  sign	  this	  part	  of	  the	  consent	  form.	  
	  
6.	  Will	  any	  genetic	  tests	  be	  done?	  	  
No	  familial	  genetic	  testing	  will	  be	  done	  on	  these	  samples	  during	  the	  current	  study,	  but	  
genetic	  material	  may	  be	  stored	  for	  future	  analysis.	  
	  
7.	  What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  	  	  
It	  is	  intended	  to	  submit	  the	  results	  of	  this	  study	  for	  publication	  in	  medical	  journals	  and	  to	  
present	  the	  results	  at	  national	  and	  international	  meetings.	  You	  will	  not	  be	  identified	  in	  any	  
report/publication.	  
	  
8.	  Who	  is	  organising	  and	  funding	  the	  research?	  	  
This	  study	  is	  being	  funded	  by	  charitable	  trusts	  and	  scientific	  grant	  giving	  bodies.	  The	  funding	  
will	  pay	  for	  the	  salaries	  of	  some	  of	  the	  participating	  researchers,	  for	  purchasing	  the	  reagents	  
required	  for	  carrying	  out	  these	  studies,	  and	  for	  disseminating	  the	  new	  knowledge	  gained	  by	  
these	  studies.	  
	  
	  
9.	  Who	  has	  reviewed	  the	  study?	  	  
All	  research	  in	  the	  NHS	  is	  looked	  at	  by	  an	  independent	  group	  of	  people,	  called	  a	  Research	  
Ethics	  Committee	  to	  protect	  your	  safety,	  rights,	  wellbeing	  and	  dignity.	  This	  study	  has	  been	  
reviewed	  and	  given	  favourable	  opinion	  by	  the	  Research	  Ethics	  Committee.	  
	  
Contact	  details	  of	  the	  Researcher	  for	  further	  information:	  
	  
	  
Professor	  Andrew	  Godkin	  
Henry	  Wellcome	  Building,	  
Cardiff	  University	  
Heath	  Park,	  
Cardiff.	  CF14	  4XW.	  
Tel	  029	  20687129	  
Email:	  godkinaj@cf.ac.uk	  
	  
	  
	  
	  
	  
	  
	  
	  
Please 
initial 
boxes 
CONSENT	  FORM	  
The	  role	  of	  leukocytes	  in	  the	  colon	  and	  blood	  
Chief	  Investigator	  Prof	  Andrew	  Godkin	  (Consultant	  Gastroenterologist	  and	  Hepatologist)	  
1. I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  information	  sheet	  Version	  1.3	  
for	  the	  above	  study	  and	  have	  had	  the	  opportunity	  to	  ask	  questions.	  
2. I	  understand	  that	  my	  participation	  is	  voluntary	  and	  that	  I	  am	  free	  to	  withdraw	  at	  
any	  time,	  without	  giving	  any	  reason,	  without	  my	  medical	  care	  or	  legal	  rights	  
being	  affected.	  
3. I	  understand	  that	  relevant	  sections	  of	  my	  medical	  notes	  and	  data	  collected	  
during	  the	  study,	  may	  be	  looked	  at	  by	  responsible	  individuals	  from	  regulatory	  
bodies,	  Cardiff	  University	  or	  the	  Cardiff	  and	  Vale	  University	  Health	  Board.	  I	  give	  
permission	  to	  these	  individuals	  to	  have	  access	  to	  my	  records.	  All	  information	  will	  
remain	  confidential.	  
4. I	  agree	  for	  blood	  and/or	  clinical	  waste	  samples	  to	  be	  collected	  and	  used	  for	  the	  
purposes	  of	  this	  study	  (Groups	  1-­‐3)	  
5. I	  agree	  for	  additional	  biopsies	  and	  a	  blood	  sample	  to	  be	  collected	  and	  used	  for	  
the	  purposes	  of	  this	  study	  (Group	  4	  only)	  
6. I	  consent	  for	  my	  anonymised	  results	  of	  this	  study	  to	  be	  published	  in	  scientific	  /	  
medical	  journals.	  
7. I	  consent	  for	  obtained	  samples	  to	  be	  stored	  for	  future	  research	  in	  the	  UK	  and	  
abroad,	  I	  understand	  the	  research	  may	  involve	  DNA	  analysis	  and	  use	  by	  the	  
commercial	  sector	  (Please	  cross	  out	  if	  you	  do	  not	  wish	  your	  samples	  to	  stored)	  
8. I	  agree	  to	  take	  part	  in	  the	  above	  study	  
	  
Name	  of	  Patient	   	   	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  Signature	   	   	   	   	  	  	  Date	  
	  
Name	  of	  Person	  taking	  consent	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Signature	   	   	   	   	  	  	  Date	  
	  
When	  completed	  make	  two	  copies:	  1	  offered	  to	  participant;	  1	  to	  be	  kept	  in	  medical	  notes.	  
Original	  kept	  and	  filed	  by	  CI.	  
